BRCA1,B
is,O
secreted,O
and,O
exhibits,O
properties,O
of,O
a,O
granin,O
.,O
Germline,O
mutations,O
in,O
BRCA1,B
are,O
responsible,O
for,O
most,O
cases,O
of,O
inherited,O
breast,B
and,O
ovarian,B
cancer,I
.,O
However,O
",",O
the,O
function,O
of,O
the,O
BRCA1,B
protein,O
has,O
remained,O
elusive,O
.,O
We,O
now,O
show,O
that,O
BRCA1,B
encodes,O
a,O
190,O
-,O
kD,O
protein,O
with,O
sequence,O
homology,O
and,O
biochemical,O
analogy,O
to,O
the,O
granin,O
protein,O
family,O
.,O
Interestingly,O
",",O
BRCA2,B
also,O
includes,O
a,O
motif,O
similar,O
to,O
the,O
granin,B
consensus,I
at,O
the,O
C,O
terminus,O
of,O
the,O
protein,O
.,O
Both,O
BRCA1,B
and,O
the,O
granins,B
localize,O
to,O
secretory,O
vesicles,O
",",O
are,O
secreted,O
by,O
a,O
regulated,O
pathway,O
",",O
are,O
post,O
-,O
translationally,O
glycosylated,O
and,O
are,O
responsive,O
to,O
hormones,O
.,O
As,O
a,O
regulated,O
secretory,O
protein,O
",",O
BRCA1,B
appears,O
to,O
function,O
by,O
a,O
mechanism,O
not,O
previously,O
described,O
for,O
tumour,O
suppressor,O
gene,O
products,O
.,O
.0,O
Ovarian,B
cancer,I
risk,O
in,O
BRCA1,B
carriers,O
is,O
modified,O
by,O
the,O
HRAS1,B
variable,O
number,O
of,O
tandem,O
repeat,O
(,O
VNTR,B
),O
locus,O
.,O
Women,O
who,O
carry,O
a,O
mutation,O
in,O
the,O
BRCA1,B
gene,O
(,O
on,O
chromosome,O
17q21,O
),O
",",O
have,O
an,O
80,O
%,O
risk,O
of,O
breast,B
cancer,I
and,O
a,O
40,O
%,O
risk,O
of,O
ovarian,B
cancer,I
by,O
the,O
age,O
of,O
70,O
(,O
ref,O
.,O
1,O
),O
.,O
The,O
variable,O
penetrance,O
of,O
BRCA1,B
suggests,O
that,O
other,O
genetic,O
and,O
non,O
-,O
genetic,O
factors,O
play,O
a,O
role,O
in,O
tumourigenesis,O
in,O
these,O
individuals,O
.,O
The,O
HRAS1,B
variable,O
number,O
of,O
tandem,O
repeats,O
(,O
VNTR,B
),O
polymorphism,O
",",O
located,O
1,O
kilobase,O
(,O
kb,O
),O
downstream,O
of,O
the,O
HRAS1,B
proto,O
-,O
oncogene,O
(,O
chromosome,O
11p15,O
.,O
5,O
),O
is,O
one,O
possible,O
genetic,O
modifier,O
of,O
cancer,B
penetrance,O
.,O
Individuals,O
who,O
have,O
rare,O
alleles,O
of,O
the,O
VNTR,B
have,O
an,O
increased,O
risk,O
of,O
certain,O
types,O
of,O
cancers,O
",",O
including,O
breast,B
cancer,I
(,O
2,O
-,O
4,O
),O
.,O
To,O
investigate,O
whether,O
the,O
presence,O
of,O
rare,O
HRAS1,B
alleles,O
increases,O
susceptibility,O
to,O
hereditary,O
breast,B
and,O
ovarian,B
cancer,I
",",O
we,O
have,O
typed,O
a,O
panel,O
of,O
307,O
female,O
BRCA1,B
carriers,O
at,O
this,O
locus,O
using,O
a,O
PCR,O
-,O
based,O
technique,O
.,O
The,O
risk,O
for,O
ovarian,B
cancer,I
was,O
2,O
.,O
11,O
times,O
greater,O
for,O
BRCA1,B
carriers,O
harbouring,O
one,O
or,O
two,O
rare,O
HRAS1,B
alleles,O
",",O
compared,O
to,O
carriers,O
with,O
only,O
common,O
alleles,O
(,O
P,O
=,O
0,O
.,O
015,O
),O
.),O
The,O
magnitude,O
of,O
the,O
relative,O
risk,O
associated,O
with,O
a,O
rare,O
HRAS1,B
allele,O
was,O
not,O
altered,O
by,O
adjusting,O
for,O
the,O
other,O
known,O
risk,O
factors,O
for,O
hereditary,O
ovarian,B
cancer,I
(,O
5,O
),O
.,O
Susceptibility,O
to,O
breast,B
cancer,I
did,O
not,O
appear,O
to,O
be,O
affected,O
by,O
the,O
presence,O
of,O
rare,O
HRAS1,B
alleles,O
.,O
This,O
study,O
is,O
the,O
first,O
to,O
show,O
the,O
effect,O
of,O
a,O
modifying,O
gene,O
on,O
the,O
penetrance,O
of,O
an,O
inherited,O
cancer,O
syndrome,O
A,O
novel,O
homeodomain,O
-,O
encoding,O
gene,O
is,O
associated,O
with,O
a,O
large,O
CpG,O
island,O
interrupted,O
by,O
the,O
myotonic,B
dystrophy,I
unstable,I
(,O
CTG,B
),O
n,O
repeat,O
.,O
Myotonic,B
dystrophy,I
(,O
DM,B
),O
is,O
associated,O
with,O
a,O
(,O
CTG,B
),O
n,O
trinucleotide,O
repeat,O
expansion,O
in,O
the,O
3,O
-,O
untranslated,O
region,O
of,O
a,O
protein,O
kinase,O
-,O
encoding,O
gene,O
",",O
DMPK,B
",",O
which,O
maps,O
to,O
chromosome,O
19q13,O
.,O
3,O
Characterisation,O
of,O
the,O
expression,O
of,O
this,O
gene,O
in,O
patient,O
tissues,O
has,O
thus,O
far,O
generated,O
conflicting,O
data,O
on,O
alterations,O
in,O
the,O
steady,O
state,O
levels,O
of,O
DMPK,B
mRNA,O
",",O
and,O
on,O
the,O
final,O
DMPK,B
protein,I
levels,O
in,O
the,O
presence,O
of,O
the,O
expansion,O
.,O
The,O
DM,B
region,O
of,O
chromosome,O
19,O
is,O
gene,O
rich,O
",",O
and,O
it,O
is,O
possible,O
that,O
the,O
repeat,O
expansion,O
may,O
lead,O
to,O
dysfunction,O
of,O
a,O
number,O
of,O
transcription,O
units,O
in,O
the,O
vicinity,O
",",O
perhaps,O
as,O
a,O
consequence,O
of,O
chromatin,O
disruption,O
.,O
We,O
have,O
searched,O
for,O
genes,O
associated,O
with,O
a,O
CpG,O
island,O
at,O
the,O
3,O
end,O
of,O
DMPK,B
.,O
Sequencing,O
of,O
this,O
region,O
shows,O
that,O
the,O
island,O
extends,O
over,O
3,O
.,O
5,O
kb,O
and,O
is,O
interrupted,O
by,O
the,O
(,O
CTG,B
),O
n,O
repeat,O
.,O
Comparison,O
of,O
genomic,O
sequences,O
downstream,O
(,O
centromeric,O
),O
of,O
the,O
repeat,O
in,O
human,O
and,O
mouse,O
identified,O
regions,O
of,O
significant,O
homology,O
.,O
These,O
correspond,O
to,O
exons,O
of,O
a,O
gene,O
predicted,O
to,O
encode,O
a,O
homeodomain,O
protein,O
.,O
RT,O
-,O
PCR,O
analysis,O
shows,O
that,O
this,O
gene,O
",",O
which,O
we,O
have,O
called,O
DM,B
locus,I
-,I
associated,I
homeodomain,I
protein,I
(,I
DMAHP,I
),I
",",O
is,O
expressed,O
in,O
a,O
number,O
of,O
human,O
tissues,O
",",O
including,O
skeletal,O
muscle,O
",",O
heart,O
and,O
brain,O
.,O
Germline,O
mutations,O
in,O
the,O
RB1,B
gene,I
in,O
patients,O
with,O
hereditary,O
retinoblastoma,B
.,O
We,O
have,O
analyzed,O
the,O
27,O
exons,O
and,O
the,O
promoter,O
region,O
of,O
the,O
RB1,B
gene,I
in,O
familial,O
or,O
sporadic,O
bilateral,O
retinoblastoma,B
by,O
using,O
single,O
-,O
strand,O
conformation,O
polymorphism,O
analysis,O
.,O
For,O
improvement,O
over,O
previous,O
studies,O
",",O
a,O
new,O
set,O
of,O
primers,O
has,O
been,O
designed,O
",",O
which,O
allow,O
for,O
amplification,O
of,O
the,O
coding,O
and,O
splicing,O
sequences,O
only,O
.,O
The,O
positioning,O
of,O
the,O
polymerase,O
chain,O
reaction,O
(,O
PCR,B
),O
primers,O
was,O
such,O
that,O
the,O
resulting,O
PCR,B
products,O
were,O
of,O
different,O
sizes,O
",",O
which,O
enabled,O
us,O
to,O
analyze,O
two,O
different,O
exons,O
simultaneously,O
and,O
still,O
distinguish,O
between,O
the,O
banding,O
profiles,O
for,O
both,O
(,O
biplex,O
analysis,O
),O
.,O
By,O
using,O
this,O
approach,O
",",O
we,O
were,O
able,O
to,O
identify,O
mutation,B
in,O
22,O
new,O
patients,O
",",O
but,O
the,O
overall,O
efficiency,O
of,O
the,O
procedure,O
when,O
we,O
used,O
a,O
single,O
-,O
pass,O
regimen,O
was,O
only,O
48,O
%,O
.,O
The,O
mutations,O
were,O
small,O
insertions,O
and,O
deletions,O
and,O
point,O
mutations,O
in,O
roughly,O
equal,O
proportions,O
.,O
Type,O
II,O
human,O
complement,O
C2,B
deficiency,I
.,O
Allele,O
-,O
specific,O
amino,O
acid,O
substitutions,O
(,O
Ser189,B
-,I
-,I
>,I
Phe,I
;,O
Gly444,B
-,I
-,I
>,I
Arg,I
),O
cause,O
impaired,O
C2,B
secretion,I
.,O
Type,O
II,O
complement,O
protein,O
C2,B
deficiency,I
is,O
characterized,O
by,O
a,O
selective,O
block,O
in,O
C2,B
secretion,I
.,O
The,O
Type,B
II,I
C2,I
null,O
allele,O
(,O
C2Q0,B
),O
is,O
linked,O
to,O
two,O
major,O
histocompatibility,O
haplotypes,O
(,O
MHC,B
),O
that,O
differ,O
from,O
the,O
MHC,B
of,O
the,O
more,O
common,O
Type,B
I,I
C2,I
deficiency,I
.,O
To,O
determine,O
the,O
molecular,O
basis,O
of,O
Type,B
II,I
deficiency,I
the,O
two,O
Type,B
II,I
C2Q0,I
genes,O
were,O
isolated,O
and,O
transfected,O
separately,O
into,O
L,O
-,O
cells,O
.,O
Subsequent,O
molecular,O
biology,O
",",O
biosynthetic,O
",",O
and,O
immunofluorescence,O
studies,O
demonstrated,O
that,O
C2,B
secretion,O
is,O
impaired,O
in,O
Type,B
II,I
C2,I
deficiency,I
because,O
of,O
different,O
missense,O
mutations,O
at,O
highly,O
conserved,O
residues,O
in,O
each,O
of,O
the,O
C2Q0,B
alleles,O
.,O
One,O
is,O
in,O
exon,O
5,O
(,O
nucleotide,O
C566,B
-,I
-,I
>,I
T,I
;,O
Ser189,B
-,I
-,I
>,I
Phe,I
),O
of,O
the,O
C2Q0,B
gene,O
linked,O
to,O
the,O
MHC,B
haplotype,O
A11,B
",",O
B35,B
",",O
DRw1,B
",",O
BFS,B
",",O
C4A0B1,B
.,O
The,O
other,O
is,O
in,O
exon,O
11,O
(,O
G1930,O
-,O
-,O
>,O
A,O
;,O
Gly444,O
-,O
-,O
>,O
Arg,O
),O
of,O
the,O
C2Q0,O
gene,O
linked,O
to,O
the,O
MHC,O
haplotype,O
A2,O
",",O
B5,O
",",O
DRw4,O
",",O
BFS,O
",",O
C4A3B1,O
.,O
Each,O
mutant,O
C2,O
gene,O
product,O
is,O
retained,O
early,O
in,O
the,O
secretory,O
pathway,O
.,O
These,O
mutants,O
provide,O
models,O
for,O
elucidating,O
the,O
C2,O
secretory,O
pathway,O
.,O
Defective,O
dimerization,O
of,O
von,O
Willebrand,O
factor,O
subunits,O
due,O
to,O
a,O
Cys,O
-,O
>,O
Arg,O
mutation,O
in,O
type,O
IID,O
von,O
Willebrand,O
disease,B
.,O
The,O
same,O
heterozygous,O
T,O
-,O
>,O
C,O
transition,O
at,O
nt,O
8567,O
of,O
the,O
von,B
Willebrand,I
factor,I
(,O
vWF,O
),O
transcript,O
was,O
found,O
in,O
two,O
unrelated,O
patients,O
with,O
type,O
IID,B
von,I
Willebrand,I
disease,I
",",O
with,O
no,O
other,O
apparent,O
abnormality,O
.,O
In,O
one,O
family,O
",",O
both,O
alleles,O
were,O
normal,O
in,O
the,O
parents,O
and,O
one,O
sister,O
;,O
thus,O
",",O
the,O
mutation,O
originated,O
de,O
novo,O
in,O
the,O
proposita,O
.,O
The,O
second,O
patient,O
also,O
had,O
asymptomatic,O
parents,O
who,O
",",O
however,O
",",O
were,O
not,O
available,O
for,O
study,O
.,O
The,O
structural,O
consequences,O
of,O
the,O
identified,O
mutation,O
",",O
resulting,O
in,O
the,O
CyS2010,B
-,I
>,I
Arg,I
substitution,O
",",O
were,O
evaluated,O
by,O
expression,O
of,O
the,O
vWF,O
carboxyl,O
-,O
terminal,O
domain,O
containing,O
residues,O
1366,O
-,O
2050,O
.,O
Insect,O
cells,O
infected,O
with,O
recombinant,O
baculovirus,O
expressing,O
normal,B
vWF,I
sequence,I
secreted,O
a,O
disulfide,O
linked,O
dimeric,O
molecule,O
with,O
an,O
apparent,O
molecular,O
mass,O
of,O
150,O
kDa,O
before,O
reduction,O
",",O
yielding,O
a,O
single,O
band,O
of,O
80,O
kDa,O
after,O
disulfide,O
bond,O
reduction,O
.,O
In,O
contrast,O
",",O
cells,O
expressing,O
the,O
mutant,B
fragment,I
secreted,O
a,O
monomeric,O
molecule,O
of,O
apparent,O
molecular,O
mass,O
of,O
80,O
kDa,O
",",O
which,O
remained,O
unchanged,O
after,O
reduction,O
.,O
We,O
conclude,O
that,O
CyS2010,B
is,O
essential,O
for,O
normal,O
dimerization,O
of,O
vWF,B
subunits,O
through,O
disulfide,O
bonding,O
of,O
carboxyl,O
-,O
terminal,O
domains,O
and,O
that,O
a,O
heterozygous,O
mutation,O
in,O
the,O
corresponding,O
codon,O
is,O
responsible,O
for,O
defective,O
multimer,O
formation,O
in,O
type,O
IID,B
von,I
Willebrand,I
disease,I
.,O
.,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
protein,O
",",O
a,O
novel,O
effector,O
for,O
the,O
GTPase,O
CDC42Hs,B
",",O
is,O
implicated,O
in,O
actin,O
polymerization,O
.,O
The,O
Rho,B
family,I
of,I
GTPases,I
control,O
diverse,O
biological,O
processes,O
",",O
including,O
cell,O
morphology,O
and,O
mitogenesis,O
.,O
We,O
have,O
identified,O
WASP,B
",",O
the,O
protein,O
that,O
is,O
defective,O
in,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
(,O
WAS,B
),O
",",O
as,O
a,O
novel,O
effector,O
for,O
CDC42Hs,B
",",O
but,O
not,O
for,O
the,O
other,O
Rho,B
family,I
members,I
",",O
Rac,B
and,O
Rho,B
.,O
This,O
interaction,O
is,O
dependent,O
on,O
the,O
presence,O
of,O
the,O
G,B
protein,I
-,I
binding,I
domain,I
.,O
Cellular,O
expression,O
of,O
epitope,O
-,O
tagged,O
WASP,B
produces,O
clusters,O
of,O
WASP,B
that,O
are,O
highly,O
enriched,O
in,O
polymerized,O
actin,O
.,O
This,O
clustering,O
is,O
not,O
observed,O
with,O
a,O
C,O
-,O
terminally,O
deleted,O
WASP,B
and,O
is,O
inhibited,O
by,O
coexpression,O
with,O
dominant,O
negative,O
CDC42Hs,B
-,I
N17,I
",",O
but,O
not,O
with,O
dominant,O
negative,O
forms,O
of,O
Rac,B
or,O
Rho,B
.,O
Thus,O
",",O
WASP,O
provides,O
a,O
novel,O
link,O
between,O
CDC42Hs,O
and,O
the,O
actin,O
cytoskeleton,O
",",O
which,O
suggests,O
a,O
molecular,O
mechanism,O
for,O
many,O
of,O
the,O
cellular,O
abnormalities,O
in,O
WAS,B
.,O
The,O
WASP,O
sequence,O
contains,O
two,O
novel,O
domains,O
that,O
are,O
homologous,O
to,O
other,O
proteins,O
involved,O
in,O
action,O
organization,O
.,O
.,O
X,O
-,O
linked,O
adrenoleukodystrophy,B
is,O
a,O
frequent,O
cause,O
of,O
idiopathic,O
Addison,B
',O
s,O
disease,I
in,O
young,O
adult,O
male,O
patients,O
.,O
X,O
-,O
Linked,O
adrenoleukodystrophy,B
(,O
ALD,O
),O
is,O
a,O
genetic,O
disease,O
associated,O
with,O
demyelination,B
of,I
the,I
central,I
nervous,I
system,I
",",O
adrenal,B
insufficiency,I
",",O
and,O
accumulation,O
of,O
very,O
long,O
chain,O
fatty,O
acids,O
in,O
tissue,O
and,O
body,O
fluids,O
.,O
ALD,B
is,O
due,O
to,O
mutation,O
of,O
a,O
gene,O
located,O
in,O
Xq28,O
that,O
encodes,O
a,O
peroxisomal,O
transporter,O
protein,O
of,O
unknown,O
function,O
.,O
The,O
most,O
common,O
phenotype,O
of,O
ALD,B
is,O
the,O
cerebral,O
form,O
(,O
45,O
%,O
),O
that,O
develops,O
in,O
boys,O
between,O
5,O
-,O
12,O
yr,O
.,O
Adrenomyeloneuropathy,B
(,O
AMN,B
),O
involves,O
the,O
spinal,O
cord,O
and,O
peripheral,O
nerves,O
in,O
young,O
adults,O
(,O
35,O
%,O
),O
.,O
Adrenal,B
insufficiency,I
(,O
Addisons,B
disease,I
),O
is,O
frequently,O
associated,O
with,O
AMN,B
or,O
cerebral,O
ALD,B
and,O
may,O
remain,O
the,O
only,O
clinical,O
expression,O
of,O
ALD,B
(,O
8,O
%,O
of,O
cases,O
),O
.,O
The,O
prevalence,O
of,O
ALD,B
among,O
adults,O
with,O
Addisons,B
disease,I
remains,O
unknown,O
.,O
To,O
evaluate,O
this,O
prevalence,O
",",O
we,O
performed,O
biochemical,O
analysis,O
of,O
very,O
long,O
chain,O
fatty,O
acids,O
in,O
14,O
male,O
patients,O
(,O
age,O
ranging,O
from,O
12,O
-,O
45,O
yr,O
at,O
diagnosis,O
),O
previously,O
diagnosed,O
as,O
having,O
primary,O
idiopathic,O
adrenocortical,O
insufficiency,O
.,O
In,O
5,O
of,O
14,O
patients,O
(,O
35,O
%,O
),O
",",O
elevated,O
plasma,O
concentrations,O
of,O
very,O
long,O
chain,O
fatty,O
acids,O
were,O
detected,O
.,O
None,O
of,O
these,O
patients,O
had,O
adrenocortical,B
antibodies,I
.,O
By,O
electrophysiological,O
tests,O
and,O
magnetic,O
resonance,O
imaging,O
it,O
was,O
determined,O
that,O
two,O
patients,O
had,O
cerebral,B
ALD,I
",",O
one,O
had,O
adrenomyeloneuropathy,B
with,I
cerebral,I
involvement,I
",",O
and,O
two,O
had,O
preclinical,B
AMN,I
.,O
Our,O
data,O
support,O
the,O
hypothesis,O
that,O
ALD,B
is,O
a,O
frequent,O
cause,O
of,O
idiopathic,O
Addisons,B
disease,I
in,O
children,O
and,O
adults,O
.,O
Tumor,O
suppression,O
and,O
apoptosis,O
of,O
human,O
prostate,B
carcinoma,I
mediated,O
by,O
a,O
genetic,O
locus,O
within,O
human,O
chromosome,O
10pter,O
-,O
q11,O
.,O
Prostate,B
cancer,I
is,O
the,O
second,O
leading,O
cause,O
of,O
male,O
cancer,O
deaths,O
in,O
the,O
United,O
States,O
.,O
Yet,O
",",O
despite,O
a,O
large,O
international,O
effort,O
",",O
little,O
is,O
known,O
about,O
the,O
molecular,O
mechanisms,O
that,O
underlie,O
this,O
devastating,O
disease,B
.,O
Prostate,B
secretory,I
epithelial,I
cells,I
and,O
androgen,B
-,I
dependent,I
prostate,I
carcinomas,I
undergo,O
apoptosis,O
in,O
response,O
to,O
androgen,B
deprivation,I
and,O
",",O
furthermore,O
",",O
most,O
prostate,B
carcinomas,I
become,O
androgen,B
independent,I
and,O
refractory,O
to,O
further,O
therapeutic,O
manipulations,O
during,O
disease,B
progression,O
.,O
Definition,O
of,O
the,O
genetic,O
events,O
that,O
trigger,O
apoptosis,B
in,O
the,O
prostate,O
could,O
provide,O
important,O
insights,O
into,O
critical,O
pathways,O
in,O
normal,O
development,O
as,O
well,O
as,O
elucidate,O
the,O
perturbations,O
of,O
those,O
key,O
pathways,O
in,O
neoplastic,O
transformation,O
.,O
We,O
report,O
the,O
functional,O
definition,O
of,O
a,O
novel,O
genetic,O
locus,O
within,O
human,O
chromosome,O
10pter,O
-,O
q11,O
that,O
mediates,O
both,O
in,O
vivo,O
tumor,B
suppression,I
and,O
in,O
vitro,O
apoptosis,B
of,O
prostatic,O
adenocarcinoma,B
cells,O
.,O
A,O
defined,O
fragment,O
of,O
human,O
chromosome,O
10,B
was,O
transferred,O
via,O
microcell,O
fusion,O
into,O
a,O
prostate,O
adenocarcinoma,B
cell,I
line,I
.,O
Microcell,O
hybrids,O
containing,O
only,O
the,O
region,O
10pter,B
-,I
q11,I
were,O
suppressed,O
for,O
tumorigenicity,O
following,O
injection,O
of,O
microcell,O
hybrids,O
into,O
nude,O
mice,O
.,O
Furthermore,O
",",O
the,O
complemented,O
hybrids,O
undergo,O
programmed,O
cell,O
death,O
in,O
vitro,O
via,O
a,O
mechanism,O
that,O
does,O
not,O
require,O
nuclear,O
localization,O
of,O
p53,B
.,O
These,O
data,O
functionally,O
define,O
a,O
novel,O
genetic,O
locus,O
",",O
designated,O
PAC1,B
",",O
for,O
prostate,B
adenocarcinoma,I
1,O
",",O
involved,O
in,O
tumor,O
suppression,O
of,O
human,O
prostate,B
carcinoma,I
and,O
furthermore,O
strongly,O
suggest,O
that,O
the,O
cell,O
death,O
pathway,O
can,O
be,O
functionally,O
restored,O
in,O
prostatic,B
adenocarcinoma,I
.,O
Low,O
incidence,O
of,O
BRCA2,B
mutations,O
in,O
breast,B
carcinoma,I
and,O
other,O
cancers,O
.,O
Inherited,O
mutant,O
alleles,O
of,O
familial,O
tumour,B
suppressor,I
genes,I
predispose,O
individuals,O
to,O
particular,O
types,O
of,O
cancer,B
.,O
In,O
addition,O
to,O
an,O
involvement,O
in,O
inherited,O
susceptibility,O
to,O
cancer,B
",",O
these,O
tumour,B
suppressor,I
genes,I
are,O
targets,O
for,O
somatic,O
mutations,O
in,O
sporadic,O
cancers,B
of,O
the,O
same,O
type,O
found,O
in,O
the,O
familial,O
forms,O
.,O
An,O
exception,O
is,O
BRCA1,B
",",O
which,O
contributes,O
to,O
a,O
significant,O
fraction,O
of,O
familial,O
breast,B
and,O
ovarian,B
cancer,I
",",O
but,O
undergoes,O
mutation,O
at,O
very,O
low,O
rates,O
in,O
sporadic,O
breast,B
and,O
ovarian,B
cancers,I
.,O
This,O
finding,O
suggests,O
that,O
other,O
genes,O
may,O
be,O
the,O
principal,O
targets,O
for,O
somatic,O
mutation,O
in,O
breast,B
carcinoma,I
.,O
A,O
second,O
",",O
recently,O
identified,O
familial,O
breast,B
cancer,I
gene,O
",",O
BRCA2,B
(,O
refs,O
5,O
-,O
8,O
),O
",",O
accounts,O
for,O
a,O
proportion,O
of,O
breast,B
cancer,I
roughly,O
equal,O
to,O
BRCA1,B
.,O
Like,O
BRCA1,B
",",O
BRCA2,B
behaves,O
as,O
a,O
dominantly,O
inherited,O
tumour,O
suppressor,O
gene,O
.,O
Individuals,O
who,O
inherit,O
one,O
mutant,O
allele,O
are,O
at,O
increased,O
risk,O
for,O
breast,O
cancer,O
",",O
and,O
the,O
tumours,O
they,O
develop,O
lose,O
the,O
wild,O
-,O
type,O
allele,O
by,O
heterozygous,O
deletion,O
.,O
The,O
BRCA2,B
coding,O
sequence,O
is,O
huge,O
",",O
composed,O
of,O
26,O
exons,O
that,O
span,O
10,O
",",O
443,O
bp,O
.,O
Here,O
we,O
investigate,O
the,O
rate,O
of,O
BRCA2,B
mutation,O
in,O
sporadic,O
breast,B
cancers,I
and,O
in,O
a,O
set,O
of,O
cell,O
lines,O
that,O
represent,O
twelve,O
other,O
tumour,O
types,O
.,O
Surprisingly,O
",",O
mutations,O
in,O
BRCA2,B
are,O
infrequent,O
in,O
cancers,O
including,O
breast,B
carcinoma,I
.,O
However,O
",",O
a,O
probable,O
germline,O
mutation,O
in,O
a,O
pancreatic,B
tumour,I
cell,I
line,I
suggests,O
a,O
role,O
for,O
BRCA2,B
in,O
susceptibility,O
to,O
pancreatic,B
cancer,I
.,O
Founding,O
BRCA1,B
mutations,O
in,O
hereditary,O
breast,B
and,O
ovarian,B
cancer,I
in,O
southern,O
Sweden,O
.,O
Nine,O
different,O
germ,O
-,O
line,O
mutations,O
in,O
the,O
BRCA1,B
breast,B
and,O
ovarian,B
cancer,I
susceptibility,O
gene,O
were,O
identified,O
in,O
15,O
of,O
47,O
kindreds,O
from,O
southern,O
Sweden,O
",",O
by,O
use,O
of,O
SSCP,O
and,O
heteroduplex,O
analysis,O
of,O
all,O
exons,O
and,O
flanking,O
intron,O
region,O
and,O
by,O
a,O
protein,O
-,O
truncation,O
test,O
for,O
exon,O
11,O
",",O
followed,O
by,O
direct,O
sequencing,O
.,O
All,O
but,O
one,O
of,O
the,O
mutations,O
are,O
predicted,O
to,O
give,O
rise,O
to,O
premature,O
translation,O
termination,O
and,O
include,O
seven,O
frameshift,O
insertions,O
or,O
deletions,O
",",O
a,O
nonsense,B
mutation,I
",",O
and,O
a,O
splice,B
acceptor,I
site,I
mutation,I
.,O
The,O
remaining,O
mutation,O
is,O
a,O
missense,B
mutation,I
(,O
Cys61Gly,O
),O
in,O
the,O
zinc,B
-,I
binding,I
motif,I
.,O
Four,O
novel,O
Swedish,O
founding,O
mutations,O
were,O
identified,O
the,O
nucleotide,O
2595,O
deletion,B
A,I
was,O
found,O
in,O
five,O
families,O
",",O
the,O
C,B
1806,I
T,I
nonsense,I
mutation,I
in,O
three,O
families,O
",",O
the,O
3166,B
insertion,I
TGAGA,I
in,O
three,O
families,O
",",O
and,O
the,O
nucleotide,O
1201,O
deletion,B
11,I
in,O
two,O
families,O
.,O
Analysis,O
of,O
the,O
intragenic,O
polymorphism,O
D17S855,O
supports,O
common,O
origins,O
of,O
the,O
mutations,O
.,O
Eleven,O
of,O
the,O
15,O
kindreds,O
manifesting,O
BRCA1,B
mutations,O
were,O
breast,B
-,I
ovarian,I
cancer,I
families,O
",",O
several,O
of,O
them,O
with,O
a,O
predominant,O
ovarian,B
cancer,I
phenotype,O
.,O
The,O
set,O
of,O
32,O
families,O
in,O
which,O
no,O
BRCA1,B
alterations,O
were,O
detected,O
included,O
1,O
breast,B
-,I
ovarian,I
cancer,I
kindred,O
manifesting,O
clear,O
linkage,O
to,O
the,O
BRCA1,B
region,O
and,O
loss,O
of,O
the,O
wild,O
-,O
type,O
chromosome,O
in,O
associated,O
tumors,O
.,O
Other,O
tumor,O
types,O
found,O
in,O
BRCA1,B
mutation,I
/,O
haplotype,O
carriers,O
included,O
prostatic,B
",",O
pancreas,B
",",O
skin,B
",",O
and,O
lung,B
cancer,I
",",O
a,O
malignant,B
melanoma,I
",",O
an,O
oligodendroglioma,B
",",O
and,O
a,O
carcinosarcoma,B
.,O
In,O
all,O
",",O
12,O
of,O
16,O
kindreds,O
manifesting,O
BRCA1,B
mutation,I
or,O
linkage,O
contained,O
ovarian,B
cancer,I
",",O
as,O
compared,O
with,O
only,O
6,O
of,O
the,O
remaining,O
31,O
families,O
(,O
P,O
<,O
.,O
001,O
),O
.),O
The,O
present,O
study,O
confirms,O
the,O
involvement,O
of,O
BRCA1,B
in,O
disease,O
predisposition,O
for,O
a,O
subset,O
of,O
hereditary,O
breast,O
cancer,O
families,O
often,O
characterized,O
by,O
ovarian,O
cancers,O
.,O
Rapid,O
detection,O
of,O
regionally,O
clustered,O
germ,O
-,O
line,O
BRCA1,B
mutations,O
by,O
multiplex,O
heteroduplex,O
analysis,O
.,O
UKCCCR,O
Familial,O
Ovarian,O
Cancer,O
Study,O
Group,O
.,O
Germ,O
-,O
line,O
mutations,O
of,O
the,O
BRCA1,B
gene,I
are,O
responsible,O
for,O
a,O
substantial,O
proportion,O
of,O
families,O
with,O
multiple,O
cases,O
of,O
early,O
-,O
onset,O
breast,O
and,O
/,O
or,O
ovarian,O
cancer,B
.,O
Since,O
the,O
isolation,O
of,O
BRCA1,B
last,O
year,O
",",O
>,O
65,O
distinct,O
mutations,O
scattered,O
throughout,O
the,O
coding,O
region,O
have,O
been,O
detected,O
",",O
making,O
analysis,O
of,O
the,O
gene,O
time,O
consuming,O
and,O
technically,O
challenging,O
.,O
We,O
have,O
developed,O
a,O
multiplex,O
heteroduplex,O
analysis,O
that,O
is,O
designed,O
to,O
analyze,O
one,O
-,O
quarter,O
of,O
the,O
coding,O
sequence,O
in,O
a,O
single,O
-,O
step,O
screening,O
procedure,O
and,O
that,O
will,O
detect,O
approximately,O
50,O
%,O
of,O
all,O
BRCA1,B
mutations,O
so,O
far,O
reported,O
in,O
breast,O
/,O
ovarian,O
cancer,O
families,O
.,O
We,O
have,O
used,O
this,O
technique,O
to,O
analyze,O
BRCA1,B
in,O
162,O
families,O
with,O
a,O
history,O
of,O
breast,O
and,O
/,O
or,O
ovarian,O
cancer,O
and,O
identified,O
12,O
distinct,O
mutations,O
in,O
35,O
families,O
.,O
A,O
previously,O
undescribed,O
mutation,O
within,O
the,O
tetramerisation,O
domain,O
of,O
TP53,B
in,O
a,O
family,O
with,O
Li,B
-,I
Fraumeni,I
syndrome,I
.,O
We,O
report,O
details,O
of,O
a,O
family,O
with,O
classic,O
Li,B
-,I
Fraumeni,I
syndrome,I
in,O
which,O
there,O
is,O
a,O
mutation,O
in,O
codon,O
344,O
of,O
the,O
tumour,O
suppressor,O
gene,O
TP53,B
.,O
Codon,O
344,O
is,O
a,O
key,O
residue,O
within,O
the,O
tetramerisation,O
domain,O
",",O
and,O
the,O
amino,O
acid,O
substitution,O
of,O
a,O
proline,O
for,O
a,O
leucine,O
is,O
predicted,O
to,O
have,O
profound,O
implications,O
for,O
tetramerisation,O
and,O
potentially,O
DNA,O
binding,O
.,O
This,O
is,O
the,O
first,O
report,O
of,O
a,O
mutation,O
at,O
this,O
residue,O
in,O
either,O
sporadic,O
tumours,B
or,O
in,O
the,O
germline,B
and,O
the,O
first,O
report,O
of,O
a,O
germline,B
mutation,O
within,O
the,O
tetramerisation,O
domain,O
.,O
The,O
family,O
does,O
not,O
appear,O
to,O
be,O
remarkable,O
in,O
the,O
spectrum,O
of,O
tumours,O
",",O
and,O
there,O
is,O
loss,O
of,O
the,O
wild,O
-,O
type,O
allele,O
in,O
a,O
leiomyosarcoma,B
from,O
the,O
proband,O
.,O
A,O
cell,O
line,O
has,O
been,O
established,O
from,O
the,O
tumour,B
of,O
the,O
proband,O
and,O
cytogenetic,O
and,O
molecular,O
studies,O
carried,O
out,O
",",O
providing,O
an,O
extensive,O
analysis,O
in,O
this,O
family,O
.,O
The,O
spectrum,O
of,O
RB1,B
germ,I
-,I
line,I
mutations,I
in,I
hereditary,I
retinoblastoma,I
.,O
We,O
have,O
searched,O
for,O
germ,B
-,I
line,I
RB1,I
mutations,I
in,I
119,O
patients,O
with,O
hereditary,O
retinoblastoma,O
.,O
Previous,O
investigations,O
by,O
Southern,O
blot,O
hybridization,O
and,O
PCR,O
fragment,O
-,O
length,O
analysis,O
had,O
revealed,O
mutations,O
in,O
48,O
patients,O
.,O
Here,O
we,O
report,O
on,O
the,O
analysis,O
of,O
the,O
remaining,O
71,O
patients,O
.,O
By,O
applying,O
heteroduplex,O
analysis,O
",",O
nonisotopic,O
SSCP,O
",",O
and,O
direct,O
sequencing,O
",",O
we,O
detected,O
germ,O
-,O
line,O
mutations,B
resulting,O
in,O
premature,O
termination,O
codons,O
or,O
disruption,O
of,O
splice,O
signals,O
in,O
51,O
(,O
72,O
%,O
),O
of,O
the,O
71,O
patients,O
.,O
Four,O
patients,O
also,O
showed,O
rare,O
sequence,O
variants,O
.,O
No,O
region,O
of,O
the,O
RB1,B
gene,O
was,O
preferentially,O
involved,O
in,O
single,O
base,O
substitutions,O
.,O
Recurrent,O
transitions,O
were,O
observed,O
at,O
most,O
of,O
the,O
14,O
codons,O
within,O
the,O
RB1,B
.,O
No,O
mutation,O
was,O
observed,O
in,O
exons,O
25,O
-,O
27,O
",",O
although,O
this,O
region,O
contains,O
two,O
CGA,B
codons,O
.,O
This,O
suggests,O
that,O
mutations,O
within,O
the,O
3,O
-,O
terminal,O
region,O
of,O
the,O
RB1,B
gene,I
may,O
not,O
be,O
oncogenic,O
.,O
When,O
these,O
data,O
were,O
combined,O
with,O
the,O
results,O
of,O
our,O
previous,O
investigations,O
",",O
mutations,O
were,O
identified,O
in,O
a,O
total,O
of,O
99,O
(,O
83,O
%,O
),O
of,O
119,O
patients,O
.,O
The,O
spectrum,O
comprises,O
15,O
%,O
large,O
deletions,O
",",O
26,O
%,O
small,O
length,O
alterations,O
",",O
and,O
42,O
%,O
base,O
substitutions,O
.,O
No,O
correlation,O
between,O
the,O
location,O
of,O
frameshift,B
or,O
nonsense,I
mutations,I
and,O
phenotypic,O
features,O
",",O
including,O
age,O
at,O
diagnosis,O
",",O
the,O
number,O
of,O
tumor,O
foci,O
",",O
and,O
manifestation,O
of,O
nonocular,O
tumors,O
was,O
observed,O
.,O
Phenotypic,O
characterization,O
of,O
individuals,O
with,O
30,O
-,O
40,O
CAG,O
repeats,O
in,O
the,O
Huntington,B
disease,I
(,O
HD,B
),O
gene,O
reveals,O
HD,B
cases,O
with,O
36,O
repeats,O
and,O
apparently,O
normal,O
elderly,O
individuals,O
with,O
36,O
-,O
39,O
repeats,O
.,O
Abnormal,O
CAG,B
expansions,O
in,O
the,O
IT,O
-,O
15,O
gene,O
are,O
associated,O
with,O
Huntington,B
disease,I
(,O
HD,B
),O
.,O
In,O
the,O
diagnostic,O
setting,O
it,O
is,O
necessary,O
to,O
define,O
the,O
limits,O
of,O
the,O
CAG,B
size,I
ranges,I
on,O
normal,O
and,O
HD,B
-,I
associated,I
chromosomes,I
.,O
Most,O
large,O
analyses,O
that,O
defined,O
the,O
limits,O
of,O
the,O
normal,O
and,O
pathological,O
size,O
ranges,O
employed,O
PCR,O
assays,O
",",O
which,O
included,O
the,O
CAG,B
repeats,I
and,O
a,O
CCG,O
repeat,O
tract,O
that,O
was,O
thought,O
to,O
be,O
invariant,O
.,O
Many,O
of,O
these,O
experiments,O
found,O
an,O
overlap,O
between,O
the,O
normal,O
and,O
disease,B
size,I
ranges,I
.,O
Subsequent,O
findings,O
that,O
the,O
CCG,O
repeats,O
vary,O
by,O
8,O
trinucleotide,O
lengths,O
suggested,O
that,O
the,O
limits,O
of,O
the,O
normal,O
and,O
disease,B
size,I
ranges,I
should,O
be,O
reevaluated,O
with,O
assays,O
that,O
exclude,O
the,O
CCG,O
polymorphism,O
.,O
Since,O
patients,O
with,O
between,O
30,O
and,O
40,O
repeats,O
are,O
rare,O
",",O
a,O
consortium,O
was,O
assembled,O
to,O
collect,O
such,O
individuals,O
.,O
All,O
178,O
samples,O
were,O
reanalyzed,O
in,O
Cambridge,O
by,O
using,O
assays,O
specific,O
for,O
the,O
CAG,B
repeats,I
.,O
We,O
have,O
optimized,O
methods,O
for,O
reliable,O
sizing,O
of,O
CAG,B
repeats,I
and,O
show,O
cases,O
that,O
demonstrate,O
the,O
dangers,O
of,O
using,O
PCR,O
assays,O
that,O
include,O
both,O
the,O
CAG,B
and,O
CCG,B
polymorphisms,I
.,O
Seven,O
HD,B
patients,O
had,O
36,O
repeats,O
",",O
which,O
confirms,O
that,O
this,O
allele,O
is,O
associated,O
with,O
disease,B
.,O
Individuals,O
without,O
apparent,O
symptoms,O
or,O
signs,O
of,O
HD,B
were,O
found,O
at,O
36,O
repeats,O
(,O
aged,O
74,O
",",O
78,O
",",O
79,O
",",O
and,O
87,O
years,O
),O
",",O
37,O
repeats,O
(,O
aged,O
69,O
years,O
),O
",",O
38,O
repeats,O
(,O
aged,O
69,O
and,O
90,O
years,O
),O
",",O
and,O
39,O
repeats,O
(,O
aged,O
67,O
",",O
90,O
",",O
and,O
95,O
years,O
),O
.,O
The,O
detailed,O
case,O
histories,O
of,O
an,O
exceptional,O
case,O
from,O
this,O
series,O
will,O
be,O
presented,O
a,O
95,O
-,O
year,O
-,O
old,O
man,O
with,O
39,O
repeats,O
who,O
did,O
not,O
have,O
classical,O
features,O
of,O
HD,B
.,O
The,O
apparently,O
healthy,O
survival,O
into,O
old,O
age,O
of,O
some,O
individuals,O
with,O
36,O
-,O
39,O
repeats,O
suggests,O
that,O
the,O
HD,B
mutation,O
may,O
not,O
always,O
be,O
fully,O
penetrant,O
.,O
Identification,O
and,O
expression,O
of,O
eight,O
novel,O
mutations,O
among,O
non,O
-,O
Jewish,O
patients,O
with,O
Canavan,B
disease,I
.,O
Canavan,B
disease,I
is,O
inherited,O
as,O
an,O
autosomal,O
recessive,O
trait,O
that,O
is,O
caused,O
by,O
the,O
deficiency,O
of,O
aspartoacylase,O
(,O
ASPA,B
),O
.,O
The,O
majority,O
of,O
patients,O
with,O
Canavan,B
disease,I
are,O
from,O
an,O
Ashkenazi,O
Jewish,O
background,O
.,O
Mutations,O
in,O
ASPA,B
that,O
lead,O
to,O
loss,O
of,O
enzymatic,O
activity,O
have,O
been,O
identified,O
",",O
and,O
E285A,B
and,O
Y231X,B
are,O
the,O
two,O
predominant,O
mutations,O
that,O
account,O
for,O
97,O
%,O
of,O
the,O
mutant,O
chromosomes,O
in,O
Ashkenazi,O
Jewish,O
patients,O
.,O
The,O
current,O
study,O
was,O
aimed,O
at,O
finding,O
the,O
molecular,O
basis,O
of,O
Canavan,B
disease,I
in,O
25,O
independent,O
patients,O
of,O
non,O
-,O
Jewish,O
background,O
.,O
Eight,O
novel,O
and,O
three,O
previously,O
characterized,O
mutations,O
accounted,O
for,O
80,O
%,O
(,O
40,O
/,O
50,O
),O
of,O
mutant,O
chromosomes,O
.,O
The,O
A305E,B
missense,I
mutation,I
accounted,O
for,O
48,O
%,O
(,O
24,O
/,O
50,O
),O
of,O
mutant,O
chromosomes,O
in,O
patients,O
of,O
western,O
European,O
descent,O
",",O
while,O
the,O
two,O
predominant,O
Jewish,B
mutations,I
each,O
accounted,O
for,O
a,O
single,O
mutant,O
chromosome,O
.,O
The,O
eight,O
novel,O
mutations,O
identified,O
included,O
1,O
-,O
and,O
4,O
-,O
bp,O
deletions,O
(,O
32,B
deltaT,I
and,O
876,B
deltaAGAA,I
",",O
respectively,O
),O
and,O
I16T,B
",",O
G27R,B
",",O
D114E,B
",",O
G123E,B
",",O
C152Y,B
",",O
and,O
R168C,B
missense,O
mutations,O
.,O
The,O
homozygous,O
32,B
deltaT,I
deletion,O
was,O
identified,O
in,O
the,O
only,O
known,O
patient,O
of,O
African,O
-,O
American,O
origin,O
with,O
Canavan,B
disease,I
.,O
The,O
heterozygosity,O
for,O
876,O
deltaAGAA,B
mutation,O
was,O
identified,O
in,O
three,O
independent,O
patients,O
from,O
England,O
.,O
Six,O
single,O
-,O
base,O
changes,O
leading,O
to,O
missense,O
mutations,O
were,O
identified,O
in,O
patients,O
from,O
Turkey,O
(,O
D114E,B
",",O
R168C,B
),O
",",O
The,O
Netherlands,O
(,O
I16T,B
),O
",",O
Germany,O
(,O
G27R,B
),O
",",O
Ireland,O
(,O
C152Y,B
),O
",",O
and,O
Canada,O
(,O
G123E,B
),O
.,O
A,O
PCR,O
-,O
based,O
protocol,O
is,O
described,O
that,O
was,O
used,O
to,O
introduce,O
mutations,O
in,O
wild,O
-,O
type,O
cDNA,O
.,O
In,O
vitro,O
expression,O
of,O
mutant,O
cDNA,O
clones,O
demonstrated,O
that,O
all,O
of,O
these,O
mutations,O
led,O
to,O
a,O
deficiency,O
of,O
ASPA,B
and,O
should,O
therefore,O
result,O
in,O
Canavan,B
disease,I
.,O
Identification,O
and,O
chromosomal,O
localization,O
of,O
Atm,B
",",O
the,O
mouse,O
homolog,O
of,O
the,O
ataxia,B
-,I
telangiectasia,I
gene,I
.,O
Atm,B
",",O
the,O
mouse,O
homolog,O
of,O
the,O
human,O
ATM,B
gene,O
defective,O
in,O
ataxia,B
-,I
telangiectasia,I
(,O
A,O
-,O
T,O
),O
",",O
has,O
been,O
identified,O
.,O
The,O
entire,O
coding,O
sequence,O
of,O
the,O
Atm,B
transcript,O
was,O
cloned,O
and,O
found,O
to,O
contain,O
an,O
open,O
reading,O
frame,O
encoding,O
a,O
protein,O
of,O
3066,O
amino,O
acids,O
with,O
84,O
%,O
overall,O
identity,O
and,O
91,O
%,O
similarity,O
to,O
the,O
human,O
ATM,B
protein,O
.,O
Variable,O
levels,O
of,O
expression,O
of,O
Atm,B
were,O
observed,O
in,O
different,O
tissues,O
.,O
Fluorescence,O
in,O
situ,O
hybridization,O
and,O
linkage,O
analysis,O
located,O
the,O
Atm,B
gene,O
on,O
mouse,O
chromosome,O
9,O
",",O
band,O
9C,O
",",O
in,O
a,O
region,O
homologous,O
to,O
the,O
ATM,B
region,O
on,O
human,O
chromosome,O
11q22,O
-,O
q23,O
.,O
The,O
mouse,O
homolog,O
of,O
the,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
protein,I
(,I
WASP,I
),I
gene,O
is,O
highly,O
conserved,O
and,O
maps,O
near,O
the,O
scurfy,B
(,O
sf,O
),O
mutation,O
on,O
the,O
X,O
chromosome,O
.,O
The,O
mouse,O
WASP,B
gene,I
",",O
the,O
homolog,O
of,O
the,O
gene,O
mutated,O
in,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
",",O
has,O
been,O
isolated,O
and,O
sequenced,O
.,O
the,O
predicted,O
amino,O
acid,O
sequence,O
is,O
86,O
%,O
identical,O
to,O
the,O
human,O
WASP,B
sequence,I
.,O
A,O
distinct,O
feature,O
of,O
the,O
mouse,O
gene,O
is,O
an,O
expanded,O
polymorphic,O
GGA,O
trinucleotide,O
repeat,O
that,O
codes,O
for,O
polyglycine,O
and,O
varies,O
from,O
15,O
to,O
17,O
triplets,O
in,O
different,O
Mus,O
musculus,O
strains,O
.,O
The,O
genomic,O
structure,O
of,O
the,O
mouse,O
WASP,B
gene,O
is,O
expressed,O
as,O
an,O
approximately,O
2,O
.,O
4,O
-,O
kb,O
mRNA,O
in,O
thymus,O
and,O
spleen,O
.,O
Chromosomal,O
mapping,O
in,O
an,O
interspecific,O
M,O
.,O
Musculus,O
/,O
M,O
.,O
spretus,O
backcross,O
placed,O
the,O
Wasp,B
locus,O
near,O
the,O
centromere,O
of,O
the,O
mouse,O
X,O
chromosome,O
",",O
inseparable,O
from,O
Gata1,B
",",O
Tcfe3,B
",",O
and,O
scurfy,B
(,O
sf,B
),O
.,O
This,O
localization,O
makes,O
Wasp,B
a,O
candidate,O
for,O
involvement,O
in,O
scurfy,B
",",O
a,O
T,B
cell,I
-,I
mediated,I
fatal,I
lymphoreticular,I
disease,I
of,I
mice,I
that,O
has,O
previously,O
been,O
proposed,O
as,O
a,O
mouse,B
homolog,I
of,I
Wiskott,I
-,I
Aldrich,I
syndrome,I
.,O
Northern,O
analysis,O
of,O
sf,O
tissue,O
samples,O
indicated,O
the,O
presence,O
of,O
WASP,B
mRNA,I
in,I
liver,I
and,O
skin,I
",",O
presumably,O
as,O
a,O
consequence,O
of,O
lymphocytic,B
infiltration,I
",",O
but,O
non,O
abnormalities,O
in,O
the,O
amount,O
or,O
size,O
of,O
mRNA,B
present,O
.,O
Colchicine,B
in,O
breast,O
milk,O
of,O
patients,O
with,O
familial,B
Mediterranean,I
fever,I
.,O
OBJECTIVE,O
.,O
To,O
clarify,O
whether,O
colchicine,O
is,O
excreted,O
in,O
breast,O
milk,O
",",O
and,O
to,O
compare,O
its,O
concentrations,O
in,O
the,O
serum,O
and,O
breast,O
milk,O
of,O
lactating,O
women,O
who,O
have,O
familial,B
Mediterranean,I
fever,I
(,O
FMF,O
),O
.,O
METHODS,O
.,O
Using,O
a,O
specific,O
radioimmunoassay,O
",",O
we,O
determined,O
colchicine,O
concentrations,O
in,O
the,O
serum,O
and,O
breast,O
milk,O
of,O
4,O
patients,O
at,O
various,O
time,O
points,O
",",O
following,O
oral,O
administration,O
of,O
the,O
drug,O
.,O
The,O
study,O
evaluated,O
4,O
patients,O
with,O
FMF,B
who,O
had,O
been,O
taking,O
colchicine,B
on,O
a,O
long,O
-,O
term,O
basis,O
.,O
RESULTS,O
.,O
Colchicine,B
was,O
found,O
to,O
be,O
excreted,O
in,O
breast,O
milk,O
.,O
Its,O
levels,O
ranged,O
between,O
1,O
.,O
9,O
and,O
8,O
.,O
6,O
ng,O
/,O
ml,O
",",O
which,O
were,O
similar,O
to,O
those,O
found,O
in,O
the,O
serum,O
(,O
parallel,O
concentration,O
time,O
curves,O
),O
.,O
However,O
",",O
there,O
appeared,O
to,O
be,O
a,O
considerable,O
variation,O
in,O
colchicine,B
milk,O
concentration,O
among,O
the,O
different,O
patients,O
",",O
which,O
might,O
be,O
related,O
to,O
individual,O
breast,O
milk,O
composition,O
and,O
",",O
possibly,O
",",O
to,O
other,O
nutritional,O
or,O
metabolic,O
factors,O
.,O
CONCLUSION,O
.1,O
The,O
extensive,O
peripheral,O
tissue,O
binding,O
and,O
relatively,O
low,O
concentration,O
of,O
colchicine,B
in,O
breast,O
milk,O
suggests,O
that,O
the,O
amount,O
ingested,O
by,O
the,O
infant,O
is,O
small,O
.,O
Furthermore,O
",",O
based,O
on,O
our,O
clinical,O
experience,O
",",O
nursing,O
appears,O
to,O
be,O
safe,O
for,O
lactating,O
women,O
with,O
FMF,B
who,O
continue,O
to,O
take,O
colchicine,O
.,O
Abnormal,O
myotonic,B
dystrophy,I
protein,I
kinase,I
levels,O
produce,O
only,O
mild,O
myopathy,B
in,O
mice,O
.,O
Myotonic,B
dystrophy,I
(,O
DM,B
),O
is,O
commonly,O
associated,O
with,O
CTG,O
repeat,O
expansions,O
within,O
the,O
gene,O
for,O
DM,B
-,I
protein,I
kinase,I
(,O
DMPK,B
),O
.,O
The,O
effect,O
of,O
altered,O
expression,O
levels,O
of,O
DMPK,B
",",O
which,O
is,O
ubiquitously,O
expressed,O
in,O
all,O
muscle,O
cell,O
lineages,O
during,O
development,O
",",O
was,O
examined,O
by,O
disrupting,O
the,O
endogenous,O
Dmpk,B
gene,O
and,O
overexpressing,O
a,O
normal,O
human,O
DMPK,B
transgene,O
in,O
mice,O
.,O
Nullizygous,O
(,O
-,O
/,O
-,O
),O
mice,O
showed,O
only,O
inconsistent,O
and,O
minor,O
size,O
changes,O
in,O
head,O
and,O
neck,O
muscle,O
fibres,O
at,O
older,O
age,O
",",O
animals,O
with,O
the,O
highest,O
DMPK,O
transgene,O
expression,O
showed,O
hypertrophic,B
cardiomyopathy,I
and,O
enhanced,O
neonatal,O
mortality,O
.,O
However,O
",",O
both,O
models,O
lack,O
other,O
frequent,O
DM,B
symptoms,O
including,O
the,O
fibre,O
-,O
type,O
dependent,O
atrophy,O
",",O
myotonia,O
",",O
cataract,B
and,O
male,O
-,O
infertility,O
.,O
These,O
results,O
strengthen,O
the,O
contention,O
that,O
simple,O
loss,O
-,O
or,O
gain,O
-,O
of,O
-,O
-,O
expression,O
of,O
DMPK,B
is,O
not,O
the,O
only,O
crucial,O
requirement,O
for,O
development,O
of,O
the,O
disease,O
.,O
Mice,O
lacking,O
the,O
myotonic,B
dystrophy,I
protein,I
kinase,I
develop,O
a,O
late,O
onset,O
progressive,O
myopathy,O
.,O
Myotonic,B
dystrophy,I
(,O
DM,B
),O
is,O
an,O
autosomal,O
dominant,O
disorder,O
resulting,O
from,O
the,O
expansion,O
of,O
a,O
CTG,B
repeat,I
in,O
the,O
3,O
untranslated,O
region,O
of,O
a,O
putative,O
protein,O
kinase,O
(,O
DMPK,B
),O
.,O
To,O
elucidate,O
the,O
role,O
of,O
DMPK,B
in,O
DM,B
pathogenesis,O
we,O
have,O
developed,O
Dmpk,B
deficient,O
(,O
Dmpk,I
-,I
/,I
-,I
),O
mice,O
.,O
Dmpk,B
-,I
/,I
-,I
mice,O
develop,O
a,O
late,O
-,O
onset,O
",",O
progressive,O
skeletal,O
myopathy,O
that,O
shares,O
some,O
pathological,O
features,O
with,O
DM,B
.,O
Muscles,O
from,O
mature,O
mice,O
show,O
variation,O
in,O
fibre,O
size,O
",",O
increased,O
fibre,O
degeneration,O
and,O
fibrosis,O
.,O
Adult,O
Dmpk,B
-,O
/,O
-,O
mice,O
show,O
ultrastructural,O
changes,O
in,O
muscle,O
and,O
a,O
50,O
%,O
decrease,O
in,O
force,O
generation,O
compared,O
to,O
young,O
mice,O
.,O
Our,O
results,O
indicate,O
that,O
DMPK,B
may,O
be,O
necessary,O
for,O
the,O
maintenance,O
of,O
skeletal,O
muscle,O
structure,O
and,O
function,O
and,O
suggest,O
that,O
a,O
decrease,O
in,O
DMPK,B
levels,O
may,O
contribute,O
to,O
DM,B
pathology,O
.,O
The,O
tumor,B
suppressor,I
gene,I
Brca1,B
is,O
required,O
for,O
embryonic,O
cellular,O
proliferation,O
in,O
the,O
mouse,O
.,O
Mutations,O
of,O
the,O
BRCA1,B
gone,O
in,O
humans,O
are,O
associated,O
with,O
predisposition,O
to,O
breast,B
and,O
ovarian,B
cancers,O
.,O
We,O
show,O
here,O
that,O
Brca1,B
+,O
/,O
-,O
mice,O
are,O
normal,O
and,O
fertile,O
and,O
lack,O
tumors,O
by,O
age,O
eleven,O
months,O
.,O
Homozygous,O
Brca1,B
(,O
5,O
-,O
6,O
),O
mutant,O
mice,O
die,O
before,O
day,O
7,O
.,O
5,O
of,O
embryogenesis,O
.,O
Mutant,O
embryos,O
are,O
poorly,O
developed,O
",",O
with,O
no,O
evidence,O
of,O
mesoderm,O
formation,O
.,O
The,O
extraembryonic,O
region,O
is,O
abnormal,O
",",O
but,O
aggregation,O
with,O
wild,O
-,O
type,O
tetraploid,O
embryos,O
does,O
not,O
rescue,O
the,O
lethality,O
.,O
In,O
vivo,O
",",O
mutant,O
embryos,O
do,O
not,O
exhibit,O
increased,O
apoptosis,B
but,O
show,O
reduced,O
cell,O
proliferation,O
accompanied,O
by,O
decreased,O
expression,O
of,O
cyclin,B
E,I
and,O
mdm,B
-,I
2,I
",",O
a,O
regulator,O
of,O
p53,B
activity,O
.,O
The,O
expression,O
of,O
cyclin,B
-,I
dependent,I
kinase,I
inhibitor,I
p21,I
is,O
dramatically,O
increased,O
in,O
the,O
mutant,O
embryos,O
.,O
Buttressing,O
these,O
in,O
vivo,O
observations,O
is,O
the,O
fact,O
that,O
mutant,O
blastocyst,O
growth,O
is,O
grossly,O
impaired,O
in,O
vitro,O
.,O
Thus,O
",",O
the,O
death,O
of,O
Brca1,B
(,O
5,O
-,O
6,O
),O
mutant,O
embryos,O
prior,O
to,O
gastrulation,O
may,O
be,O
due,O
to,O
a,O
failure,O
of,O
the,O
proliferative,O
burst,O
required,O
for,O
the,O
development,O
of,O
the,O
different,O
germ,O
layers,O
.,O
Increased,O
coronary,B
heart,I
disease,I
in,O
Japanese,O
-,O
American,O
men,O
with,O
mutation,O
in,O
the,O
cholesteryl,O
ester,O
transfer,O
protein,O
gene,O
despite,O
increased,O
HDL,B
levels,O
.,O
Plasma,O
high,B
density,I
lipoprotein,I
(,O
HDL,B
),O
levels,O
are,O
strongly,O
genetically,O
determined,O
and,O
show,O
a,O
general,O
inverse,O
relationship,O
with,O
coronary,B
heart,I
disease,I
(,O
CHD,B
),O
.,O
The,O
cholesteryl,B
ester,I
transfer,I
protein,I
(,O
CETP,B
),O
mediates,O
the,O
transfer,O
of,O
cholesteryl,O
esters,O
from,O
HDL,O
to,O
other,O
lipoproteins,O
and,O
is,O
a,O
key,O
participant,O
in,O
the,O
reverse,O
transport,O
of,O
cholesterol,O
from,O
the,O
periphery,O
to,O
the,O
liver,O
.,O
A,O
high,O
prevalence,O
of,O
two,O
different,O
CETP,B
gene,I
mutations,I
(,O
D442G,B
",",O
5,O
.,O
1,O
%,O
;,O
intron,O
14G,B
A,I
",",O
0,O
.,O
5,O
%,O
)-2,O
",",O
was,O
found,O
in,O
3,O
",",O
469,O
men,O
of,O
Japanese,O
ancestry,O
in,O
the,O
Honolulu,O
Heart,O
Program,O
and,O
mutations,O
were,O
associated,O
with,O
decreased,O
CETP,B
(-26,O
35,O
%,O
),O
and,O
increased,O
HDL,B
chol,I
levels,O
(,O
+,O
10,O
%,O
for,O
D442G,B
),O
However,O
",",O
the,O
overall,O
prevalence,O
of,O
definite,O
CHD,B
was,O
21,O
%,O
in,O
men,O
with,O
mutations,O
and,O
16,O
%,O
in,O
men,O
without,O
mutations,O
The,O
relative,O
risk,O
(,O
RR,O
),O
of,O
CHD,B
was,O
1,O
.,O
43,O
in,O
men,O
with,O
mutations,O
(,O
P,O
<,O
.,O
05,O
),O
;,O
after,O
adjustment,O
for,O
CHD,O
risk,O
factors,O
",",O
the,O
RR,O
was,O
1,O
.,O
55,O
(,O
P,O
=,O
.,O
02,O
),O
;,O
after,O
additional,O
adjustment,O
for,O
HDL,O
levels,O
",",O
the,O
RR,O
was,O
1,O
.,O
68,O
(,O
P,O
=,O
.,O
008,O
),O
.,O
Similar,O
RR,O
values,O
were,O
obtained,O
for,O
the,O
D442G,O
mutation,O
alone,O
.,O
Increased,O
CHD,B
in,O
men,O
with,O
mutations,O
was,O
primarily,O
observed,O
for,O
HDL,O
chol,O
41,O
-,O
60,O
mg,O
/,O
dl,O
;,O
for,O
HDL,O
chol,O
>,O
60,O
mg,O
/,O
dl,O
men,O
with,O
and,O
without,O
mutations,O
had,O
low,O
CHD,B
prevalence,O
.,O
Thus,O
",",O
genetic,O
CETP,B
deficiency,O
appears,O
to,O
be,O
an,O
independent,O
risk,O
factor,O
for,O
CHD,B
",",O
primarily,O
due,O
to,O
increased,O
CHD,B
prevalence,O
in,O
men,O
with,O
the,O
D442G,B
mutation,O
and,O
HDL,B
cholesterol,O
between,O
41,O
and,O
60,O
mg,O
/,O
dl,O
.,O
The,O
findings,O
suggest,O
that,O
both,O
HDL,B
concentration,O
and,O
the,O
dynamics,O
of,O
cholesterol,O
transport,O
through,O
HDL,B
(,O
i,O
.,O
e,O
.1,O
",2",O
reverse,O
cholesterol,B
transport,O
)6,O
determine,O
the,O
anti,O
-10,O
atherogenicity,O
of,O
the,O
HDL,B
fraction,O
.,O
Mapping,O
the,O
homolog,O
of,O
the,O
human,O
Rb1,B
gene,I
to,O
chromosome,O
14,O
of,O
higher,O
primates,O
.,O
The,O
Rb1,B
gene,I
has,O
been,O
implicated,O
with,O
retinoblastoma,B
and,O
is,O
located,O
on,O
human,O
Chromosome,O
(,O
Chr,O
),O
13q14,O
.,O
2,O
2,O
.,O
A,O
unique,O
sequence,O
human,O
Rb1,B
cosmid,O
DNA,O
probe,O
has,O
been,O
used,O
to,O
localize,O
this,O
region,O
on,O
apes,O
Chr,O
14,O
by,O
the,O
FISH,O
technique,O
.,O
The,O
conservation,O
of,O
the,O
Rb1,B
gene,I
in,O
higher,O
primates,O
at,O
the,O
corresponding,O
equivalent,O
chromosome,O
locus,O
(,O
14q14,O
),O
of,O
the,O
human,O
may,O
serve,O
as,O
a,O
phylogenetic,O
marker,O
to,O
further,O
trace,O
the,O
evolutionary,O
pathway,O
of,O
human,O
descent,O
.,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
:,O
no,O
strict,O
genotype,O
-,O
phenotype,O
correlations,O
but,O
clustering,O
of,O
missense,O
mutations,O
in,O
the,O
amino,O
-,O
terminal,O
part,O
of,O
the,O
WASP,B
gene,I
product,I
.,O
The,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
protein,I
(,O
WASP,B
),O
gene,O
was,O
found,O
to,O
be,O
mutated,O
in,O
patients,O
presenting,O
with,O
WAS,B
and,O
in,O
patients,O
showing,O
X,B
-,I
linked,I
thrombocytopenia,I
.,O
Mutation,O
analysis,O
in,O
19,O
families,O
of,O
German,O
",",O
Swiss,O
and,O
Turkish,O
descent,O
by,O
single,O
-,O
strand,O
conformation,O
polymorphism,O
and,O
sequencing,O
resulted,O
in,O
the,O
detection,O
of,O
seven,O
novel,O
and,O
10,O
known,O
mutations,O
.,O
A,O
striking,O
clustering,O
of,O
missense,B
mutations,I
in,O
the,O
first,O
four,O
exons,O
contrasted,O
with,O
a,O
random,O
distribution,O
of,O
nonsense,B
mutations,I
.,O
More,O
than,O
85,O
%,O
of,O
all,O
known,O
missense,B
mutations,I
were,O
localized,O
in,O
the,O
amino,O
-,O
terminal,O
stretch,O
of,O
the,O
WASP,O
gene,O
product,O
;,O
this,O
region,O
contained,O
a,O
mutational,O
hot,O
spot,O
at,O
codon,O
86,O
.,O
No,O
genotype,O
-,O
phenotype,O
correlation,O
emerged,O
after,O
a,O
comparison,O
of,O
the,O
identified,O
mutations,O
with,O
the,O
resulting,O
clinical,O
picture,O
for,O
a,O
classical,O
WAS,B
phenotype,I
.,O
A,O
substitution,O
at,O
codon,O
86,O
resulted,O
in,O
an,O
extremely,O
variable,O
expression,O
of,O
the,O
disease,B
in,O
a,O
large,O
Swiss,O
family,O
.,O
An,O
extended,O
homology,O
search,O
revealed,O
a,O
distant,O
relationship,O
of,O
this,O
stretch,O
to,O
the,O
vasodilator,O
-,O
stimulated,O
phosphoprotein,O
(,O
VASP,B
),O
",",O
which,O
is,O
involved,O
in,O
the,O
maintenance,O
of,O
cyto,O
-,O
architecture,O
by,O
interacting,O
with,O
actin,O
-,O
like,O
filaments,O
.,O
Influence,O
of,O
PAX6,B
gene,I
dosage,O
on,O
development,O
:,O
overexpression,O
causes,O
severe,O
eye,O
abnormalities,O
.,O
Aniridia,B
in,O
man,O
and,O
Small,B
eye,I
in,O
mice,O
are,O
semidominant,O
developmental,O
disorders,O
caused,O
by,O
mutations,O
within,O
the,O
paired,O
box,O
gene,O
PAX6,B
.,O
Whereas,O
heterozygotes,O
suffer,O
from,O
iris,O
hypoplasia,O
",",O
homozygous,O
mice,O
lack,O
eyes,O
and,O
nasal,O
cavities,O
and,O
exhibit,O
brain,O
abnormalities,O
.,O
To,O
investigate,O
the,O
role,O
of,O
gene,O
dosage,O
in,O
more,O
detail,O
",",O
we,O
have,O
generated,O
yeast,O
artificial,O
chromosome,O
transgenic,O
mice,O
carrying,O
the,O
human,O
PAX6,B
locus,O
.,O
When,O
crossed,O
onto,O
the,O
Small,B
eye,I
background,I
",",O
the,O
transgene,O
rescues,O
the,O
mutant,O
phenotype,O
.,O
Strikingly,O
",",O
mice,O
carrying,O
multiple,O
copies,O
on,O
a,O
wild,O
-,O
type,O
background,O
show,O
specific,O
developmental,O
abnormalities,O
of,O
the,O
eye,B
",",O
but,O
not,O
of,O
other,O
tissues,O
expressing,O
the,O
gene,O
.,O
Thus,O
",",O
at,O
least,O
five,O
different,O
eye,B
phenotypes,O
are,O
associated,O
with,O
changes,O
in,O
PAX6,B
expression,O
.,O
We,O
provide,O
evidence,O
that,O
not,O
only,O
reduced,O
",",O
but,O
also,O
increased,O
levels,O
of,O
transcriptional,O
regulators,O
can,O
cause,O
developmental,O
defects,O
.,O
Heterodimer,O
formation,O
and,O
activity,O
in,O
the,O
human,O
enzyme,O
galactose,B
-,I
1,I
-,I
phosphate,I
uridylyltransferase,I
.,O
One,O
of,O
the,O
fundamental,O
questions,O
concerning,O
expression,O
and,O
function,O
of,O
dimeric,O
enzymes,O
involves,O
the,O
impact,O
of,O
naturally,O
occurring,O
mutations,O
on,O
subunit,O
assembly,O
and,O
heterodimer,O
activity,O
.,O
This,O
question,O
is,O
of,O
particular,O
interest,O
for,O
the,O
human,O
enzyme,O
galactose,B
-,I
l,I
-,I
phosphate,I
uridylyl,I
-,I
transferase,I
(,O
GALT,B
),O
",",O
impairment,O
of,O
which,O
results,O
in,O
the,O
inherited,O
metabolic,O
disorder,O
galactosemia,B
",",O
because,O
many,O
if,O
not,O
most,O
patients,O
studied,O
to,O
date,O
are,O
compound,O
heterozygotes,O
rather,O
than,O
TRUE,O
molecular,O
homozygotes,O
.,O
Furthermore,O
",",O
the,O
broad,O
range,O
of,O
phenotypic,O
severity,O
observed,O
in,O
these,O
patients,O
raises,O
the,O
possibility,O
that,O
allelic,O
combination,O
",",O
not,O
just,O
allelic,O
constitution,O
",",O
may,O
play,O
some,O
role,O
in,O
determining,O
outcome,O
.,O
In,O
the,O
work,O
described,O
herein,O
",",O
we,O
have,O
selected,O
two,O
distinct,O
naturally,O
occurring,O
null,O
mutations,O
of,O
GALT,B
",",O
Q188R,B
and,O
R333W,B
",",O
and,O
asked,O
the,O
questions,O
(,O
i,O
),O
what,O
are,O
the,O
impacts,O
of,O
these,O
mutations,O
on,O
subunit,O
assembly,O
",",O
and,O
(,O
ii,O
),O
if,O
heterodimers,O
do,O
form,O
",",O
are,O
they,O
active,O
.,O
To,O
answer,O
these,O
questions,O
",",O
we,O
have,O
established,O
a,O
yeast,O
system,O
for,O
the,O
coexpression,O
of,O
epitope,O
-,O
tagged,O
alleles,O
of,O
human,O
GALT,B
and,O
investigated,O
both,O
the,O
extent,O
of,O
specific,O
GALT,B
subunit,O
interactions,O
and,O
the,O
activity,O
of,O
defined,O
heterodimer,O
pools,O
.,O
We,O
have,O
found,O
that,O
both,O
homodimers,O
and,O
heterodimers,O
do,O
form,O
involving,O
each,O
of,O
the,O
mutant,O
subunits,O
tested,O
and,O
that,O
both,O
heterodimer,O
pools,O
retain,O
substantial,O
enzymatic,O
activity,O
.,O
These,O
results,O
are,O
significant,O
not,O
only,O
in,O
terms,O
of,O
their,O
implications,O
for,O
furthering,O
our,O
understanding,O
of,O
galactosemia,B
and,O
GALT,B
holoenzyme,O
structure,O
-,O
function,O
relationships,O
but,O
also,O
because,O
the,O
system,O
described,O
may,O
serve,O
as,O
a,O
model,O
for,O
similar,O
studies,O
of,O
other,O
complexes,O
composed,O
of,O
multiple,O
subunits,O
.,O
Cleavage,O
of,O
huntingtin,O
by,O
apopain,O
",",O
a,O
proapoptotic,O
cysteine,O
protease,O
",",O
is,O
modulated,O
by,O
the,O
polyglutamine,O
tract,O
.,O
Apoptosis,O
has,O
recently,O
been,O
recognized,O
as,O
a,O
mode,O
of,O
cell,O
death,O
in,O
Huntington,B
disease,I
(,O
HD,O
),O
.,O
Apopain,O
",",O
a,O
human,O
counterpart,O
of,O
the,O
nematode,O
cysteine,O
protease,O
death,O
-,O
gene,O
product,O
",",O
CED,O
-,O
3,O
",",O
has,O
a,O
key,O
role,O
in,O
proteolytic,O
events,O
leading,O
to,O
apoptosis,O
.,O
Here,O
we,O
show,O
that,O
apoptotic,O
extracts,O
and,O
apopain,O
itself,O
specifically,O
cleave,O
the,O
HD,B
gene,I
product,I
",",O
huntingtin,B
.,O
The,O
rate,O
of,O
cleavage,O
increases,O
with,O
the,O
length,O
of,O
the,O
huntingtin,B
polyglutamine,I
tract,I
",",O
providing,O
an,O
explanation,O
for,O
the,O
gain,O
-,O
of,O
-,O
function,O
associated,O
with,O
CAG,B
expansion,O
.,O
Our,O
results,O
show,O
that,O
huntingtin,B
is,O
cleaved,O
by,O
cysteine,O
proteases,O
and,O
suggest,O
that,O
HD,B
might,O
be,O
a,O
disorder,O
of,O
inappropriate,O
apoptosis,O
.,O
The,O
5,O
',O
end,O
of,O
the,O
BRCA1,B
gene,O
lies,O
within,O
a,O
duplicated,O
region,O
of,O
human,O
chromosome,O
17q21,O
.,O
To,O
begin,O
to,O
address,O
the,O
hypothesis,O
that,O
abnormal,O
regulation,O
of,O
the,O
breast,O
/,O
ovarian,O
cancer,B
susceptibility,I
gene,O
BRCA1,B
is,O
a,O
critical,O
step,O
in,O
sporadic,O
breast,O
/,O
ovarian,O
tumorigenesis,O
",",O
we,O
have,O
determined,O
the,O
detailed,O
structure,O
of,O
the,O
BRCA1,B
genomic,O
region,O
.,O
We,O
show,O
that,O
this,O
region,O
of,O
the,O
genome,O
contains,O
a,O
tandem,O
duplication,O
of,O
approximately,O
30,O
kilobases,O
",",O
which,O
results,O
in,O
two,O
copies,O
of,O
BRCA1,B
exons,O
1,B
and,O
2,I
",",O
of,O
exons,O
1,B
and,O
3,I
of,O
the,O
adjacent,O
1A1,B
-,I
3B,I
gene,I
and,O
of,O
the,O
previously,O
reported,O
295,O
base,O
pair,O
intergenic,O
region,O
.,O
Sequence,O
analysis,O
of,O
the,O
duplicated,O
exons,O
of,O
BRCA1,B
and,O
1A1,B
-,I
3B,I
and,O
flanking,O
genomic,O
DNA,O
reveals,O
maintenance,O
of,O
the,O
intron,O
-,O
exon,O
structure,O
and,O
a,O
high,O
degree,O
of,O
nucleotide,O
sequence,O
identity,O
",",O
suggesting,O
that,O
these,O
are,O
non,O
-,O
processed,O
pseudogenes,O
and,O
that,O
the,O
duplication,O
is,O
a,O
recent,O
event,O
in,O
evolutionary,O
terms,O
.,O
We,O
also,O
show,O
that,O
a,O
processed,O
pseudogene,O
of,O
the,O
acidic,O
ribosomal,O
phosphoprotein,O
P1,B
(,O
ARPP1,B
),O
is,O
inserted,O
directly,O
upstream,O
of,O
pseudo,O
-,O
BRCA1,B
exon,O
1A,O
.,O
We,O
believe,O
that,O
these,O
findings,O
could,O
not,O
only,O
confound,O
BRCA1,B
mutation,O
analysis,O
",",O
but,O
could,O
have,O
implications,O
for,O
the,O
normal,O
and,O
abnormal,O
regulation,O
of,O
BRCA1,B
transcription,O
",",O
translation,O
and,O
function,O
.,O
Deletion,O
of,O
small,O
nuclear,O
ribonucleoprotein,O
polypeptide,O
N,O
(,O
SNRPN,B
),O
in,O
Prader,O
-,O
Willi,O
syndrome,O
detected,O
by,O
fluorescence,O
in,O
situ,O
hybridization,O
:,O
two,O
sibs,O
with,O
the,O
typical,O
phenotype,O
without,O
a,O
cytogenetic,O
deletion,O
in,O
chromosome,O
15q,O
.,O
The,O
small,O
nuclear,O
ribonucleoprotein,O
polypeptide,O
N,O
(,O
SNRPN,B
),O
gene,O
is,O
regarded,O
as,O
one,O
of,O
the,O
candidates,O
for,O
Prader,O
-,O
Willi,O
syndrome,O
(,O
PWS,B
),O
.,O
We,O
describe,O
two,O
sibs,O
with,O
typical,O
PWS,B
presenting,O
deletion,O
of,O
SNRPN,B
detected,O
by,O
fluorescence,O
in,O
situ,O
hybridization,O
(,O
FISH,O
),O
.,O
Neither,O
a,O
cytogenetically,O
detectable,O
15q12,B
deletion,O
nor,O
a,O
deletion,O
for,O
the,O
D15S11,B
",",O
D15S10,B
",",O
and,O
GABRB3,B
cosmid,O
probes,O
were,O
found,O
in,O
either,O
patient,O
.,O
This,O
implies,O
a,O
smaller,O
deletion,O
limited,O
to,O
the,O
PWS,B
critical,O
region,O
.,O
FISH,O
with,O
a,O
SNRPN,O
probe,O
will,O
permit,O
analysis,O
of,O
PWS,B
patients,O
with,O
limited,O
deletions,O
not,O
detectable,O
with,O
other,O
probes,O
.,O
Expression,O
of,O
the,O
von,B
Hippel,I
-,I
Lindau,I
disease,I
tumour,I
suppressor,I
gene,I
during,O
human,O
embryogenesis,O
.,O
The,O
von,B
Hippel,I
-,I
Lindau,I
(,O
VHL,B
),O
disease,I
product,I
is,O
thought,O
to,O
down,O
-,O
regulate,O
transcription,O
by,O
antagonizing,O
elongin,O
-,O
enhanced,O
transcriptional,O
elongation,O
.,O
Germline,B
VHL,I
gene,I
mutations,O
predispose,O
to,O
the,O
development,O
of,O
retinal,B
",",O
cerebellar,B
and,O
spinal,B
haemangioblastomas,O
",",O
renal,B
cell,I
carcinoma,I
and,O
phaeochromocytoma,B
.,O
In,O
addition,O
",",O
somatic,O
Inactivation,O
of,O
the,O
VHL,B
gene,I
is,O
frequent,O
in,O
sporadic,O
renal,B
cell,I
carcinoma,I
and,O
haemangioblastoma,B
.,O
Regulation,O
of,O
transcript,O
elongation,O
is,O
an,O
important,O
control,O
mechanism,O
for,O
gene,O
expression,O
and,O
the,O
VHL,B
gene,I
might,O
modify,O
the,O
expression,O
of,O
proto,O
-,O
oncogenes,O
and,O
growth,O
suppressor,O
genes,O
during,O
embryogenesis,O
.,O
We,O
therefore,O
investigated,O
the,O
expression,O
of,O
VHL,B
mRNA,I
during,O
human,O
embryogenesis,O
by,O
in,O
situ,O
hybridization,O
studies,O
at,O
4,O
",",O
6,O
and,O
10,O
weeks,O
post,O
conception,O
.,O
Although,O
VHL,B
mRNA,I
was,O
expressed,O
in,O
all,O
three,O
germ,O
layers,O
",",O
strong,O
expression,O
was,O
noted,O
in,O
the,O
central,O
nervous,O
system,O
",",O
kidneys,B
",",O
testis,B
and,O
lung,B
.,O
Within,O
the,O
kidney,B
",",O
VHL,B
mRNA,I
was,O
differentially,O
expressed,O
within,O
renal,O
tubules,O
suggesting,O
that,O
the,O
VHL,B
gene,O
product,O
may,O
have,O
a,O
specific,O
role,O
in,O
kidney,B
development,O
.,O
Two,O
alternatively,O
spliced,O
VHL,B
mRNAs,O
characterized,O
by,O
inclusion,O
(,O
isoform,O
I,O
),O
or,O
exclusion,O
(,O
isoform,O
II,O
),O
of,O
exon,O
2,O
are,O
transcribed,O
in,O
adult,O
tissues,O
.,O
To,O
investigate,O
if,O
the,O
two,O
isoforms,O
are,O
differentially,O
expressed,O
during,O
embryogenesis,O
",",O
VHL,B
mRNA,O
was,O
reverse,O
transcribed,O
from,O
13,O
fetal,O
tissues,O
(,O
8,O
-,O
10,O
weeks,O
gestation,O
),O
.,O
The,O
quantitative,O
distribution,O
of,O
VHL,B
mRNA,I
within,O
fetal,O
tissues,O
reflected,O
that,O
seen,O
by,O
in,O
situ,O
hybridization,O
and,O
the,O
ratio,O
of,O
the,O
two,O
VHL,B
isoforms,O
was,O
similar,O
between,O
tissues,O
.,O
Although,O
the,O
genes,O
regulated,O
by,O
the,O
VHL,B
gene,I
product,I
have,O
not,O
yet,O
been,O
identified,O
",",O
our,O
findings,O
are,O
compatible,O
with,O
the,O
hypothesis,O
that,O
VHL,B
-,I
mediated,I
control,I
of,I
transcriptional,I
elongation,I
may,O
have,O
a,O
role,O
in,O
normal,O
human,O
development,O
.,O
.0,O
Genetic,O
heterogeneity,O
in,O
hereditary,O
breast,B
cancer,I
:,O
role,O
of,O
BRCA1,B
and,O
BRCA2,B
.,O
The,O
common,O
hereditary,O
forms,O
of,O
breast,B
cancer,I
have,O
been,O
largely,O
attributed,O
to,O
the,O
inheritance,O
of,O
mutations,O
in,O
the,O
BRCA1,B
or,O
BRCA2,B
genes,O
.,O
However,O
",",O
it,O
is,O
not,O
yet,O
clear,O
what,O
proportion,O
of,O
hereditary,O
breast,B
cancer,I
is,O
explained,O
by,O
BRCA1,B
and,O
BRCA2,B
or,O
by,O
some,O
other,O
unidentified,O
susceptibility,O
gene,O
(,O
s,O
),O
.,O
We,O
describe,O
the,O
proportion,O
of,O
hereditary,B
breast,I
cancer,I
explained,O
by,O
BRCA1,B
or,O
BRCA2,B
in,O
a,O
sample,O
of,O
North,O
American,O
hereditary,B
breast,I
cancers,I
and,O
assess,O
the,O
evidence,O
for,O
additional,O
susceptibility,O
genes,O
that,O
may,O
confer,O
hereditary,B
breast,I
or,O
ovarian,B
cancer,I
risk,O
.,O
Twenty,O
-,O
three,O
families,O
were,O
identified,O
through,O
two,O
high,O
-,O
risk,O
breast,I
cancer,I
research,O
programs,O
.,O
Genetic,O
analysis,O
was,O
undertaken,O
to,O
establish,O
linkage,O
between,O
the,O
breast,B
or,O
ovarian,B
cancer,I
cases,O
and,O
markers,O
on,O
chromosomes,O
17q,O
(,O
BRCA1,B
),O
and,O
13q,O
(,O
BRCA2,B
),O
.,O
Mutation,O
analysis,O
in,O
the,O
BRCA1,B
and,O
BRCA2,B
genes,O
was,O
also,O
undertaken,O
in,O
all,O
families,O
.,O
The,O
pattern,O
of,O
hereditary,O
cancer,O
in,O
14,O
(,O
61,O
%,O
),O
of,O
the,O
23,O
families,O
studied,O
was,O
attributed,O
to,O
BRCA1,B
by,O
a,O
combination,O
of,O
linkage,O
and,O
mutation,O
analyses,O
.,O
No,O
families,O
were,O
attributed,O
to,O
BRCA2,B
.,O
Five,O
families,O
(,O
22,O
%,O
),O
provided,O
evidence,O
against,O
linkage,O
to,O
both,O
BRCA1,B
and,O
BRCA2,B
.,O
No,O
BRCA1,B
or,O
BRCA2,B
mutations,O
were,O
detected,O
in,O
these,O
five,O
families,O
.,O
The,O
BRCA1,B
or,O
BRCA2,B
status,O
of,O
four,O
families,O
(,O
17,O
%,O
),O
could,O
not,O
be,O
determined,O
.,O
BRCA1,B
and,O
BRCA2,B
probably,O
explain,O
the,O
majority,O
of,O
hereditary,O
breast,O
cancer,O
that,O
exists,O
in,O
the,O
North,O
American,O
population,O
.,O
However,O
",",O
one,O
or,O
more,O
additional,O
genes,O
may,O
yet,O
be,O
found,O
that,O
explain,O
some,O
proportion,O
of,O
hereditary,B
breast,I
cancer,I
.,O
An,O
intronic,B
mutation,I
in,O
a,O
lariat,O
branchpoint,O
sequence,O
is,O
a,O
direct,O
cause,O
of,O
an,O
inherited,B
human,I
disorder,I
(,O
fish,B
-,I
eye,I
disease,I
),O
.,O
The,O
first,O
step,O
in,O
the,O
splicing,O
of,O
an,O
intron,B
from,O
nuclear,B
precursors,I
of,I
mRNA,I
results,O
in,O
the,O
formation,O
of,O
a,O
lariat,O
structure,O
.,O
A,O
distinct,O
intronic,O
nucleotide,O
sequence,O
",",O
known,O
as,O
the,O
branchpoint,O
region,O
",",O
plays,O
a,O
central,O
role,O
in,O
this,O
process,O
.,O
We,O
here,O
describe,O
a,O
point,O
mutation,O
in,O
such,O
a,O
sequence,O
.,O
Three,O
sisters,O
were,O
shown,O
to,O
suffer,O
from,O
fish,B
-,I
eye,I
disease,I
(,O
FED,B
),O
",",O
a,O
disorder,O
which,O
is,O
caused,O
by,O
mutations,O
in,O
the,O
gene,O
coding,O
for,O
lecithin,B
cholesterol,I
acyltransferase,I
(,O
LCAT,B
),O
.,O
Sequencing,O
of,O
the,O
LCAT,B
gene,I
of,O
all,O
three,O
probands,O
revealed,O
compound,O
heterozygosity,O
for,O
a,O
missense,O
mutation,O
in,O
exon,O
4,O
which,O
is,O
reported,O
to,O
underlie,O
the,O
FED,B
phenotype,O
",",O
and,O
a,O
point,O
mutation,O
located,O
in,O
intron,O
4,O
(,O
IVS4,B
T,I
-,I
22C,I
),O
.,O
By,O
performing,O
in,O
vitro,O
expression,O
of,O
LCAT,B
minigenes,O
and,O
reverse,O
transcriptase,O
PCR,O
on,O
mRNA,O
isolated,O
from,O
leukocytes,O
of,O
the,O
patient,O
",",O
this,O
gene,O
defect,O
was,O
shown,O
to,O
cause,O
a,O
null,O
allele,O
as,O
the,O
result,O
of,O
complete,O
intron,O
retention,O
.,O
In,O
conclusion,O
",",O
we,O
demonstrated,O
that,O
a,O
point,O
mutation,O
in,O
a,O
lariat,O
branchpoint,O
consensus,O
sequence,O
causes,O
a,O
null,B
allele,I
in,O
a,O
patient,O
with,O
FED,B
.,O
In,O
addition,O
",",O
our,O
finding,O
illustrates,O
the,O
importance,O
of,O
this,O
sequence,O
for,O
normal,O
human,O
mRNA,O
processing,O
.,O
Finally,O
",",O
this,O
report,O
provides,O
a,O
widely,O
applicable,O
strategy,O
which,O
ensures,O
fast,O
and,O
effective,O
screening,O
for,O
intronic,O
defects,O
that,O
underlie,O
differential,O
gene,O
expression,O
.,O
Mutations,O
associated,O
with,O
variant,O
phenotypes,O
in,O
ataxia,B
-,I
telangiectasia,I
.,O
We,O
have,O
identified,O
14,O
families,O
with,O
ataxia,B
-,I
telangiectasia,I
(,O
A,B
-,I
T,I
),O
in,O
which,O
mutation,O
of,O
the,O
ATM,B
gene,O
is,O
associated,O
with,O
a,O
less,O
severe,O
clinical,O
and,O
cellular,O
phenotype,O
(,O
approximately,O
10,O
%,O
-,O
15,O
%,O
of,O
A,O
-,O
T,O
families,O
identified,O
in,O
the,O
United,O
Kingdom,O
),O
.,O
In,O
10,O
of,O
these,O
families,O
",",O
all,O
the,O
homozygotes,O
have,O
a,O
137,O
-,O
bp,O
insertion,O
in,O
their,O
cDNA,O
caused,O
by,O
a,O
point,O
mutation,O
in,O
a,O
sequence,O
resembling,O
a,O
splice,O
-,O
donor,O
site,O
.,O
The,O
second,O
A,O
-,O
T,O
allele,O
has,O
a,O
different,O
mutation,O
in,O
each,O
patient,O
.,O
We,O
show,O
that,O
the,O
less,O
severe,O
phenotype,O
in,O
these,O
patients,O
is,O
caused,O
by,O
some,O
degree,O
of,O
normal,O
splicing,O
",",O
which,O
occurs,O
as,O
an,O
alternative,O
product,O
from,O
the,O
insertion,O
-,O
containing,O
allele,O
.,O
The,O
level,O
of,O
the,O
137,O
-,O
bp,O
PCR,O
product,O
containing,O
the,O
insertion,O
was,O
lowest,O
in,O
two,O
patients,O
who,O
showed,O
a,O
later,O
onset,O
of,O
cerebellar,B
ataxia,I
.,O
A,O
further,O
four,O
families,O
who,O
do,O
not,O
have,O
this,O
insertion,O
have,O
been,O
identified,O
.,O
Mutations,O
detected,O
in,O
two,O
of,O
four,O
of,O
these,O
are,O
missense,B
mutations,I
",",O
normally,O
rare,O
in,O
A,O
-,O
T,O
patients,O
.,O
The,O
demonstration,O
of,O
mutations,O
giving,O
rise,O
to,O
a,O
slightly,O
milder,O
phenotype,O
in,O
A,B
-,I
T,I
raises,O
the,O
interesting,O
question,O
of,O
what,O
range,O
of,O
phenotypes,O
might,O
occur,O
in,O
individuals,O
in,O
whom,O
both,O
mutations,O
are,O
milder,O
.,O
One,O
possibility,O
might,O
be,O
that,O
individuals,O
who,O
are,O
compound,O
heterozygotes,O
for,O
ATM,B
mutations,O
are,O
more,O
common,O
than,O
we,O
realize,O
.,O
Mutation,O
of,O
the,O
VHL,B
gene,I
is,O
associated,O
exclusively,O
with,O
the,O
development,O
of,O
non,O
-,O
papillary,O
renal,B
cell,I
carcinomas,I
.,O
To,O
define,O
the,O
possible,O
role,O
of,O
the,O
VHL,B
gene,I
in,O
the,O
development,O
of,O
sporadic,O
renal,B
cell,I
carcinomas,I
",",O
91,O
different,O
parenchymal,O
tumours,O
of,O
the,O
kidney,O
have,O
been,O
investigated,O
for,O
mutation,O
of,O
the,O
VHL,B
gene,I
by,O
single,O
strand,O
conformation,O
polymorphism,O
(,O
SSCP,O
),O
and,O
/,O
or,O
heteroduplex,O
(,O
HD,O
),O
techniques,O
.,O
Chromosome,O
3p,O
deletion,O
was,O
detected,O
in,O
98,O
per,O
cent,O
of,O
non,O
-,O
papillary,O
renal,B
cell,I
carcinomas,I
and,O
in,O
25,O
per,O
cent,O
of,O
chromophobe,B
renal,I
cell,I
carcinomas,I
.,O
In,O
22,O
of,O
the,O
43,O
non,O
-,O
papillary,O
renal,B
cell,I
carcinomas,I
",",O
abnormally,O
migrating,O
DNA,O
bands,O
were,O
detected,O
by,O
SSCP,O
and,O
/,O
or,O
HD,O
analysis,O
.,O
No,O
mobility,O
shift,O
was,O
seen,O
in,O
any,O
of,O
the,O
23,O
chromophobe,B
renal,I
cell,I
carcinomas,I
.,O
In,O
addition,O
",",O
15,O
papillary,B
renal,I
cell,I
tumours,I
and,O
ten,O
renal,B
oncocytomas,I
",",O
which,O
are,O
characterized,O
by,O
genetic,O
changes,O
other,O
than,O
loss,O
of,O
chromosome,O
3p,O
sequences,O
",",O
were,O
analysed,O
for,O
mutation,O
of,O
the,O
VHL,B
gene,I
.,O
None,O
of,O
these,O
tumours,O
showed,O
abnormal,O
migration,O
patterns,O
.,O
The,O
results,O
indicate,O
that,O
mutation,O
of,O
the,O
VHL,B
gene,I
is,O
associated,O
exclusively,O
with,O
the,O
development,O
of,O
non,O
-,O
papillary,O
renal,B
cell,I
carcinoma,I
.,O
The,O
Emery,B
-,O
Dreifuss,B
muscular,I
dystrophy,I
protein,O
",",O
emerin,B
",",O
is,O
a,O
nuclear,O
membrane,O
protein,O
.,O
A,O
large,O
fragment,O
of,O
emerin,B
cDNA,I
was,O
prepared,O
by,O
PCR,O
and,O
expressed,O
as,O
a,O
recombinant,O
protein,O
in,O
Escherichia,O
coli,O
.,O
Using,O
this,O
as,O
immunogen,O
",",O
we,O
prepared,O
a,O
panel,O
of,O
12,O
monoclonal,O
antibodies,O
which,O
recognise,O
at,O
least,O
four,O
different,O
epitopes,O
on,O
emerin,B
in,O
order,O
to,O
ensure,O
that,O
emerin,B
can,O
be,O
distinguished,O
from,O
non,O
-,O
specific,O
cross,O
-,O
reacting,O
proteins,O
.,O
All,O
the,O
mAbs,O
recognised,O
a,O
34,O
kDa,O
protein,O
in,O
all,O
tissues,O
tested,O
",",O
though,O
minor,O
emerin,B
-,O
related,O
bands,O
were,O
also,O
detected,O
in,O
some,O
tissues,O
.,O
Immunofluorescence,O
microscopy,O
showed,O
that,O
emerin,B
is,O
located,O
at,O
the,O
nuclear,O
rim,O
in,O
all,O
tissues,O
examined,O
.,O
A,O
muscle,O
biopsy,O
from,O
an,O
Emery,B
-,I
Dreifuss,I
muscular,I
dystrophy,I
(,I
EMDM,I
),I
patient,O
showed,O
complete,O
absence,O
of,O
emerin,B
by,O
both,O
Western,O
blotting,O
and,O
immunohistochemistry,O
",",O
suggesting,O
a,O
simple,O
diagnostic,O
antibody,O
test,O
for,O
EDMD,B
families,O
.,O
Biochemical,O
fractionation,O
of,O
brain,O
and,O
liver,O
tissues,O
showed,O
that,O
emerin,B
was,O
present,O
in,O
nuclei,O
purified,O
by,O
centrifugation,O
through,O
65,O
%,O
sucrose,O
and,O
was,O
absent,O
from,O
soluble,O
fractions,O
(,O
post,O
-,O
100,O
",",O
000,O
g,O
),O
.,O
From,O
these,O
results,O
",",O
together,O
with,O
sequence,O
and,O
structural,O
homologies,O
between,O
emerin,B
",",O
thymopoietins,O
and,O
the,O
nuclear,O
lamina,O
-,O
associated,O
protein,O
",",O
LAP2,B
",",O
we,O
suggest,O
that,O
emerin,O
will,O
prove,O
to,O
be,O
one,O
member,O
of,O
a,O
family,O
of,O
inner,O
nuclear,O
membrane,O
proteins,O
.,O
Mutation,O
of,O
MSH3,B
in,O
endometrial,B
cancer,I
and,O
evidence,O
for,O
its,O
functional,O
role,O
in,O
heteroduplex,O
repair,O
.,O
Many,O
human,O
tumours,O
have,O
length,O
alterations,O
in,O
repetitive,O
sequence,O
elements,O
.,O
Although,O
this,O
microsatellite,O
instability,O
has,O
been,O
attributed,O
to,O
mutations,O
in,O
four,O
DNA,O
mismatch,O
repair,O
genes,O
in,O
hereditary,O
nonpolyposis,O
colorectal,B
cancer,I
(,O
HNPCC,O
),O
kindreds,O
",",O
many,O
sporadic,O
tumours,O
exhibit,O
instability,O
but,O
no,O
detectable,O
mutations,O
in,O
these,O
genes,O
.,O
It,O
is,O
therefore,O
of,O
interest,O
to,O
identify,O
other,O
genes,O
that,O
contribute,O
to,O
this,O
instability,O
.,O
In,O
yeast,O
",",O
mutations,O
in,O
several,O
genes,O
",",O
including,O
RTH,B
and,O
MSH3,B
",",O
cause,O
microsatellite,O
instability,O
.,O
Thus,O
",",O
we,O
screened,O
16,O
endometrial,O
carcinomas,O
with,O
microsatellite,O
instability,O
for,O
alterations,O
in,O
FEN1,B
(,O
the,O
human,O
homolog,O
of,O
RTH,O
),O
and,O
in,O
MSH3,B
(,O
refs,O
12,O
-,O
14,O
),O
.,O
Although,O
we,O
found,O
no,O
FEN1,B
mutations,O
",",O
a,O
frameshift,O
mutation,O
in,O
MSH3,B
was,O
observed,O
in,O
an,O
endometrial,O
carcinoma,B
and,O
in,O
an,O
endometrial,O
carcinoma,O
cell,O
line,O
.,O
Extracts,O
of,O
the,O
cell,O
line,O
were,O
deficient,O
in,O
repair,O
of,O
DNA,O
substrates,O
containing,O
mismatches,B
or,O
extra,O
nucleotides,O
.,O
Introducing,O
chromosome,O
5,O
",",O
encoding,O
the,O
MSH3,B
gene,O
",",O
into,O
the,O
mutant,O
cell,O
line,O
increased,O
the,O
stability,O
of,O
some,O
but,O
not,O
all,O
microsatellites,O
.,O
Extracts,O
of,O
these,O
cells,O
repaired,O
certain,O
substrates,O
containing,O
extra,O
nucleotides,O
",",O
but,O
were,O
deficient,O
in,O
repair,O
of,O
those,O
containing,O
mismatches,B
or,O
other,O
extra,O
nucleotides,O
.,O
A,O
subsequent,O
search,O
revealed,O
a,O
second,O
gene,O
mutation,O
in,O
HHUA,O
cells,O
",",O
a,O
missense,O
mutation,O
in,O
the,O
MSH6,B
gene,O
.,O
Together,O
the,O
data,O
suggest,O
that,O
the,O
MSH3,B
gene,O
encodes,O
a,O
product,O
that,O
functions,O
in,O
repair,O
of,O
some,O
but,O
not,O
all,O
pre,O
-,O
mutational,O
intermediates,O
",",O
its,O
mutation,O
in,O
tumours,O
can,O
result,O
in,O
genomic,O
instability,O
and,O
",",O
as,O
in,O
yeast,O
",",O
MSH3,B
and,O
MSH6,B
are,O
partially,O
redundant,O
for,O
mismatch,O
repair,O
.,O
Comparative,O
genome,O
mapping,O
of,O
the,O
ataxia,B
-,I
telangiectasia,I
region,O
in,O
mouse,O
",",O
rat,O
",",O
and,O
Syrian,O
hamster,O
.,O
Chromosomal,O
locations,O
of,O
the,O
Atm,B
(,O
ataxia,I
-,I
telangiectasia,I
(,I
AT,I
),I
-,I
mutated,I
),I
and,O
Acat1,B
(,O
mitochondrial,I
acetoacetyl,I
-,I
CoA,I
thiolase,I
),I
genes,O
in,O
mouse,O
",",O
rat,O
",",O
and,O
Syrian,O
hamster,O
were,O
determined,O
by,O
direct,O
R,O
-,O
banding,O
FISH,O
.,O
Both,O
genes,O
were,O
colocalized,O
to,O
the,O
C,O
-,O
D,O
band,O
of,O
mouse,O
chromosome,O
9,O
",",O
the,O
proximal,O
end,O
of,O
q24,O
.,O
1,O
of,O
rat,O
chromosome,O
8,O
",",O
and,O
qa4,O
-,O
qa5,O
of,O
Syrian,O
hamster,O
chromosome,O
12,O
.,O
The,O
regions,O
in,O
the,O
mouse,O
and,O
rat,O
were,O
homologous,O
to,O
human,O
chromosome,O
11q,O
.,O
Fine,O
genetic,O
linkage,O
mapping,O
of,O
the,O
mouse,O
AT,O
region,O
was,O
performed,O
using,O
the,O
interspecific,O
backcross,O
mice,O
.,O
Atm,B
",",O
Acat1,B
",",O
and,O
Npat,B
",",O
which,O
is,O
a,O
new,O
gene,O
isolated,O
from,O
the,O
AT,O
region,O
",",O
and,O
12,O
flanking,O
microsatellite,O
DNA,O
markers,O
were,O
examined,O
.,O
No,O
recombinations,O
were,O
found,O
among,O
the,O
Atm,B
",",O
Npat,B
",",O
Acat1,B
",",O
and,O
D9Mit6,O
loci,O
",",O
and,O
these,O
loci,O
were,O
mapped,O
2,O
.,O
0,O
cM,O
distal,O
to,O
D9Mit99,O
and,O
1,O
.,O
3,O
cM,O
proximal,O
to,O
D9Mit102,O
.,O
Comparison,O
of,O
the,O
linkage,O
map,O
of,O
mouse,O
chromosome,O
9,O
(,O
MMU9,O
),O
and,O
that,O
of,O
human,O
chromosome,O
11,O
(,O
HSA11,O
),O
indicates,O
that,O
there,O
is,O
a,O
chromosomal,O
rearrangement,O
due,O
to,O
an,O
inversion,O
between,O
Ets1,O
and,O
Atm,B
-,O
Npat,B
-,O
Acat1,B
and,O
that,O
the,O
inversion,O
of,O
MMU9,O
originated,O
from,O
the,O
chromosomal,O
breakage,O
at,O
the,O
boundary,O
between,O
Gria4,O
and,O
Atm,B
-,O
Npat,B
-,O
Acat1,B
on,O
HSA11,O
.,O
This,O
type,O
of,O
inversion,O
appeared,O
to,O
be,O
conserved,O
in,O
the,O
three,O
rodent,O
species,O
",",O
mouse,O
",",O
rat,O
",",O
and,O
Syrian,O
hamster,O
",",O
using,O
additional,O
comparative,O
mapping,O
data,O
with,O
the,O
Rck,O
gene,O
An,O
animal,O
model,O
for,O
Norrie,B
disease,I
(,O
ND,B
),O
:,O
gene,O
targeting,O
of,O
the,O
mouse,O
ND,B
gene,I
.,O
In,O
order,O
to,O
elucidate,O
the,O
cellular,O
and,O
molecular,O
processes,O
which,O
are,O
involved,O
in,O
Norrie,B
disease,I
(,O
ND,B
),O
",",O
we,O
have,O
used,O
gene,O
targeting,O
technology,O
to,O
generate,O
ND,B
mutant,O
mice,O
.,O
The,O
murine,O
homologue,O
of,O
the,O
ND,B
gene,I
was,O
cloned,O
and,O
shown,O
to,O
encode,O
a,O
polypeptide,O
that,O
shares,O
94,O
%,O
of,O
the,O
amino,O
acid,O
sequence,O
with,O
its,O
human,O
counterpart,O
.,O
RNA,O
in,O
situ,O
hybridization,O
revealed,O
expression,O
in,O
retina,B
",",O
brain,B
and,O
the,O
olfactory,O
bulb,O
and,O
epithelium,O
of,O
2,O
week,O
old,O
mice,O
.,O
Hemizygous,O
mice,O
carrying,O
a,O
replacement,O
mutation,O
in,O
exon,O
2,O
of,O
the,O
ND,B
gene,I
developed,O
retrolental,B
structures,O
in,O
the,O
vitreous,O
body,O
and,O
showed,O
an,O
overall,O
disorganization,O
of,O
the,O
retinal,B
ganglion,I
cell,I
layer,I
.,O
The,O
outer,O
plexiform,O
layer,O
disappears,O
occasionally,O
",",O
resulting,O
in,O
a,O
juxtaposed,O
inner,O
and,O
outer,O
nuclear,O
layer,O
.,O
At,O
the,O
same,O
regions,O
",",O
the,O
outer,O
segments,O
of,O
the,O
photoreceptor,B
cell,I
layer,I
are,O
no,O
longer,O
present,O
.,O
These,O
ocular,O
findings,O
are,O
consistent,O
with,O
observations,O
in,O
ND,B
patients,O
and,O
the,O
generated,O
mouse,O
line,O
provides,O
a,O
faithful,O
model,O
for,O
study,O
of,O
early,O
pathogenic,O
events,O
in,O
this,O
severe,O
X,B
-,I
linked,I
recessive,I
neurological,I
disorder,I
.,O
The,O
hybrid,O
PAX3,B
-,O
FKHR,B
fusion,O
protein,O
of,O
alveolar,B
rhabdomyosarcoma,I
transforms,O
fibroblasts,O
in,O
culture,O
.,O
Pediatric,O
alveolar,B
rhabdomyosarcoma,I
is,O
characterized,O
by,O
a,O
chromosomal,O
translocation,O
that,O
fuses,O
parts,O
of,O
the,O
PAX3,B
and,O
FKHR,B
genes,O
.,O
PAX3,B
codes,O
for,O
a,O
transcriptional,O
regulator,O
that,O
controls,O
developmental,O
programs,O
",",O
and,O
FKHR,B
codes,O
for,O
a,O
forkhead,O
-,O
winged,O
helix,O
protein,O
",",O
also,O
a,O
likely,O
transcription,O
factor,O
.,O
The,O
PAX3,B
-,O
FKHR,B
fusion,O
product,O
retains,O
the,O
DNA,O
binding,O
domains,O
of,O
the,O
PAX3,B
protein,O
and,O
the,O
putative,O
activator,O
domain,O
of,O
the,O
FKHR,B
protein,O
.,O
The,O
PAX3,B
-,O
FKHR,B
protein,O
has,O
been,O
shown,O
to,O
function,O
as,O
a,O
transcriptional,O
activator,O
.,O
Using,O
the,O
RCAS,O
retroviral,O
vector,O
",",O
we,O
have,O
introduced,O
the,O
PAX3,B
-,O
FKHR,B
gene,O
into,O
chicken,O
embryo,O
fibroblasts,O
.,O
Expression,O
of,O
the,O
PAX3,B
-,I
FKHR,I
protein,O
in,O
these,O
cells,O
leads,O
to,O
transformation,O
the,O
cells,O
become,O
enlarged,O
",",O
grow,O
tightly,O
packed,O
and,O
in,O
multiple,O
layers,O
",",O
and,O
acquire,O
the,O
ability,O
for,O
anchorage,O
-,O
independent,O
growth,O
.,O
This,O
cellular,O
transformation,O
in,O
vitro,O
will,O
facilitate,O
studies,O
on,O
the,O
mechanism,O
of,O
PAX3,B
-,I
FKHR,I
-,I
induced,I
oncogenesis,I
.,O
Somatic,O
-,O
cell,O
selection,O
is,O
a,O
major,O
determinant,O
of,O
the,O
blood,O
-,O
cell,O
phenotype,O
in,O
heterozygotes,O
for,O
glucose,B
-,I
6,I
-,I
phosphate,I
dehydrogenase,I
mutations,O
causing,O
severe,O
enzyme,O
deficiency,O
.,O
X,O
-,O
chromosome,O
inactivation,O
in,O
mammals,O
is,O
regarded,O
as,O
an,O
essentially,O
random,O
process,O
",",O
but,O
the,O
resulting,O
somatic,O
-,O
cell,O
mosaicism,O
creates,O
the,O
opportunity,O
for,O
cell,O
selection,O
.,O
In,O
most,O
people,O
with,O
red,B
-,I
blood,I
-,I
cell,I
glucose,I
-,I
6,I
-,I
phosphate,I
dehydrogenase,I
(,O
G6PD,B
),O
deficiency,O
",",O
the,O
enzyme,O
-,O
deficient,O
phenotype,O
is,O
only,O
moderately,O
expressed,O
in,O
nucleated,O
cells,O
.,O
However,O
",",O
in,O
a,O
small,O
subset,O
of,O
hemizygous,O
males,O
who,O
suffer,O
from,O
chronic,B
nonspherocytic,I
hemolytic,I
anemia,I
",",O
the,O
underlying,O
mutations,O
(,O
designated,O
class,O
I,O
),O
cause,O
more,O
-,O
severe,O
G6PD,B
deficiency,O
",",O
and,O
this,O
might,O
provide,O
an,O
opportunity,O
for,O
selection,O
in,O
heterozygous,O
females,O
during,O
development,O
.,O
In,O
order,O
to,O
test,O
this,O
possibility,O
we,O
have,O
analyzed,O
four,O
heterozygotes,O
for,O
class,O
I,O
G6PD,B
mutations,O
two,O
with,O
G6PD,B
Portici,O
(,O
1178G,O
-,O
-,O
>,O
A,O
),O
and,O
two,O
with,O
G6PD,B
Bari,O
(,O
1187C,O
-,O
-,O
>,O
T,O
),O
.,O
We,O
found,O
that,O
in,O
fractionated,O
blood,O
cell,O
types,O
(,O
including,O
erythroid,O
",",O
myeloid,O
",",O
and,O
lymphoid,O
cell,O
lineages,O
),O
there,O
was,O
a,O
significant,O
excess,O
of,O
G6PD,B
-,O
normal,O
cells,O
.,O
The,O
significant,O
concordance,O
that,O
we,O
have,O
observed,O
in,O
the,O
degree,O
of,O
imbalance,O
in,O
the,O
different,O
blood,B
-,I
cell,I
lineages,O
indicates,O
that,O
a,O
selective,O
mechanism,O
is,O
likely,O
to,O
operate,O
at,O
the,O
level,O
of,O
pluripotent,O
blood,B
stem,I
cells,I
.,O
Thus,O
",",O
it,O
appears,O
that,O
severe,O
G6PD,B
deficiency,I
affects,O
adversely,O
the,O
proliferation,O
or,O
the,O
survival,O
of,O
nucleated,O
blood,B
cells,I
and,O
that,O
this,O
phenotypic,O
characteristic,O
is,O
critical,O
during,O
hematopoiesis,O
.,O
Analysis,O
of,O
meiotic,O
segregation,O
",",O
using,O
single,O
-,O
sperm,O
typing,O
:,O
meiotic,O
drive,O
at,O
the,O
myotonic,B
dystrophy,I
locus,O
.,O
Meiotic,O
drive,O
at,O
the,O
myotonic,B
dystrophy,I
(,O
DM,O
),O
locus,O
has,O
recently,O
been,O
suggested,O
as,O
being,O
responsible,O
for,O
maintaining,O
the,O
frequency,O
",",O
in,O
the,O
human,O
population,O
",",O
of,O
DM,O
chromosomes,O
capable,O
of,O
expansion,O
to,O
the,O
disease,O
state,O
.,O
In,O
order,O
to,O
test,O
this,O
hypothesis,O
",",O
we,O
have,O
studied,O
samples,O
of,O
single,O
sperm,O
from,O
three,O
individuals,O
heterozygous,O
at,O
the,O
DM,B
locus,O
",",O
each,O
with,O
one,O
allele,O
larger,O
and,O
one,O
allele,O
smaller,O
than,O
19,O
CTG,B
repeats,O
.,O
To,O
guard,O
against,O
the,O
possible,O
problem,O
of,O
differential,O
PCR,O
amplification,O
rates,O
based,O
on,O
the,O
lengths,O
of,O
the,O
alleles,O
",",O
the,O
sperm,O
were,O
also,O
typed,O
at,O
another,O
closely,O
linked,O
marker,O
whose,O
allele,O
size,O
was,O
unrelated,O
to,O
the,O
allele,O
size,O
at,O
the,O
DM,B
locus,O
.,O
Using,O
statistical,O
models,O
specifically,O
designed,O
to,O
study,O
single,O
-,O
sperm,O
segregation,O
data,O
",",O
we,O
find,O
no,O
evidence,O
of,O
meiotic,B
segregation,I
distortion,I
.,O
The,O
upper,O
limit,O
of,O
the,O
two,O
-,O
sided,O
95,O
%,O
confidence,O
interval,O
for,O
the,O
estimate,O
of,O
the,O
common,O
segregation,O
probability,O
for,O
the,O
three,O
donors,O
is,O
at,O
or,O
below,O
.,O
515,O
for,O
all,O
models,O
considered,O
",",O
and,O
no,O
statistically,O
significant,O
difference,O
from,O
.,O
5,O
is,O
detected,O
in,O
any,O
of,O
the,O
models,O
.,O
This,O
suggests,O
that,O
any,O
greater,O
amount,O
of,O
segregation,O
distortion,O
at,O
the,O
myotonic,B
dystrophy,I
locus,O
must,O
result,O
from,O
events,O
following,O
sperm,O
ejaculation,O
.,O
LPP,B
",",O
the,O
preferred,O
fusion,O
partner,O
gene,O
of,O
HMGIC,O
in,O
lipomas,B
",",O
is,O
a,O
novel,O
member,O
of,O
the,O
LIM,O
protein,O
gene,O
family,O
.,O
A,O
major,O
cytogenetic,O
subgroup,O
of,O
lipomas,B
is,O
characterized,O
by,O
recurrent,O
chromosome,O
aberrations,O
",",O
mainly,O
translocations,O
",",O
that,O
involve,O
chromosome,O
segment,O
12q13,O
-,O
q15,O
.,O
Multiple,O
chromosomes,O
have,O
been,O
found,O
as,O
the,O
translocation,O
partners,O
of,O
chromosome,B
12,I
but,O
3q27,B
-,I
q28,I
is,O
preferentially,O
involved,O
.,O
In,O
previous,O
studies,O
",",O
it,O
has,O
been,O
shown,O
that,O
the,O
high,O
mobility,O
group,O
(,O
HMG,B
),O
protein,O
gene,O
HMGIC,B
at,O
12q15,B
is,O
consistently,O
rearranged,O
as,O
a,O
consequence,O
of,O
these,O
translocations,O
.,O
Here,O
",",O
we,O
report,O
the,O
identification,O
and,O
characterization,O
of,O
the,O
chromosome,O
3,B
-,I
derived,O
translocation,O
partner,O
gene,O
",",O
which,O
we,O
have,O
designated,O
LPP,B
(,O
lipoma,O
preferred,O
partner,O
gene,O
),O
.,O
Using,O
3,B
-,I
RACE,I
analysis,O
of,O
HMGIC,O
fusion,O
transcripts,O
in,O
lipoma,O
cell,O
line,O
Li,O
-,O
501,O
/,O
SV40,O
",",O
ectopic,O
genetic,O
sequences,O
were,O
obtained,O
",",O
which,O
by,O
CASH,O
(,O
chromosome,O
assignment,O
using,O
somatic,O
cell,O
hybrids,O
),O
and,O
FISH,O
(,O
fluorescence,O
in,O
situ,O
hybridization,O
),O
analysis,O
were,O
found,O
to,O
originate,O
from,O
chromosome,O
segment,O
3q27,B
-,I
q28,I
.,O
In,O
Northern,O
blot,O
analysis,O
",",O
an,O
mRNA,O
of,O
over,O
10,O
kb,O
was,O
detected,O
by,O
these,O
ectopic,O
sequences,O
in,O
a,O
variety,O
of,O
human,O
tissues,O
but,O
not,O
in,O
brain,B
and,O
peripheral,B
blood,I
leukocytes,I
.,O
Upon,O
partial,O
cDNA,O
cloning,O
",",O
features,O
of,O
the,O
genetic,O
organization,O
of,O
LPP,B
were,O
established,O
.,O
The,O
gene,O
was,O
found,O
to,O
span,O
a,O
genomic,O
region,O
of,O
over,O
400,O
kb,O
.,O
Nucleotide,O
sequence,O
analysis,O
of,O
a,O
composite,O
cDNA,O
of,O
LPP,B
revealed,O
an,O
open,O
reading,O
frame,O
of,O
1836,O
nucleotides,O
encoding,O
a,O
proline,O
-,O
rich,O
protein,O
containing,O
a,O
leucine,O
-,O
zipper,O
motif,O
in,O
its,O
amino,O
-,O
terminal,O
region,O
and,O
three,O
LIM,B
domains,O
in,O
its,O
carboxy,O
-,O
terminal,O
region,O
.,O
The,O
LPP,B
-,O
encoded,O
protein,O
should,O
be,O
classified,O
as,O
a,O
novel,O
member,O
of,O
the,O
group,O
3,O
proteins,O
of,O
the,O
LIM,B
protein,O
gene,O
family,O
.,O
Using,O
reverse,O
transcriptase,O
combined,O
with,O
polymerase,O
chain,O
reactions,O
in,O
the,O
analysis,O
of,O
a,O
number,O
of,O
lipoma,B
cell,I
lines,I
and,O
primary,O
lipomas,B
",",O
it,O
appeared,O
that,O
LPP,B
is,O
frequently,O
rearranged,O
also,O
in,O
cases,O
without,O
a,O
cytogenetically,O
detectable,O
involvement,O
of,O
3q27,O
-,O
q28,O
.,O
Two,O
alternative,O
HMGIC,O
/,O
LPP,B
hybrid,O
transcripts,O
have,O
been,O
detected,O
;,O
the,O
difference,O
between,O
them,O
is,O
mainly,O
the,O
presence,O
of,O
either,O
two,O
or,O
three,O
LIM,O
domains,O
in,O
the,O
predicted,O
HMGI,O
-,O
C,O
/,O
LPP,B
fusion,O
proteins,O
.,O
Absence,O
of,O
disease,B
phenotype,I
and,O
intergenerational,O
stability,O
of,O
the,O
CAG,O
repeat,O
in,O
transgenic,O
mice,O
expressing,O
the,O
human,O
Huntington,B
disease,I
transcript,O
.,O
The,O
mutation,O
underlying,O
Huntington,B
disease,I
(,O
HD,O
),O
is,O
CAG,O
expansion,O
in,O
the,O
first,O
exon,O
of,O
the,O
HD,O
gene,O
.,O
In,O
order,O
to,O
investigate,O
the,O
role,O
of,O
CAG,O
expansion,O
in,O
the,O
pathogenesis,O
of,O
HD,O
",",O
we,O
have,O
produced,O
transgenic,O
mice,O
containing,O
the,O
full,O
length,O
human,O
HD,O
cDNA,O
with,O
44,O
CAG,O
repeats,O
.,O
By,O
1,O
year,O
",",O
these,O
mice,O
have,O
no,O
behavioral,O
abnormalities,O
and,O
morphometric,O
analysis,O
at,O
6,O
(,O
one,O
animal,O
),O
and,O
9,O
(,O
two,O
animals,O
),O
months,O
age,O
revealed,O
no,O
changes,O
.,O
Despite,O
high,O
levels,O
of,O
mRNA,O
expression,O
",",O
there,O
was,O
no,O
evidence,O
of,O
the,O
HD,B
gene,I
product,I
in,O
any,O
of,O
these,O
transgenic,O
mice,O
.,O
In,O
vitro,O
transfection,O
studies,O
indicated,O
that,O
the,O
inclusion,O
of,O
120,O
bp,O
of,O
the,O
5,O
UTR,O
in,O
the,O
cDNA,O
construct,O
and,O
the,O
presence,O
of,O
a,O
frameshift,O
mutation,O
at,O
nucleotide,O
2349,O
prevented,O
expression,O
of,O
the,O
HD,B
cDNA,I
.,O
These,O
findings,O
suggest,O
that,O
the,O
pathogenesis,O
of,O
HD,B
is,O
not,O
mediated,O
through,O
DNA,B
-,O
protein,O
interaction,O
and,O
that,O
presence,O
of,O
the,O
RNA,B
transcript,O
with,O
an,O
expanded,O
CAG,B
repeat,O
is,O
insufficient,O
to,O
cause,O
the,O
disease,O
.,O
Rather,O
",",O
translation,O
of,O
the,O
CAG,B
is,O
crucial,O
for,O
the,O
pathogenesis,O
of,O
HD,B
.,O
In,O
contrast,O
to,O
that,O
seen,O
in,O
humans,O
",",O
the,O
CAG,B
repeat,O
in,O
these,O
mice,O
was,O
remarkably,O
stable,O
in,O
97,O
meioses,O
.,O
This,O
suggests,O
that,O
genomic,O
sequences,O
may,O
play,O
a,O
critical,O
role,O
in,O
influencing,O
repeat,O
instability,O
.,O
FISH,O
studies,O
in,O
a,O
patient,O
with,O
sporadic,B
aniridia,I
and,O
t,O
(,O
7,O
;,O
11,O
),O
(,O
q31,O
.,O
2,O
;,O
p13,O
),O
.,O
A,O
2,O
year,O
old,O
female,O
presenting,O
with,O
bilateral,O
sporadic,B
aniridia,I
was,O
found,O
to,O
have,O
an,O
apparently,O
balanced,O
reciprocal,O
translocation,O
with,O
a,O
chromosome,O
11,O
breakpoint,O
within,O
band,O
p13,O
.,O
Fluorescence,O
in,O
situ,O
hybridisation,O
(,O
FISH,O
),O
studies,O
with,O
distal,O
11p13,O
specific,O
cosmids,O
showed,O
that,O
the,O
chromosome,O
11,O
breakpoint,O
lay,O
between,O
the,O
aniridia,B
(,O
PAX6,B
),O
locus,O
and,O
a,O
region,O
approximately,O
100,O
kb,O
distal,O
to,O
PAX6,B
defined,O
by,O
the,O
cosmid,O
FO2121,O
.,O
Although,O
this,O
patient,O
did,O
not,O
have,O
a,O
detectable,O
deletion,O
within,O
PAX6,B
",",O
her,O
aniridia,O
may,O
have,O
resulted,O
from,O
a,O
disruption,O
of,O
the,O
distal,O
chromatin,O
domain,O
containing,O
either,O
enhancers,O
or,O
regulators,O
for,O
PAX6,B
.,O
This,O
case,O
may,O
therefore,O
be,O
another,O
example,O
of,O
aniridia,B
caused,O
by,O
a,O
position,O
effect,O
as,O
recently,O
described,O
in,O
two,O
familial,O
aniridia,B
patients,O
in,O
which,O
the,O
phenotype,O
cosegregated,O
with,O
chromosome,O
abnormalities,O
with,O
11p13,O
breakpoints,O
.,O
Muscle,O
expression,O
of,O
glucose,O
-,O
6,O
-,O
phosphate,O
dehydrogenase,O
deficiency,B
in,O
different,O
variants,O
.,O
Muscle,O
expression,O
of,O
G6PD,B
deficiency,I
has,O
been,O
investigated,O
in,O
Mediterranean,O
",",O
Seattle,O
-,O
like,O
and,O
A,O
-,O
variants,O
.,O
G6PD,B
activity,O
was,O
detected,O
in,O
samples,O
obtained,O
from,O
biopsies,O
on,O
the,O
quadriceps,O
muscle,O
of,O
seven,O
males,O
and,O
one,O
female,O
.,O
The,O
type,O
of,O
genetic,O
variant,O
was,O
determined,O
by,O
molecular,O
analysis,O
of,O
DNA,O
",",O
extracted,O
from,O
blood,O
samples,O
.,O
All,O
variants,O
showed,O
the,O
enzyme,O
defect,B
in,O
muscle,O
.,O
A,O
statistically,O
significant,O
relationship,O
was,O
found,O
in,O
the,O
activity,O
of,O
G6PD,B
between,O
erythrocytes,O
and,O
muscle,O
of,O
the,O
male,O
subjects,O
(,O
r,O
=,O
0,O
.,O
968,O
;,O
p,O
=,O
0,O
.,O
00008,O
),O
.,O
The,O
equation,O
for,O
the,O
best,O
fit,O
line,O
was,O
Y,O
=,O
0,O
.,O
390X,O
+,O
0,O
.,O
198,O
198,O
.,O
The,O
results,O
suggest,O
that,O
",",O
for,O
a,O
given,O
variant,O
",",O
the,O
extent,O
of,O
the,O
enzyme,O
defect,B
in,O
muscle,O
may,O
be,O
determined,O
",",O
using,O
this,O
equation,O
",",O
from,O
the,O
G6PD,B
activity,O
of,O
erythrocytes,O
Gene,O
therapy,O
for,O
phenylketonuria,B
.,O
Classical,B
phenylketonuria,I
(,O
PKU,B
),O
is,O
an,O
autosomal,O
recessive,O
disorder,O
caused,O
by,O
a,O
deficiency,O
of,O
hepatic,O
phenylalanine,B
hydroxylase,I
(,O
PAH,B
),O
.,O
Limitations,O
of,O
the,O
current,O
dietary,O
treatment,O
for,O
PKU,B
have,O
led,O
to,O
the,O
development,O
of,O
potential,O
treatments,O
based,O
on,O
somatic,O
gene,O
transfer,O
.,O
Three,O
different,O
vector,O
systems,O
have,O
been,O
examined,O
.,O
Vectors,O
derived,O
from,O
a,O
recombinant,O
retrovirus,B
or,O
a,O
DNA,B
/,I
protein,I
complex,I
can,O
efficiently,O
transduce,O
the,O
PAH,B
cDNA,I
into,O
PAH,B
-,I
deficient,I
hepatocytes,O
in,O
vitro,O
",",O
but,O
the,O
application,O
of,O
these,O
vector,O
systems,O
is,O
presently,O
limited,O
by,O
their,O
low,O
transduction,O
efficiency,O
in,O
vivo,O
.,O
In,O
contrast,O
",",O
a,O
vector,O
derived,O
from,O
a,O
recombinant,O
adenovirus,B
can,O
restore,O
10,O
%,O
-,O
80,O
%,O
of,O
normal,O
hepatic,O
PAH,B
activity,O
into,O
PAH,B
-,I
deficient,I
mice,O
",",O
which,O
completely,O
normalizes,O
serum,O
phenylalanine,O
levels,O
.,O
This,O
treatment,O
is,O
transient,O
and,O
cannot,O
be,O
effectively,O
re,O
-,O
administered,O
due,O
to,O
the,O
presence,O
of,O
neutralizing,O
antibodies,O
directed,O
against,O
the,O
recombinant,O
adenoviral,B
vector,I
.,O
However,O
",",O
these,O
findings,O
suggest,O
that,O
PKU,B
can,O
be,O
completely,O
corrected,O
by,O
somatic,O
gene,O
therapy,O
",",O
and,O
provide,O
some,O
direction,O
for,O
the,O
future,O
development,O
of,O
adenoviral,B
vectors,I
.,O
Exon,O
-,O
intron,O
structure,O
of,O
the,O
human,O
neuronal,O
nicotinic,O
acetylcholine,O
receptor,O
alpha,O
4,O
subunit,O
(,O
CHRNA4,B
),O
.,O
The,O
human,O
neuronal,O
nicotinic,O
acetylcholine,O
receptor,O
alpha,O
4,O
subunit,O
gene,O
(,O
CHRNA4,B
),O
is,O
located,O
in,O
the,O
candidate,O
region,O
for,O
three,O
different,O
phenotypes,O
benign,O
familial,O
neonatal,B
convulsions,I
",",O
autosomal,O
dominant,O
nocturnal,B
frontal,I
lobe,I
epilepsy,I
",",O
and,O
low,B
-,I
voltage,I
EEG,I
.,O
Recently,O
",",O
a,O
missense,O
mutation,O
in,O
transmembrane,O
domain,O
2,O
of,O
CHRNA4,B
was,O
found,O
to,O
be,O
associated,O
with,O
autosomal,O
dominant,O
nocturnal,O
frontal,O
lobe,O
epilepsy,B
in,O
one,O
extended,O
pedigree,O
.,O
We,O
have,O
determined,O
the,O
genomic,O
organization,O
of,O
CHRNA4,B
",",O
which,O
consists,O
of,O
six,O
exons,O
distributed,O
over,O
approximately,O
17,O
kb,O
of,O
genomic,O
DNA,O
.,O
The,O
nucleotide,O
sequence,O
obtained,O
from,O
the,O
genomic,O
regions,O
adjacent,O
to,O
the,O
exon,O
boundaries,O
enabled,O
us,O
to,O
develop,O
a,O
set,O
of,O
primer,O
pairs,O
for,O
PCR,O
amplification,O
of,O
the,O
complete,O
coding,O
region,O
.,O
The,O
sequence,O
analysis,O
provides,O
the,O
basis,O
for,O
a,O
comprehensive,O
mutation,O
screening,O
of,O
CHRNA4,B
in,O
the,O
above,O
-,O
mentioned,O
phenotypes,O
and,O
possibly,O
in,O
other,O
types,O
of,O
idiopathic,O
epilepsies,O
.,O
Ashkenazi,O
Jewish,O
population,O
frequencies,O
for,O
common,O
mutations,O
in,O
BRCA1,B
and,O
BRCA2,B
.,O
BRCA1,B
and,O
BRCA2,B
are,O
the,O
two,O
major,O
identified,O
causes,O
of,O
inherited,O
breast,O
cancer,O
",",O
with,O
mutations,O
in,O
either,O
gene,O
conferring,O
up,O
to,O
80,O
-,O
90,O
%,O
lifetime,O
risk,O
of,O
breast,O
cancer,O
in,O
carrier,O
females,O
.,O
Mutations,O
in,O
BRCA1,B
account,O
for,O
approximately,O
45,O
%,O
of,O
familial,O
breast,O
cancer,O
and,O
90,O
%,O
of,O
inherited,O
breast,O
/,O
ovarian,O
cancer,O
",",O
whereas,O
mutations,O
in,O
BRCA2,B
account,O
for,O
a,O
comparable,O
percentage,O
of,O
inherited,O
breast,O
cancer,O
cases,O
.,O
Over,O
85,O
distinct,O
BRCA1,B
mutations,O
and,O
a,O
growing,O
list,O
of,O
BRCA2,B
mutations,O
have,O
been,O
identified,O
",",O
with,O
the,O
majority,O
resulting,O
in,O
protein,O
truncation,O
.,O
A,O
specific,O
BRCA1,B
mutation,O
",",O
185delAG,B
",",O
has,O
a,O
reported,O
increased,O
carrier,O
frequency,O
of,O
approximately,O
0,O
.,O
9,O
%,O
in,O
the,O
Ashkenazi,O
Jewish,O
population,O
",",O
but,O
is,O
also,O
found,O
in,O
rare,O
non,O
-,O
Jewish,O
patients,O
with,O
a,O
different,O
haplotype,O
.,O
The,O
6174delT,B
mutation,O
in,O
BRCA2,B
was,O
recently,O
identified,O
as,O
a,O
frequent,O
mutation,O
in,O
8,O
out,O
of,O
107,O
Ashkenazi,O
Jewish,O
women,O
diagnosed,O
with,O
breast,B
cancer,I
by,O
age,O
50,O
(,O
ref,O
.,O
8,O
),O
",",O
as,O
well,O
as,O
in,O
three,O
Ashkenazi,O
male,O
breast,B
cancer,I
patients,O
.,O
We,O
have,O
conducted,O
a,O
large,O
-,O
scale,O
population,O
study,O
to,O
investigate,O
the,O
prevalence,O
of,O
specific,O
BRCA1,B
and,O
BRCA2,B
mutations,O
in,O
Ashkenazi,O
Jewish,O
individuals,O
who,O
were,O
unselected,O
for,O
breast,B
cancer,I
.,O
BRCA1,B
mutation,O
screening,O
on,O
approximately,O
3,O
",",O
000,O
Ashkenazi,O
Jewish,O
samples,O
determined,O
a,O
carrier,O
frequency,O
of,O
1,O
.,O
09,O
%,O
for,O
the,O
185delAG,B
mutation,O
and,O
0,O
.,O
13,O
%,O
for,O
the,O
5382insC,B
mutation,O
.,O
BRCA2,B
analysis,O
on,O
3,O
",",O
085,O
individuals,O
from,O
the,O
same,O
population,O
showed,O
a,O
carrier,O
frequency,O
of,O
1,O
.,O
52,O
%,O
for,O
the,O
6174delT,B
mutation,O
.,O
This,O
expanded,O
population,O
-,O
based,O
study,O
confirms,O
that,O
the,O
BRCA1,B
185delAG,I
mutation,I
and,O
the,O
BRCA2,B
6174delT,I
mutation,I
constitute,O
the,O
two,O
most,O
frequent,O
mutation,O
alleles,O
predisposing,O
to,O
hereditary,O
breast,O
cancer,B
among,O
the,O
Ashkenazim,O
",",O
and,O
suggests,O
a,O
relatively,O
lower,O
penetrance,O
for,O
the,O
6174delT,B
mutation,I
in,O
BRCA2,O
Dual,O
roles,O
of,O
ATM,B
in,O
the,O
cellular,O
response,O
to,O
radiation,O
and,O
in,O
cell,O
growth,O
control,O
.,O
The,O
gene,O
mutated,O
in,O
ataxia,B
-,I
telangiectasia,I
(,O
AT,B
),O
patients,O
",",O
denoted,O
ATM,B
",",O
encodes,O
a,O
putative,O
protein,O
or,O
lipid,O
kinase,O
.,O
To,O
elucidate,O
the,O
functions,O
of,O
ATM,B
",",O
we,O
disrupted,O
the,O
mouse,O
ATM,B
gene,O
through,O
homologous,O
recombination,O
in,O
mice,O
.,O
Consistent,O
with,O
cellular,O
defects,O
of,O
AT,B
patients,O
",",O
the,O
ATM,B
-,I
/,I
-,I
cells,O
are,O
hypersensitive,O
to,O
gamma,O
-,O
irradiation,O
and,O
defective,O
in,O
cell,O
-,O
cycle,O
arrest,O
following,O
radiation,O
",",O
correlating,O
with,O
a,O
defective,O
up,O
-,O
regulation,O
of,O
p53,B
.,O
In,O
addition,O
",",O
ATM,B
-,I
/,I
-,I
mouse,O
thymocytes,O
are,O
more,O
resistant,O
to,O
apoptosis,O
induced,O
by,O
gamma,O
-,O
irradiation,O
than,O
normal,O
thymocytes,O
.,O
ATM,B
-,I
/,I
-,I
fibroblasts,O
are,O
inefficient,O
in,O
G1,O
to,O
S,O
-,O
phase,O
progression,O
following,O
serum,O
stimulation,O
and,O
senesce,O
after,O
only,O
a,O
few,O
passages,O
in,O
culture,O
.,O
They,O
have,O
an,O
increased,O
constitutive,O
level,O
of,O
p21CP1,B
/,I
WAF1,I
.,O
The,O
ATM,B
protein,O
is,O
therefore,O
critical,O
both,O
for,O
cellular,O
responses,O
to,O
ionizing,O
radiation,O
and,O
for,O
normal,O
cell,O
-,O
cycle,O
progression,O
.,O
ATM,B
+,O
/,O
-,O
fibroblasts,O
and,O
thymocytes,O
showed,O
intermediately,O
defective,O
responses,O
to,O
irradiation,O
but,O
no,O
growth,O
defect,O
",",O
suggesting,O
that,O
the,O
increased,O
cancer,B
risk,I
of,I
AT,I
heterozygotes,I
could,O
be,O
attributable,O
to,O
poor,O
checkpoint,O
function,O
.,O
Targeted,O
disruption,O
of,O
ATM,B
leads,O
to,O
growth,O
retardation,O
",",O
chromosomal,O
fragmentation,O
during,O
meiosis,O
",",O
immune,O
defects,O
",",O
and,O
thymic,O
lymphoma,B
.,O
ATM,B
",",O
the,O
gene,O
mutated,O
in,O
the,O
inherited,O
human,O
disease,B
ataxia,I
-,I
telangiectasia,I
",",O
is,O
a,O
member,O
of,O
a,O
family,O
of,O
kinases,O
involved,O
in,O
DNA,O
metabolism,O
and,O
cell,O
-,O
cycle,O
checkpoint,O
control,O
.,O
To,O
help,O
clarify,O
the,O
physiological,O
roles,O
of,O
the,O
ATM,B
protein,O
",",O
we,O
disrupted,O
the,O
ATM,B
gene,O
in,O
mice,O
through,O
homologous,O
recombination,O
.,O
Initial,O
evaluation,O
of,O
the,O
ATM,B
knockout,O
animals,O
indicates,O
that,O
inactivation,O
of,O
the,O
mouse,O
ATM,B
gene,O
recreates,O
much,O
of,O
the,O
phenotype,O
of,O
ataxia,B
-,I
telangiectasia,I
.,O
The,O
homozygous,O
mutant,O
(,O
ATM,B
-,I
/,I
-,I
),I
mice,O
are,O
viable,O
",",O
growth,O
-,O
retarded,O
",",O
and,O
infertile,O
.,O
The,O
infertility,O
of,O
ATM,B
-,I
-,I
mice,O
results,O
from,O
meiotic,O
failure,O
.,O
Meiosis,O
is,O
arrested,O
at,O
the,O
zygotene,B
/,I
pachytene,I
stage,O
of,O
prophase,O
I,O
as,O
a,O
result,O
of,O
abnormal,O
chromosomal,O
synapsis,O
and,O
subsequent,O
chromosome,O
fragmentation,O
.,O
Immune,O
defects,O
also,O
are,O
evident,O
in,O
ATM,B
-,I
-,I
mice,I
",",O
including,O
reduced,O
numbers,O
of,O
B220,O
+,O
CD43,O
-,O
pre,O
-,O
B,O
cells,O
",",O
thymocytes,O
",",O
and,O
peripheral,O
T,O
cells,O
",",O
as,O
well,O
as,O
functional,O
impairment,O
of,O
T,O
-,O
cell,O
-,O
dependent,O
immune,O
responses,O
.,O
The,O
cerebella,O
of,O
ATM,B
-,I
/,I
-,I
mice,O
appear,O
normal,O
by,O
histologic,O
examination,O
at,O
3,O
to,O
4,O
months,O
and,O
the,O
mice,O
have,O
no,O
gross,O
behavioral,O
abnormalities,O
.,O
The,O
majority,O
of,O
mutant,O
mice,O
rapidly,O
develop,O
thymic,B
lymphomas,I
and,O
die,O
before,O
4,O
months,O
of,O
age,O
.,O
These,O
findings,O
indicate,O
that,O
the,O
ATM,B
gene,I
product,I
plays,O
an,O
essential,O
role,O
in,O
a,O
diverse,O
group,O
of,O
cellular,O
processes,O
",",O
including,O
meiosis,B
",",O
the,O
normal,O
growth,O
of,O
somatic,O
tissues,O
",",O
immune,O
development,O
",",O
and,O
tumor,B
suppression,I
.,O
Cloning,O
and,O
characterization,O
of,O
human,O
very,O
-,O
long,O
-,O
chain,O
acyl,O
-,O
CoA,O
dehydrogenase,O
cDNA,O
",",O
chromosomal,O
assignment,O
of,O
the,O
gene,O
and,O
identification,O
in,O
four,O
patients,O
of,O
nine,O
different,O
mutations,O
within,O
the,O
VLCAD,B
gene,O
.,O
Very,O
-,O
long,O
-,O
chain,O
acyl,O
-,O
CoA,O
dehydrogenase,O
(,O
VLCAD,B
),O
is,O
one,O
of,O
four,O
straight,O
-,O
chain,O
acyl,O
-,O
CoA,O
dehydrogenase,O
(,O
ACD,B
),O
enzymes,O
",",O
which,O
are,O
all,O
nuclear,O
encoded,O
mitochondrial,O
flavoproteins,O
catalyzing,O
the,O
initial,O
step,O
in,O
fatty,O
acid,O
beta,O
-,O
oxidation,O
.,O
We,O
have,O
used,O
the,O
very,O
fast,O
",",O
Rapid,O
Amplification,O
of,O
cDNA,O
Ends,O
(,O
RACE,O
),O
based,O
strategy,O
to,O
obtain,O
the,O
sequence,O
of,O
cDNAs,O
encoding,O
human,O
VLCAD,B
from,O
placenta,O
and,O
fibroblasts,O
.,O
Alignment,O
of,O
the,O
predicted,O
amino,O
acid,O
sequence,O
of,O
human,O
VLCAD,B
with,O
those,O
of,O
the,O
other,O
human,O
ACD,O
enzymes,O
revealed,O
extensive,O
sequence,O
homology,O
.,O
Moreover,O
",",O
human,O
VLCAD,B
and,O
human,O
acyl,O
-,O
CoA,O
oxidase,O
showed,O
extensive,O
sequence,O
homology,O
corroborating,O
the,O
notion,O
that,O
these,O
genes,O
are,O
evolutionarily,O
related,O
.,O
Southern,O
blot,O
analysis,O
of,O
genomic,O
DNA,O
from,O
hybrid,O
cell,O
lines,O
was,O
used,O
to,O
localize,O
the,O
VLCAD,B
gene,O
to,O
human,O
chromosome,O
17p11,O
.,O
2,O
-,O
p11,O
.,O
13105,O
.,O
Using,O
Northern,O
and,O
Western,O
blot,O
analysis,O
to,O
investigate,O
the,O
tissue,O
specific,O
distribution,O
of,O
VLCAD,B
mRNA,O
and,O
protein,O
in,O
several,O
human,O
tissues,O
we,O
showed,O
that,O
VLCAD,B
is,O
most,O
abundant,O
in,O
heart,B
and,O
skeletal,O
muscle,B
.,O
This,O
agrees,O
well,O
with,O
the,O
fact,O
that,O
cardiac,B
and,O
muscle,B
symptoms,O
are,O
characteristic,O
for,O
patients,O
with,O
VLCAD,B
deficiency,O
.,O
Northern,O
blot,O
analysis,O
and,O
sequencing,O
of,O
cloned,O
PCR,O
amplified,O
VLCAD,B
cDNA,I
from,O
four,O
unrelated,O
patients,O
with,O
VLCAD,B
deficiency,O
showed,O
that,O
VLCAD,B
mRNA,I
was,O
undetectable,O
in,O
one,O
patient,O
and,O
that,O
the,O
other,O
three,O
have,O
mutations,O
in,O
both,O
VLCAD,B
alleles,O
.,O
Western,O
blot,O
analysis,O
of,O
patient,O
fibroblasts,O
showed,O
that,O
the,O
identified,O
mutations,O
result,O
in,O
severely,O
reduced,O
amounts,O
of,O
VLCAD,B
protein,O
.,O
Molecular,O
bases,O
of,O
combined,O
subtotal,O
deficiencies,O
of,O
C6,B
and,I
C7,I
::,O
their,O
effects,O
in,O
combination,O
with,O
other,O
C6,B
and,I
C7,I
deficiencies,O
.,O
Combined,O
subtotal,O
deficiency,O
of,O
C6,B
and,I
C7,I
",",O
in,O
which,O
both,O
proteins,O
are,O
expressed,O
at,O
very,O
low,O
levels,O
",",O
has,O
been,O
observed,O
in,O
homozygous,O
form,O
in,O
two,O
families,O
.,O
A,O
defect,O
at,O
the,O
5,O
splice,O
donor,O
site,O
of,O
intron,O
15,O
of,O
the,O
C6,B
gene,O
explains,O
the,O
low,O
molecular,O
weight,O
of,O
the,O
C6,B
protein,O
and,O
is,O
probably,O
responsible,O
for,O
its,O
low,O
expressed,O
concentration,O
.,O
The,O
C7,B
defect,O
is,O
more,O
enigmatic,O
the,O
protein,O
is,O
of,O
normal,O
molecular,O
weight,O
",",O
low,O
circulating,O
concentration,O
",",O
and,O
altered,O
isoelectric,O
point,O
.,O
An,O
Arg,O
>,O
Ser,O
codon,O
substitution,O
in,O
exon,O
11,O
is,O
the,O
only,O
molecular,O
alteration,O
within,O
the,O
mature,O
C7,B
protein,O
.,O
These,O
defects,O
are,O
associated,O
with,O
a,O
characteristic,O
set,O
of,O
polymorphic,O
DNA,O
markers,O
in,O
the,O
C6,B
/,I
C7,I
region,O
",",O
forming,O
a,O
distinct,O
haplotype,O
.,O
The,O
haplotype,O
has,O
been,O
found,O
in,O
combination,O
with,O
a,O
number,O
of,O
other,O
haplotypes,O
containing,O
defective,O
genes,O
that,O
lead,O
either,O
to,O
C6,B
or,O
C7,B
deficiency,O
",",O
but,O
with,O
different,O
consequences,O
.,O
Where,O
it,O
is,O
combined,O
with,O
a,O
C6,O
-,O
deficient,O
gene,O
",",O
the,O
serum,O
C7,B
levels,O
can,O
be,O
surprisingly,O
high,O
",",O
possibly,O
because,O
there,O
is,O
no,O
C6,O
generating,O
C56,O
to,O
consume,O
the,O
C7,B
.,O
In,O
contrast,O
",",O
where,O
the,O
C7,B
genes,O
are,O
both,O
defective,O
(,O
but,O
still,O
partially,O
functional,O
),O
",",O
there,O
may,O
be,O
a,O
profound,O
deficit,O
of,O
circulating,O
C7,B
because,O
there,O
is,O
ample,O
C6,O
to,O
produce,O
C56,O
and,O
consume,O
the,O
already,O
small,O
amount,O
of,O
C7,B
.,O
Each,O
molecular,O
defect,O
has,O
also,O
been,O
found,O
in,O
isolation,O
and,O
has,O
the,O
expected,O
effect,O
.,O
Genetic,O
bases,O
of,O
human,O
complement,O
C7,B
deficiency,I
.,O
Complement,O
C7,B
deficiency,I
(,O
C7D,O
),O
is,O
associated,O
frequently,O
with,O
recurrent,O
bacterial,O
infections,O
",",O
especially,O
meningitis,B
caused,O
by,O
Neisseria,O
meningitidis,O
.,O
We,O
report,O
in,O
this,O
work,O
the,O
molecular,O
bases,O
of,O
C7D,B
in,O
two,O
unrelated,O
Japanese,O
males,O
.,O
We,O
used,O
exon,O
-,O
specific,O
PCR,O
/,O
single,O
-,O
strand,O
conformation,O
polymorphism,O
analysis,O
as,O
a,O
screening,O
step,O
for,O
mutations,O
.,O
Subsequent,O
direct,O
sequencing,O
of,O
the,O
target,O
exons,O
identified,O
homozygous,O
mutations,O
in,O
exon,O
16,O
of,O
case,O
1,O
and,O
in,O
exon,O
15,O
of,O
case,O
2,O
.,O
The,O
mutation,O
of,O
case,O
1,O
was,O
a,O
homozygous,O
T,O
to,O
A,O
transversion,O
at,O
nucleotide,O
2250,O
",",O
the,O
third,O
nucleotide,O
of,O
the,O
codon,O
TGT,O
for,O
Cys728,O
",",O
leading,O
to,O
a,O
stop,O
codon,O
TGA,O
(,O
C728X,O
),O
.,O
In,O
case,O
",",O
a,O
homozygous,O
2,O
-,O
bp,O
deletion,O
(,O
2137delTG,B
/,O
2138delGT,I
/,O
2139delTG,I
),O
caused,O
a,O
frameshift,O
",",O
generating,O
a,O
premature,O
termination,O
codon,O
4,O
to,O
6,O
nucleotides,O
downstream,O
.,O
Family,O
study,O
in,O
case,O
1,O
confirmed,O
the,O
genetic,O
nature,O
of,O
the,O
defect,O
.,O
Moreover,O
",",O
we,O
detected,O
a,O
novel,O
polymorphism,O
in,O
intron,O
11,O
that,O
presumably,O
is,O
linked,O
to,O
the,O
mutation,O
responsible,O
for,O
C7D,B
in,O
case,O
1,O
.,O
Our,O
results,O
indicate,O
that,O
the,O
pathogenesis,O
of,O
C7D,B
is,O
heterogeneous,O
like,O
most,O
of,O
the,O
other,O
deficiencies,O
of,O
complement,O
components,O
.,O
HPRT,B
-,I
APRT,I
-,I
deficient,I
mice,O
are,O
not,O
a,O
model,O
for,O
lesch,O
-,O
nyhan,O
syndrome,O
.,O
Complete,O
hypoxanthine,O
-,O
guanine,O
phosphoribosyl,O
-,O
transferase,O
(,O
HPRT,B
),O
deficiency,O
in,O
humans,O
results,O
in,O
the,O
Lesch,O
-,O
Nyhan,O
syndrome,O
which,O
is,O
characterized,O
",",O
among,O
other,O
features,O
",",O
by,O
compulsive,O
self,O
-,O
injurious,O
behavior,O
.,O
HPRT,B
-,O
deficient,O
mice,O
generated,O
using,O
mouse,O
embryonic,O
stem,O
cells,O
exhibit,O
none,O
of,O
the,O
behavioral,O
symptoms,O
associated,O
with,O
the,O
Lesch,B
-,I
Nyhan,I
syndrome,I
.,O
Administration,O
of,O
drugs,O
that,O
inhibit,O
adenine,B
phosphoribosyltransferase,I
(,O
APRT,B
),O
in,O
HPRT,B
-,I
deficient,I
mice,I
has,O
produced,O
the,O
suggestion,O
that,O
deficiency,O
of,O
APRT,B
in,O
combination,O
with,O
HPRT,B
-,I
deficiency,I
in,O
mice,O
may,O
lead,O
to,O
self,O
-,O
mutilation,O
behavior,O
[,O
C,O
.,O
L,O
.1,O
Wu,O
and,O
D,O
.5,O
W,O
.7,O
Melton,O
(,O
1993,O
),O
Nature,O
Genet,O
.,O
3,O
",",O
235,O
-,O
240,O
].,O
To,O
test,O
this,O
proposition,O
",",O
we,O
bred,O
HPRT,B
-,I
APRT,I
-,I
deficient,I
mice,O
.,O
Although,O
the,O
doubly,O
-,O
deficient,O
mice,O
excrete,O
adenine,B
and,O
its,O
highly,O
insoluble,O
derivative,O
",",O
2,O
",",O
8,O
-,O
dihydroxyadenine,O
",",O
which,O
are,O
also,O
associated,O
with,O
human,O
APRT,B
deficiency,I
",",O
additional,O
abnormalities,O
or,O
any,O
self,O
-,O
injurious,O
behavior,O
were,O
not,O
detected,O
.,O
Thus,O
",",O
APRT,B
-,I
HPRT,I
-,I
deficient,O
mice,O
",",O
which,O
are,O
devoid,O
of,O
any,O
purine,O
salvage,O
pathways,O
",",O
show,O
no,O
novel,O
phenotype,O
and,O
are,O
not,O
a,O
model,O
for,O
the,O
behavioral,O
abnormalities,O
associated,O
with,O
the,O
Lesch,B
-,I
Nyhan,I
syndrome,I
as,O
previously,O
suggested,O
Somatic,O
alterations,O
of,O
the,O
DPC4,B
gene,I
in,I
human,I
colorectal,I
cancers,I
in,O
vivo,O
.,O
BACKGROUND,O
&,O
AIMS,O
The,O
chromosome,O
region,O
18q21,O
has,O
been,O
shown,O
to,O
be,O
frequently,O
deleted,O
in,O
colorectal,B
cancers,I
",",O
and,O
such,O
frequent,O
allelic,O
loss,O
is,O
a,O
hallmark,O
of,O
the,O
presence,O
of,O
a,O
tumor,O
-,O
suppressor,O
gene,O
.,O
The,O
DPC4,B
gene,O
",",O
which,O
is,O
located,O
at,O
18q21,O
",",O
has,O
been,O
identified,O
as,O
a,O
tumor,O
-,O
suppressor,O
gene,O
from,O
examination,O
of,O
pancreatic,B
cancers,I
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
if,O
it,O
might,O
also,O
be,O
altered,O
in,O
colorectal,B
cancers,I
.,O
METHODS,O
Mutation,O
analyses,O
of,O
the,O
DPC4,O
gene,O
were,O
performed,O
on,O
complementary,O
DNA,O
samples,O
from,O
31,O
primary,O
colorectal,B
cancer,I
specimens,I
using,O
a,O
combination,O
of,O
polymerase,O
chain,O
reaction,O
",",O
single,O
-,O
strand,O
conformation,O
polymorphism,O
",",O
and,O
DNA,O
sequencing,O
.,O
RESULTS,O
Four,O
missense,O
mutations,O
producing,O
amino,O
acid,O
substitutions,O
and,O
a,O
somatic,O
12,O
-,O
base,O
pair,O
deletion,O
in,O
the,O
coding,O
region,O
of,O
the,O
DPC4,B
gene,O
were,O
detected,O
in,O
the,O
31,O
cancers,O
(,O
16,O
%,O
;,O
5,O
of,O
31,O
),O
.,O
CONCLUSIONS,O
The,O
DPC4,B
gene,O
may,O
play,O
a,O
role,O
as,O
a,O
tumor,O
-,O
suppressor,O
gene,O
in,O
a,O
fraction,O
of,O
colorectal,B
cancers,O
;,O
however,O
",",O
while,O
allelic,O
loss,O
at,O
18q21,O
is,O
very,O
often,O
seen,O
in,O
colorectal,O
cancers,O
",",O
only,O
a,O
minority,O
show,O
DPC4,B
mutations,O
",",O
suggesting,O
that,O
there,O
might,O
be,O
another,O
tumor,O
-,O
suppressor,O
gene,O
in,O
this,O
chromosome,O
region,O
.,O
Pleiotropic,O
defects,O
in,O
ataxia,B
-,I
telangiectasia,I
protein,I
-,O
deficient,O
mice,O
.,O
We,O
have,O
generated,O
a,O
mouse,O
model,O
for,O
ataxia,B
-,I
telangiectasia,I
by,O
using,O
gene,O
targeting,O
to,O
generate,O
mice,O
that,O
do,O
not,O
express,O
the,O
Atm,B
protein,I
.,O
Atm,B
-,I
deficient,I
mice,I
are,O
retarded,O
in,O
growth,O
",",O
do,O
not,O
produce,O
mature,O
sperm,O
",",O
and,O
exhibit,O
severe,O
defects,O
in,O
T,B
cell,I
maturation,I
while,O
going,O
on,O
to,O
develop,O
thymomas,O
.,O
Atm,B
-,O
deficient,O
fibroblasts,O
grow,O
poorly,O
in,O
culture,O
and,O
display,O
a,O
high,O
level,O
of,O
double,O
-,O
stranded,O
chromosome,O
breaks,O
.,O
Atm,B
-,O
deficient,O
thymocytes,O
undergo,O
spontaneous,O
apoptosis,O
in,O
vitro,O
significantly,O
more,O
than,O
controls,O
.,O
Atm,B
-,O
deficient,O
mice,O
then,O
exhibit,O
many,O
of,O
the,O
same,O
symptoms,O
found,O
in,O
ataxia,B
-,I
telangiectasia,I
patients,O
and,O
in,O
cells,O
derived,O
from,O
them,O
.,O
Furthermore,O
",",O
we,O
demonstrate,O
that,O
the,O
Atm,B
protein,I
exists,O
as,O
two,O
discrete,O
molecular,O
species,O
",",O
and,O
that,O
loss,O
of,O
one,O
or,O
of,O
both,O
of,O
these,O
can,O
lead,O
to,O
the,O
development,O
of,O
the,O
disease,B
.,O
The,O
DCC,B
protein,I
and,O
prognosis,O
in,O
colorectal,B
cancer,I
.,O
BACKGROUND,O
Allelic,O
loss,O
of,O
chromosome,O
18q,O
predicts,O
a,O
poor,O
outcome,O
in,O
patients,O
with,O
stage,O
II,O
colorectal,B
cancer,I
.,O
Although,O
the,O
specific,O
gene,O
inactivated,O
by,O
this,O
allelic,O
loss,O
has,O
not,O
been,O
elucidated,O
",",O
the,O
DCC,B
(,O
deleted,O
in,O
colorectal,O
cancer,O
),O
gene,O
is,O
a,O
candidate,O
.,O
We,O
investigated,O
whether,O
the,O
expression,O
of,O
the,O
DCC,B
protein,O
in,O
tumor,O
cells,O
is,O
a,O
prognostic,O
marker,O
in,O
colorectal,O
carcinoma,O
.,O
METHODS,O
The,O
expression,O
of,O
DCC,B
was,O
evaluated,O
immunohistochemically,O
in,O
132,O
paraffin,O
-,O
embedded,O
samples,O
from,O
patients,O
with,O
curatively,O
resected,O
stage,O
II,O
and,O
III,O
colorectal,O
carcinomas,O
.,O
The,O
Cox,O
proportional,O
-,O
hazards,O
model,O
was,O
used,O
to,O
adjust,O
for,O
covariates,O
including,O
age,O
",",O
sex,O
",",O
tumor,O
site,O
",",O
degree,O
of,O
tumor,O
differentiation,O
",",O
and,O
use,O
of,O
adjuvant,O
therapy,O
.,O
RESULTS,O
The,O
expression,O
of,O
DCC,B
was,O
a,O
strong,O
positive,O
predictive,O
factor,O
for,O
survival,O
in,O
both,O
stage,O
II,O
and,O
stage,O
III,O
colorectal,O
carcinomas,O
.,O
In,O
patients,O
with,O
stage,O
II,O
disease,B
whose,O
tumors,O
expressed,O
DCC,B
",",O
the,O
five,O
-,O
year,O
survival,O
rate,O
was,O
94,O
.19,O
3,O
percent,O
",",O
whereas,O
in,O
DCC,B
-,I
negative,I
tumors,O
",",O
the,O
survival,O
rate,O
was,O
61,O
.35,O
6,O
percent,O
(,O
P,O
<,O
0,O
.42,O
001,O
),O
.,O
In,O
patients,O
with,O
stage,O
III,O
disease,B
",",O
the,O
respective,O
survival,O
rates,O
were,O
59,O
.59,O
3,O
percent,O
and,O
33,O
.64,O
2,O
percent,O
(,O
P,O
=,O
0,O
.,O
CONCLUSIONS,O
DCC,B
is,O
a,O
prognostic,O
marker,O
in,O
patients,O
with,O
stage,O
II,B
or,O
stage,O
III,B
colorectal,O
cancer,O
.,O
In,O
stage,O
II,B
colorectal,O
carcinomas,O
",",O
the,O
absence,O
of,O
DCC,B
identifies,O
a,O
subgroup,O
of,O
patients,O
with,O
lesions,O
that,O
behave,O
like,O
stage,O
III,B
cancers,O
.,O
These,O
findings,O
may,O
thus,O
have,O
therapeutic,O
implications,O
in,O
this,O
group,O
of,O
patients,O
Association,O
of,O
anxiety,O
-,O
related,O
traits,O
with,O
a,O
polymorphism,O
in,O
the,O
serotonin,O
transporter,O
gene,O
regulatory,O
region,O
.,O
Transporter,O
-,O
facilitated,O
uptake,O
of,O
serotonin,B
(,O
5,I
-,I
hydroxytryptamine,I
or,O
5,B
-,I
HT,I
),O
has,O
been,O
implicated,O
in,O
anxiety,B
in,O
humans,O
and,O
animal,O
models,O
and,O
is,O
the,O
site,O
of,O
action,O
of,O
widely,O
used,O
uptake,O
-,O
inhibiting,O
antidepressant,O
and,O
antianxiety,O
drugs,O
.,O
Human,O
5,B
-,I
HT,I
transporter,I
(,O
5,B
-,I
HTT,I
),O
gene,O
transcription,O
is,O
modulated,O
by,O
a,O
common,O
polymorphism,O
in,O
its,O
upstream,O
regulatory,O
region,O
.,O
The,O
short,O
variant,O
of,O
the,O
polymorphism,O
reduces,O
the,O
transcriptional,O
efficiency,O
of,O
the,O
5,B
-,I
HTT,I
gene,O
promoter,O
",",O
resulting,O
in,O
decreased,O
5,B
-,I
HTT,I
expression,O
and,O
5,B
-,I
HT,I
uptake,O
in,O
lymphoblasts,O
.,O
Association,O
studies,O
in,O
two,O
independent,O
samples,O
totaling,O
505,O
individuals,O
revealed,O
that,O
the,O
5,B
-,I
HTT,I
polymorphism,O
accounts,O
for,O
3,O
to,O
4,O
percent,O
of,O
total,O
variation,O
and,O
7,O
to,O
9,O
percent,O
of,O
inherited,O
variance,O
in,O
anxiety,B
-,I
related,I
personality,I
traits,O
in,O
individuals,O
as,O
well,O
as,O
sibships,O
.,O
.0,O
Phenotypic,O
and,O
genotypic,O
overlap,O
between,O
atelosteogenesis,B
type,I
2,I
and,O
diastrophic,B
dysplasia,I
.,O
Mutations,O
in,O
the,O
diastrophic,B
dysplasia,I
sulfate,O
transporter,O
gene,O
DTDST,O
have,O
been,O
associated,O
with,O
a,O
family,O
of,O
chondrodysplasias,O
that,O
comprises,O
",",O
in,O
order,O
of,O
increasing,O
severity,O
",",O
diastrophic,B
dysplasia,I
(,O
DTD,O
),O
",",O
atelosteogenesis,B
type,I
2,I
(,O
AO2,O
),O
",",O
and,O
achondrogenesis,B
type,I
1B,I
(,O
ACG1B,O
),O
.,O
To,O
learn,O
more,O
about,O
the,O
molecular,O
basis,O
of,O
DTDST,B
chondrodysplasias,O
and,O
about,O
genotype,O
-,O
phenotype,O
correlations,O
",",O
we,O
studied,O
fibroblast,O
cultures,O
of,O
three,O
new,O
patients,O
one,O
with,O
AO,B
-,I
2,I
",",O
one,O
with,O
DTD,B
",",O
and,O
one,O
with,O
an,O
intermediate,O
phenotype,O
(,O
AO2,B
/,I
DTD,I
),O
.,O
Reduced,O
incorporation,O
of,O
inorganic,O
sulfate,O
into,O
macromolecules,O
was,O
found,O
in,O
all,O
three,O
.,O
Each,O
of,O
the,O
three,O
patients,O
was,O
found,O
to,O
be,O
heterozygous,O
for,O
a,O
c862t,B
transition,I
predicting,O
a,O
R279W,B
substitution,I
in,O
the,O
third,O
extracellular,O
loop,O
of,O
DTDST,O
.,O
In,O
two,O
patients,O
(,O
DTD,B
and,O
AO2,B
/,O
DTD,B
),O
",",O
no,O
other,O
structural,O
mutation,O
was,O
found,O
",",O
but,O
polymerase,O
chain,O
reaction,O
amplification,O
and,O
single,O
-,O
strand,O
conformation,O
polymorphism,O
analysis,O
of,O
fibroblast,O
cDNA,O
showed,O
reduced,O
mRNA,O
levels,O
of,O
the,O
wild,O
-,O
type,O
DTDST,O
allele,O
these,O
two,O
patients,O
may,O
be,O
compound,O
heterozygotes,O
for,O
the,O
Finnish,B
mutation,I
(,O
as,O
yet,O
uncharacterized,O
at,O
the,O
DNA,O
level,O
),O
",",O
which,O
causes,O
reduced,O
expression,O
of,O
DTDST,O
.,O
The,O
third,O
patient,O
(,O
with,O
AO2,O
),O
had,O
the,O
R279W,B
mutation,I
compounded,O
with,O
a,O
novel,O
mutation,O
",",O
the,O
deletion,O
of,O
cytosine,B
418,I
(,O
delta,B
c418,I
),O
",",O
predicting,O
a,O
frameshift,O
with,O
premature,O
termination,O
.,O
Also,O
the,O
delta,B
c418,I
allele,O
was,O
underrepresented,O
in,O
the,O
cDNA,O
",",O
in,O
accordance,O
with,O
previous,O
observations,O
that,O
premature,O
stop,O
codons,O
reduce,O
mRNA,O
levels,O
.,O
The,O
presence,O
of,O
the,O
DTDST,B
R279W,I
mutation,O
in,O
a,O
total,O
of,O
11,O
patients,O
with,O
AO2,B
or,O
DTD,B
emphasizes,O
the,O
overlap,O
between,O
these,O
conditions,O
.,O
This,O
mutation,O
has,O
not,O
been,O
found,O
so,O
far,O
in,O
8,O
analyzed,O
ACG1B,B
patients,O
",",O
suggesting,O
that,O
it,O
allows,O
some,O
residual,O
activity,O
of,O
the,O
sulfate,O
transporter,O
.,O
Identification,O
of,O
WASP,B
mutations,O
",",O
mutation,O
hotspots,O
and,O
genotype,O
-,O
phenotype,O
disparities,O
in,O
24,O
patients,O
with,O
the,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
.,O
The,O
Wiskott,B
-,I
Aldrich,I
syndrome,I
(,O
WAS,B
),O
",",O
an,O
X,O
-,O
linked,O
immunodeficiency,O
disease,O
caused,O
by,O
mutation,O
in,O
the,O
recently,O
isolated,O
gene,O
encoding,O
WAS,B
protein,I
(,O
WASP,B
),O
",",O
is,O
known,O
to,O
be,O
associated,O
with,O
extensive,O
clinical,O
heterogeneity,O
.,O
Cumulative,O
mutation,O
data,O
have,O
revealed,O
that,O
WASP,B
genotypes,O
are,O
also,O
highly,O
variable,O
among,O
WAS,B
patients,O
",",O
but,O
the,O
relationship,O
of,O
phenotype,O
with,O
genotype,O
in,O
this,O
disease,O
remains,O
unclear,O
.,O
To,O
address,O
this,O
issue,O
we,O
characterized,O
WASP,B
mutations,O
in,O
24,O
unrelated,O
WAS,B
patients,O
",",O
including,O
18,O
boys,O
with,O
severe,O
classical,O
WAS,B
and,O
6,O
boys,O
expressing,O
mild,O
forms,O
of,O
the,O
disease,B
",",O
and,O
then,O
examined,O
the,O
degree,O
of,O
correlation,O
of,O
these,O
as,O
well,O
as,O
all,O
previously,O
published,O
WASP,B
mutations,O
with,O
disease,B
severity,O
.,O
By,O
analysis,O
of,O
these,O
compiled,O
mutation,O
data,O
",",O
we,O
demonstrated,O
clustering,O
of,O
WASP,B
mutations,O
within,O
the,O
four,O
most,O
N,O
-,O
terminal,O
exons,O
of,O
the,O
gene,O
and,O
also,O
identified,O
several,O
sites,O
within,O
this,O
region,O
as,O
hotspots,O
for,O
WASP,B
mutation,O
.,O
These,O
characteristics,O
were,O
observed,O
",",O
however,O
",",O
in,O
both,O
severe,B
and,O
mild,B
cases,O
of,O
the,O
disease,B
.,O
Similarly,O
",",O
while,O
the,O
cumulative,O
data,O
revealed,O
a,O
predominance,O
of,O
missense,B
mutations,I
among,O
the,O
WASP,B
gene,I
lesions,I
observed,O
in,O
boys,O
with,O
isolated,O
thrombocytopenia,B
",",O
missense,B
mutations,I
were,O
not,O
exclusively,O
associated,O
with,O
milder,O
WAS,B
phenotypes,I
",",O
but,O
also,O
comprised,O
a,O
substantial,O
portion,O
(,O
38,O
%,O
),O
of,O
the,O
WASP,B
gene,I
defects,I
found,O
in,O
patients,O
with,O
severe,B
disease,I
.,O
These,O
findings,O
",",O
as,O
well,O
as,O
the,O
detection,O
of,O
identical,O
WASP,B
mutations,O
in,O
patients,O
with,O
disparate,O
phenotypes,O
",",O
reveal,O
a,O
lack,O
of,O
phenotype,O
concordance,O
with,O
genotype,O
in,O
WAS,B
and,O
thus,O
imply,O
that,O
phenotypic,O
outcome,O
in,O
this,O
disease,B
cannot,O
be,O
reliably,O
predicted,O
solely,O
on,O
the,O
basis,O
of,O
WASP,B
genotypes,O
.,O
.,O
Germline,O
mutations,O
in,O
the,O
3,O
',O
part,O
of,O
APC,B
exon,O
15,O
do,O
not,O
result,O
in,O
truncated,O
proteins,O
and,O
are,O
associated,O
with,O
attenuated,O
adenomatous,B
polyposis,I
coli,I
.,O
Familial,B
adenomatous,I
polyposis,I
(,O
FAP,O
),O
is,O
an,O
inherited,O
predisposition,O
to,O
colorectal,B
cancer,O
characterized,O
by,O
the,O
development,O
of,O
numerous,O
adenomatous,O
polyps,O
predominantly,O
in,O
the,O
colorectal,B
region,O
.,O
Germline,O
mutations,O
in,O
the,O
adenomatous,B
polyposis,I
coli,I
(,O
APC,O
),O
gene,O
are,O
responsible,O
for,O
most,O
cases,O
of,O
FAP,O
.,O
Mutations,O
at,O
the,O
5,O
end,O
of,O
APC,B
are,O
known,O
to,O
be,O
associated,O
with,O
a,O
relatively,O
mild,O
form,O
of,O
the,O
disease,B
",",O
called,O
attenuated,O
adenomatous,O
polyposis,O
coli,O
(,O
AAPC,B
),O
.,O
We,O
identified,O
a,O
frameshift,O
mutation,O
in,O
the,O
3,O
part,O
of,O
exon,O
15,O
",",O
resulting,O
in,O
a,O
stop,O
codon,O
at,O
1862,O
",",O
in,O
a,O
large,O
Dutch,O
kindred,O
with,O
AAPC,B
.,O
Western,O
blot,O
analysis,O
of,O
lymphoblastoid,O
cell,O
lines,O
derived,O
from,O
affected,O
family,O
members,O
from,O
this,O
kindred,O
",",O
as,O
well,O
as,O
from,O
a,O
previously,O
reported,O
Swiss,O
family,O
carrying,O
a,O
frameshift,O
mutation,O
at,O
codon,O
1987,O
and,O
displaying,O
a,O
similar,O
attenuated,O
phenotype,O
",",O
showed,O
only,O
the,O
wild,O
-,O
type,O
APC,B
protein,O
.,O
Our,O
study,O
indicates,O
that,O
chain,O
-,O
terminating,O
mutations,O
located,O
in,O
the,O
3,O
part,O
of,O
APC,B
do,O
not,O
result,O
in,O
detectable,O
truncated,O
polypeptides,O
and,O
we,O
hypothesize,O
that,O
this,O
is,O
likely,O
to,O
be,O
the,O
basis,O
for,O
the,O
observed,O
AAPC,B
phenotype,O
.,O
Complete,O
genomic,O
sequence,O
and,O
analysis,O
of,O
117,O
kb,O
of,O
human,O
DNA,O
containing,O
the,O
gene,O
BRCA1,B
.,O
Over,O
100,O
distinct,O
disease,O
-,O
associated,O
mutations,O
have,O
been,O
identified,O
in,O
the,O
breast,B
-,I
ovarian,I
cancer,I
susceptibility,I
gene,I
BRCA1,I
.,O
Loss,O
of,O
the,O
wild,B
-,I
type,I
allele,I
in,O
>,O
90,O
%,O
of,O
tumors,O
from,O
patients,O
with,O
inherited,O
BRCA1,B
mutations,I
indicates,O
tumor,O
suppressive,O
function,O
.,O
The,O
low,O
incidence,O
of,O
somatic,O
mutations,O
suggests,O
that,O
BRCA1,B
inactivation,O
in,O
sporadic,O
tumors,O
occurs,O
by,O
alternative,O
mechanisms,O
",",O
such,O
as,O
interstitial,O
chromosomal,O
deletion,O
or,O
reduced,O
transcription,O
.,O
To,O
identify,O
possible,O
features,O
of,O
the,O
BRCA1,B
genomic,I
region,I
that,O
may,O
contribute,O
to,O
chromosomal,O
instability,O
as,O
well,O
as,O
potential,O
transcriptional,O
regulatory,O
elements,O
",",O
a,O
117,O
",",O
143,O
-,O
bp,O
DNA,O
sequence,O
encompassing,O
BRCA1,B
was,O
obtained,O
by,O
random,O
sequencing,O
of,O
four,O
cosmids,O
identified,O
from,O
a,O
human,O
chromosome,O
17,O
specific,O
library,O
.,O
The,O
24,O
exons,O
of,O
BRCA1,B
span,O
an,O
81,O
-,O
kb,O
region,O
that,O
has,O
an,O
unusually,O
high,O
density,O
of,O
Alu,O
repetitive,O
DNA,O
(,O
41,O
.,O
5,O
%,O
),O
",",O
but,O
relatively,O
low,O
density,O
(,O
4,O
.,O
8,O
%,O
),O
of,O
other,O
repetitive,O
sequences,O
.,O
BRCA1,B
intron,O
lengths,O
range,O
in,O
size,O
from,O
403,O
bp,O
to,O
9,O
.,O
2,O
kb,O
and,O
contain,O
the,O
intragenic,O
microsatellite,O
markers,O
D17S1323,B
",",O
D17S1322,B
",",O
and,O
D17S855,B
",",O
which,O
localize,O
to,O
introns,O
12,O
",",O
19,O
",",O
and,O
20,O
",",O
respectively,O
.,O
In,O
addition,O
to,O
BRCA1,B
",",O
the,O
contig,O
contains,O
two,O
complete,O
genes,O
Rho7,B
",",O
a,O
member,O
of,O
the,O
rho,O
family,O
of,O
GTP,O
binding,O
proteins,O
",",O
and,O
VAT1,B
",",O
an,O
abundant,O
membrane,O
protein,O
of,O
cholinergic,O
synaptic,O
vesicles,O
.,O
Partial,O
sequences,O
of,O
the,O
1A1,B
-,I
3B,I
B,I
-,I
box,I
protein,I
pseudogene,I
and,O
IFP,B
35,I
",",O
an,O
interferon,O
induced,O
leucine,O
zipper,O
protein,O
",",O
reside,O
within,O
the,O
contig,O
.,O
An,O
L21,O
ribosomal,O
protein,O
pseudogene,O
is,O
embedded,O
in,O
BRCA1,B
intron,O
13,O
.,O
The,O
order,O
of,O
genes,O
on,O
the,O
chromosome,O
is,O
centromere,O
-,O
1FP,O
35,O
-,O
VAT1,O
-,O
Rho7,O
-,O
BRCA1,B
-,O
1A1,O
-,O
3B,O
-,O
telomere,O
Identification,O
of,O
a,O
RING,O
protein,O
that,O
can,O
interact,O
in,O
vivo,O
with,O
the,O
BRCA1,B
gene,O
product,O
.,O
The,O
hereditary,O
breast,O
and,O
ovarian,O
cancer,B
gene,O
",",O
BRCA1,B
",",O
encodes,O
a,O
large,O
polypeptide,O
that,O
contains,O
the,O
cysteine,O
-,O
rich,O
RING,O
motif,O
",",O
a,O
zinc,O
-,O
binding,O
domain,O
found,O
in,O
a,O
variety,O
of,O
regulatory,O
proteins,O
.,O
Here,O
we,O
describe,O
a,O
novel,O
protein,O
that,O
interacts,O
in,O
vivo,O
with,O
the,O
N,B
-,I
terminal,I
region,O
of,O
BRCA1,B
.,O
This,O
BRCA1,B
-,I
associated,I
RING,I
domain,I
(,O
BARD1,B
),O
protein,O
contains,O
an,O
N,B
-,I
terminal,I
RING,I
motif,I
",",O
three,O
tandem,O
ankyrin,O
repeats,O
",",O
and,O
a,O
C,B
-,I
terminal,I
sequence,O
with,O
significant,O
homology,O
to,O
the,O
phylogenetically,O
conserved,O
BRCT,O
domains,O
that,O
lie,O
near,O
the,O
C,B
terminus,I
of,O
BRCA1,B
.,O
The,O
BARD1,B
/,O
BRCA1,B
interaction,O
is,O
disrupted,O
by,O
BRCA1,B
missense,O
mutations,O
that,O
segregate,O
with,O
breast,B
cancer,I
susceptibility,I
",",O
indicating,O
that,O
BARD1,B
may,O
be,O
involved,O
in,O
mediating,O
tumour,O
suppression,O
by,O
BRCA1,B
.,O
Detection,O
of,O
heterozygous,O
mutations,O
in,O
BRCA1,B
using,O
high,O
density,O
oligonucleotide,O
arrays,O
and,O
two,O
-,O
colour,O
fluorescence,O
analysis,O
.,O
The,O
ability,O
to,O
scan,O
a,O
large,O
gene,O
rapidly,O
and,O
accurately,O
for,O
all,O
possible,O
heterozygous,B
mutations,I
in,O
large,O
numbers,O
of,O
patient,O
samples,O
will,O
be,O
critical,O
for,O
the,O
future,O
of,O
medicine,O
.,O
We,O
have,O
designed,O
high,O
-,O
density,O
arrays,O
consisting,O
of,O
over,O
96,O
",",O
600,O
oligonucleotides,O
20,O
-,O
nucleotides,O
(,O
nt,O
),O
in,O
length,O
to,O
screen,O
for,O
a,O
wide,O
range,O
of,O
heterozygous,B
mutations,I
in,O
the,O
3,O
.,O
45,O
-,O
kilobases,O
(,O
kb,O
),O
exon,O
11,O
of,O
the,O
hereditary,O
breast,B
and,I
ovarian,I
cancer,I
gene,O
BRCA1,O
.,O
Reference,O
and,O
test,O
samples,O
were,O
co,O
-,O
hybridized,O
to,O
these,O
arrays,O
and,O
differences,O
in,O
hybridization,O
patterns,O
quantitated,O
by,O
two,O
-,O
colour,O
analysis,O
.,O
Fourteen,O
of,O
fifteen,O
patient,O
samples,O
with,O
known,O
mutations,B
were,O
accurately,O
diagnosed,O
",",O
and,O
no,O
FALSE,O
positive,O
mutations,O
were,O
identified,O
in,O
20,O
control,O
samples,O
.,O
Eight,O
single,O
nucleotide,O
polymorphisms,O
were,O
also,O
readily,O
detected,O
.,O
DNA,O
chip,O
-,O
based,O
assays,O
may,O
provide,O
a,O
valuable,O
new,O
technology,O
for,O
high,O
-,O
throughput,O
cost,O
-,O
efficient,O
detection,O
of,O
genetic,O
alterations,O
.,O
Autosomal,B
dominant,I
primary,I
hyperparathyroidism,I
and,I
jaw,I
tumor,I
syndrome,I
associated,O
with,O
renal,B
hamartomas,I
and,I
cystic,I
kidney,I
disease,I
:,O
linkage,O
to,O
1q21,O
-,O
q32,O
and,O
loss,O
of,O
the,O
wild,O
type,O
allele,O
in,O
renal,B
hamartomas,I
.,O
Hereditary,B
hyperparathyroidism,I
-,I
jaw,I
tumor,I
syndrome,I
(,O
HPT,B
-,I
JT,I
),O
is,O
an,O
autosomal,O
dominant,O
disease,O
(,O
OMIM,O
145001,O
),O
that,O
has,O
recently,O
been,O
mapped,O
to,O
chromosomal,O
region,O
1q21,O
-,O
q32,O
(,O
HRPT2,O
),O
.,O
Here,O
we,O
report,O
two,O
families,O
with,O
HPT,B
-,I
JT,I
syndrome,I
in,O
which,O
adult,O
renal,O
hamartomas,O
or,O
cystic,O
kidney,O
disease,O
were,O
prominent,O
associated,O
features,O
",",O
possibly,O
representing,O
a,O
new,O
phenotypic,O
variant,O
of,O
the,O
HPT,B
-,I
JT,I
syndrome,I
.,O
In,O
the,O
first,O
family,O
",",O
renal,B
lesions,I
were,O
present,O
in,O
five,O
out,O
of,O
six,O
affected,O
individuals,O
",",O
whereas,O
HPT,B
and,O
JT,B
were,O
seen,O
in,O
four,O
and,O
two,O
cases,O
",",O
respectively,O
.,O
In,O
the,O
second,O
family,O
",",O
JT,B
was,O
found,O
in,O
three,O
of,O
the,O
five,O
affected,O
individuals,O
and,O
two,O
affected,O
members,O
also,O
exhibited,O
polycystic,B
kidney,I
disease,I
.,O
The,O
possibility,O
of,O
the,O
latter,O
cosegregating,O
as,O
a,O
separate,O
autosomal,B
dominant,I
gene,I
can,O
not,O
be,O
ruled,O
out,O
.,O
A,O
sex,O
-,O
dependent,O
penetrance,O
of,O
primary,B
HPT,I
",",O
resulting,O
in,O
predominantly,O
male,O
-,O
affected,O
cases,O
was,O
evident,O
in,O
the,O
two,O
families,O
.,O
Twenty,O
microsatellite,O
markers,O
in,O
the,O
HRPT2,B
region,I
were,O
typed,O
",",O
in,O
addition,O
to,O
markers,O
in,O
the,O
multiple,O
endocrine,B
neoplasia,I
(,O
MEN,B
),O
types,O
1,O
and,O
2,O
regions,O
at,O
11q13,O
and,O
10q11,O
.,O
The,O
disease,B
in,O
these,O
two,O
kindreds,O
was,O
linked,O
to,O
five,O
markers,O
in,O
the,O
1q21,O
-,O
q32,O
region,O
(,O
logarithm,O
-,O
of,O
-,O
odds,O
scores,O
3,O
.,O
2,O
-,O
4,O
2,O
),O
",",O
whereas,O
linkage,O
to,O
the,O
MEN1,O
and,O
MEN2,O
regions,O
was,O
excluded,O
.,O
Meiotic,O
recombinations,O
detected,O
in,O
affected,O
individuals,O
placed,O
the,O
locus,O
telomeric,O
of,O
D1S215,O
",",O
thus,O
narrowing,O
the,O
HRPT2,B
region,O
from,O
>,O
60,O
to,O
approximately,O
34,O
centimorgans,O
.,O
Loss,B
of,I
heterozygosity,I
was,O
studied,O
in,O
seven,O
renal,B
hamartomas,I
from,O
two,O
affected,O
individuals,O
in,O
the,O
first,O
family,O
",",O
as,O
well,O
as,O
in,O
a,O
jaw,B
tumor,I
and,O
a,O
parathyroid,B
tumor,I
from,O
the,O
second,O
family,O
.,O
All,O
renal,B
hamartomas,I
showed,O
loss,B
of,I
heterozygosity,I
at,O
the,O
1q21,O
-,O
q32,O
region,O
.,O
The,O
losses,O
invariably,O
involved,O
the,O
wild,O
type,O
allele,O
derived,O
from,O
the,O
unaffected,O
parent,O
",",O
suggesting,O
the,O
inactivation,O
of,O
a,O
tumor,O
suppressor,O
gene,O
in,O
this,O
region,O
Independent,O
origin,O
of,O
single,O
and,O
double,O
mutations,O
in,O
the,O
human,O
glucose,O
6,O
-,O
phosphate,O
dehydrogenase,O
gene,O
.,O
The,O
vast,O
majority,O
of,O
both,O
polymorphic,O
and,O
sporadic,O
G6PD,B
variants,O
are,O
due,O
to,O
single,O
missense,O
mutations,O
.,O
In,O
the,O
four,O
polymorphic,O
variants,O
that,O
have,O
two,O
point,O
mutations,O
",",O
one,O
of,O
the,O
mutations,O
is,O
always,O
376,O
A,O
-,O
-,O
>,O
G,O
(,O
126,O
Asn,B
-,I
-,I
>,I
Asp,I
),O
",",O
which,O
on,O
its,O
own,O
gives,O
rise,O
to,O
the,O
nondeficient,O
polymorphic,O
variant,O
",",O
G6PD,B
A,I
.,O
In,O
a,O
study,O
of,O
G6PD,B
deficient,O
patients,O
who,O
presented,O
with,O
clinical,O
favism,B
in,O
Spain,O
",",O
we,O
have,O
found,O
a,O
new,O
polymorphic,O
variant,O
that,O
we,O
have,O
called,O
G6PD,B
Malaga,O
",",O
whose,O
only,O
abnormality,O
is,O
a,O
542,O
A,O
-,O
-,O
>,O
T,O
(,O
181,O
Asp,O
-,O
-,O
>,O
Val,O
),O
mutation,O
.,O
This,O
is,O
the,O
same,O
mutation,O
as,O
previously,O
found,O
in,O
association,O
with,O
the,O
mutation,O
of,O
G6PD,B
A,I
in,O
the,O
double,O
mutant,O
",",O
G6PD,B
Santamaria,O
.,O
G6PD,B
Malaga,I
is,O
associated,O
with,O
enzyme,O
deficiency,O
(,O
class,O
III,O
),O
",",O
and,O
the,O
enzymic,O
properties,O
of,O
G6PD,B
Malaga,I
and,O
G6PD,B
Santamaria,I
are,O
quite,O
similar,O
",",O
indicating,O
that,O
in,O
this,O
case,O
the,O
effects,O
of,O
the,O
two,O
mutations,O
are,O
additive,O
rather,O
than,O
synergistic,O
.,O
G6PD,B
Santamaria,I
might,O
have,O
been,O
produced,O
by,O
recombination,O
between,O
G6PD,B
A,I
and,O
G6PD,B
Malaga,I
;,O
however,O
haplotype,O
analysis,O
",",O
including,O
the,O
use,O
of,O
a,O
new,O
silent,O
polymorphism,O
",",O
suggests,O
that,O
the,O
same,O
542,O
A,O
-,O
->,O
T,O
mutation,O
has,O
taken,O
place,O
independently,O
in,O
a,O
G6PD,B
B,I
gene,O
to,O
give,O
G6PD,B
Malaga,I
and,O
in,O
a,O
G6PD,B
A,I
gene,O
to,O
give,O
G6PD,B
Santamaria,I
.,O
These,O
findings,O
help,O
to,O
outline,O
the,O
relationship,O
and,O
evolution,O
of,O
mutations,O
in,O
the,O
human,O
G6PD,B
locus,O
.,O
BRCA1,B
R841W,O
:,O
a,O
strong,O
candidate,O
for,O
a,O
common,O
mutation,O
with,O
moderate,O
phenotype,O
.,O
BRCA1,B
mutations,O
cause,O
increased,O
risk,O
for,O
breast,B
and,O
ovarian,B
cancer,I
",",O
frequently,O
of,O
early,O
onset,O
.,O
Many,O
different,O
mutations,O
occur,O
in,O
BRCA1,B
",",O
including,O
several,O
examples,O
of,O
recurrent,O
mutations,O
",",O
each,O
of,O
which,O
accounts,O
for,O
a,O
significant,O
number,O
of,O
families,O
with,O
heritable,O
cancer,I
predisposition,I
.,O
These,O
common,O
mutations,O
have,O
an,O
etiological,O
role,O
in,O
many,O
breast,B
and,O
ovarian,B
cancer,I
cases,O
and,O
provide,O
the,O
opportunity,O
to,O
examine,O
genotype,O
-,O
phenotype,O
correlations,O
and,O
genotype,O
-,O
environment,O
interactions,O
in,O
individuals,O
with,O
the,O
identical,O
BRCA1,B
lesion,O
.,O
We,O
report,O
a,O
novel,O
missense,O
change,O
in,O
BRCA1,B
",",O
2640,O
C,O
-,O
-,O
>,O
T,O
(,O
R841W,O
),O
",",O
found,O
in,O
3,O
cases,O
from,O
a,O
subject,O
group,O
of,O
305,O
breast,B
and,O
79,O
ovarian,B
cancer,I
cases,O
from,O
Orange,O
County,O
",",O
CA,O
.,O
These,O
are,O
consecutive,O
",",O
population,O
-,O
based,O
cases,O
not,O
selected,O
for,O
age,O
or,O
family,O
history,O
.,O
In,O
all,O
three,O
cases,O
",",O
there,O
is,O
a,O
strong,O
family,O
history,O
of,O
breast,B
",",O
ovarian,B
",",O
or,O
other,O
cancers,B
possibly,O
related,O
to,O
a,O
BRCA1,B
defect,O
and,O
family,O
members,O
showed,O
a,O
high,O
concordance,O
of,O
cancer,O
incidence,O
with,O
the,O
presence,O
of,O
R841W,O
.,O
The,O
age,O
of,O
cancer,B
onset,I
was,O
not,O
always,O
distinct,O
from,O
typical,O
sporadic,O
cases,O
.,O
Testing,O
of,O
a,O
sample,O
of,O
413,O
unrelated,O
individuals,O
to,O
examine,O
the,O
hypothesis,O
that,O
R841W,O
might,O
be,O
a,O
rare,O
polymorphism,O
detected,O
one,O
additional,O
instance,O
in,O
a,O
woman,O
with,O
breast,B
cancer,I
diagnosed,O
at,O
age,O
77,O
years,O
",",O
and,O
cancer,B
in,O
one,O
parent,O
.,O
R841W,O
is,O
likely,O
to,O
be,O
an,O
etiologically,O
significant,O
lesion,O
with,O
involvement,O
in,O
close,O
to,O
1,O
%,O
(,O
95,O
%,O
confidence,O
interval,O
of,O
0,O
-,O
1,O
.,O
7,O
%,O
),O
of,O
all,O
breast,B
and,I
ovarian,I
cancers,I
in,O
this,O
population,O
.,O
Ataxia,B
-,I
telangiectasia,I
:,O
founder,O
effect,O
among,O
north,O
African,O
Jews,O
.,O
The,O
ATM,B
gene,O
is,O
responsible,O
for,O
the,O
autosomal,O
recessive,O
disorder,O
ataxia,B
-,I
telangiectasia,I
(,I
A,I
-,I
T,I
),I
",",O
characterized,O
by,O
cerebellar,O
degeneration,O
",",O
immunodeficiency,O
and,O
cancer,B
predisposition,I
.,O
A,O
-,O
T,O
carriers,O
were,O
reported,O
to,O
be,O
moderately,O
cancer,O
-,O
prone,O
.,O
A,O
wide,O
variety,O
of,O
A,O
-,O
T,B
mutations,O
",",O
most,O
of,O
which,O
are,O
unique,O
to,O
single,O
families,O
",",O
were,O
identified,O
in,O
various,O
ethnic,O
groups,O
",",O
precluding,O
carrier,O
screening,O
with,O
mutation,O
-,O
specific,O
assays,O
.,O
However,O
",",O
a,O
single,O
mutation,O
was,O
observed,O
in,O
32,O
/,O
33,O
defective,O
ATM,B
alleles,O
in,O
Jewish,O
A,O
-,O
T,B
families,O
of,O
North,O
African,O
origin,O
",",O
coming,O
from,O
various,O
regions,O
of,O
Morocco,O
and,O
Tunisia,O
.,O
This,O
mutation,O
",",O
103C,O
-,O
-,O
>,O
T,O
",",O
results,O
in,O
a,O
stop,O
codon,O
at,O
position,O
35,O
of,O
the,O
ATM,B
protein,I
.,O
In,O
keeping,O
with,O
the,O
nature,O
of,O
this,O
mutation,O
",",O
various,O
antibodies,O
directed,O
against,O
the,O
ATM,B
protein,I
failed,O
to,O
defect,O
this,O
protein,O
in,O
patient,O
cells,O
.,O
A,O
rapid,O
carrier,O
detection,O
assay,O
detected,O
this,O
mutation,O
in,O
three,O
out,O
of,O
488,O
ATM,B
alleles,O
of,O
Jewish,O
Moroccan,O
or,O
Tunisian,O
origin,O
.,O
This,O
founder,O
effect,O
provides,O
a,O
unique,O
opportunity,O
for,O
population,O
-,O
based,O
screening,O
for,O
A,B
-,I
T,I
carriers,O
in,O
a,O
large,O
Jewish,O
community,O
.,O
Mutation,O
analysis,O
of,O
BRCA1,B
and,O
BRCA2,B
in,O
a,O
male,O
breast,O
cancer,O
population,O
.,O
A,O
population,O
-,O
based,O
series,O
of,O
54,O
male,O
breast,O
cancer,O
cases,O
from,O
Southern,O
California,O
were,O
analyzed,O
for,O
germ,O
-,O
line,O
mutations,O
in,O
the,O
inherited,O
breast,O
/,O
ovarian,O
cancer,O
genes,O
",",O
BRCA1,B
and,O
BRCA2,B
.,O
Nine,O
(,O
17,O
%,O
),O
of,O
the,O
patients,O
had,O
a,O
family,O
history,O
of,O
breast,B
and,O
/,O
or,O
ovarian,B
cancer,I
in,O
at,O
least,O
one,O
first,O
-,O
degree,O
relative,O
.,O
A,O
further,O
seven,O
(,O
13,O
%,O
),O
of,O
the,O
patients,O
reported,O
breast,B
/,O
ovarian,B
cancer,I
in,O
at,O
least,O
one,O
second,O
-,O
degree,O
relative,O
and,O
in,O
no,O
first,O
-,O
degree,O
relatives,O
.,O
No,O
germ,O
-,O
line,O
BRCA1,O
mutations,O
were,O
found,O
.,O
Two,O
male,O
breast,B
cancer,I
patients,O
(,O
4,O
%,O
of,O
the,O
total,O
),O
were,O
found,O
to,O
carry,O
novel,O
truncating,O
mutations,O
in,O
the,O
BRCA2,B
gene,O
.,O
Only,O
one,O
of,O
the,O
two,O
male,O
breast,B
cancer,I
patients,O
carrying,O
a,O
BRCA2,B
mutation,O
had,O
a,O
family,O
history,O
of,O
cancer,O
",",O
with,O
one,O
case,O
of,O
ovarian,B
cancer,I
in,O
a,O
first,O
-,O
degree,O
relative,O
.,O
The,O
remaining,O
eight,O
cases,O
(,O
89,O
%,O
),O
of,O
male,O
breast,B
cancer,I
with,O
a,O
family,O
history,O
of,O
breast,B
/,O
ovarian,B
cancer,I
in,O
first,O
-,O
degree,O
relatives,O
remain,O
unaccounted,O
for,O
by,O
mutations,O
in,O
either,O
the,O
BRCA1,B
gene,O
or,O
the,O
BRCA2,B
gene,O
.,O
.0,O
Molecular,O
basis,O
for,O
Duarte,B
and,O
Los,B
Angeles,I
variant,I
galactosemia,I
.,O
Human,O
orythrocytes,O
that,O
are,O
homozygous,O
for,O
the,O
Duarte,B
enzyme,O
variant,I
of,I
galactosemia,I
(,O
D,B
/,I
D,I
),O
have,O
a,O
characteristic,O
isoform,O
on,O
isoelectric,O
focusing,O
and,O
50,O
%,O
reduction,O
in,O
galactose,O
-,O
1,O
-,O
phosphate,O
uridyltransferase,O
(,O
GALT,B
),O
enzyme,O
activity,O
.,O
The,O
Duarte,B
biochemical,I
phenotype,I
has,O
a,O
molecular,O
genotype,O
of,O
N314D,B
/,O
N314D,B
.,O
The,O
characteristic,O
Duarte,B
isoform,I
is,O
also,O
associated,O
with,O
a,O
variant,O
called,O
the,O
Los,B
Angeles,I
(,O
LA,B
),O
phenotype,I
",",O
which,O
has,O
increased,O
GALT,O
enzyme,O
activity,O
.,O
We,O
evaluated,O
GALT,O
enzyme,O
activity,O
and,O
screened,O
the,O
GALT,O
genes,O
of,O
145,O
patients,O
with,O
one,O
or,O
more,O
N314D,B
-,I
containing,I
alleles,I
.,O
We,O
found,O
seven,O
with,O
the,O
LA,B
biochemical,I
phenotype,I
",",O
and,O
all,O
had,O
a,O
1721C,O
-,O
-,O
>,O
T,O
transition,O
in,O
exon,O
7,O
in,O
cis,O
with,O
the,O
N314D,B
missense,I
mutation,I
.,O
The,O
1721C,O
-,O
-,O
>,O
T,O
transition,O
is,O
a,O
neutral,O
polymorphism,O
for,O
leucine,O
at,O
amino,O
acid,O
218,O
(,O
L218L,O
),O
.,O
In,O
pedigree,O
analyses,O
",",O
this,O
1721C,O
-,O
-,O
>,O
T,O
transition,O
segregated,O
with,O
the,O
LA,B
phenotype,I
of,O
increased,O
GALT,B
activity,O
in,O
three,O
different,O
biochemical,O
phenotypes,O
(,O
LA,B
/,O
N,B
",",O
LA,B
/,O
G,B
",",O
and,O
LA,B
/,O
D,B
),O
.,O
To,O
determine,O
the,O
mechanism,O
for,O
increased,O
activity,O
of,O
the,O
LA,B
variant,I
",",O
we,O
compared,O
GALT,O
mRNA,O
",",O
protein,O
abundance,O
",",O
and,O
enzyme,O
thermal,O
stability,O
in,O
lymphoblast,O
cell,O
lines,O
of,O
D,B
and,O
LA,B
phenotypes,O
with,O
comparable,O
genotypes,O
.,O
GALT,O
protein,O
abundance,O
was,O
increased,O
in,O
LA,B
compared,O
to,O
D,B
alleles,O
",",O
but,O
mRNA,O
was,O
similar,O
among,O
all,O
genotypes,O
.,O
When,O
LA,B
/,O
D,B
and,O
D,B
/,O
D,B
GALT,B
biochemical,O
phenotypes,O
were,O
compared,O
to,O
N,B
/,O
N,B
GALT,B
phenotypes,O
",",O
both,O
had,O
50,O
%,O
",",O
as,O
compared,O
to,O
21,O
%,O
",",O
reduction,O
in,O
GALT,B
activity,O
in,O
the,O
wild,O
type,O
(,O
N,B
/,O
N,B
),O
after,O
exposure,O
at,O
identical,O
initial,O
enzyme,O
activity,O
to,O
50,O
degrees,O
C,O
for,O
15,O
min,O
.,O
We,O
conclude,O
that,O
the,O
codon,O
change,O
N314D,B
in,O
cis,O
with,O
the,O
base,O
-,O
pair,O
transition,O
1721C,O
-,O
-,O
>,O
T,O
produces,O
the,O
LA,B
variant,O
of,O
galactosemia,B
and,O
that,O
this,O
nucleotide,O
change,O
increases,O
GALT,B
activity,O
by,O
increasing,O
GALT,B
protein,O
abundance,O
without,O
increasing,O
transcription,O
or,O
decreasing,O
thermal,O
lability,O
.,O
A,O
favorable,O
codon,O
bias,O
for,O
the,O
mutated,O
codon,O
with,O
consequently,O
increased,O
translation,O
rates,O
is,O
postulated,O
as,O
the,O
mechanism,O
.,O
The,O
TSG101,B
tumor,I
susceptibility,I
gene,I
is,O
located,O
in,O
chromosome,O
11,O
band,O
p15,O
and,O
is,O
mutated,O
in,O
human,O
breast,B
cancer,I
.,O
Recent,O
work,O
has,O
identified,O
a,O
mouse,O
gene,O
(,O
tsg101,B
),O
whose,O
inactivation,O
in,O
fibroblasts,O
results,O
in,O
cellular,O
transformation,O
and,O
the,O
ability,O
to,O
produce,O
metastatic,O
tumors,O
in,O
nude,O
mice,O
.,O
Here,O
",",O
we,O
report,O
that,O
the,O
human,O
homolog,O
",",O
TSG101,B
",",O
which,O
we,O
isolated,O
and,O
mapped,O
to,O
chromosome,O
11,O
",",O
bands,O
15,O
.,O
1,O
-,O
15,O
1,O
-,O
15,O
.,O
2,O
",",O
a,O
region,O
proposed,O
to,O
contain,O
tumor,B
suppressor,I
gene,I
(,O
s,O
),O
",",O
is,O
mutated,O
at,O
high,O
frequency,O
in,O
human,O
breast,B
cancer,I
.,O
In,O
7,O
of,O
15,O
uncultured,O
primary,O
human,O
breast,B
carcinomas,I
",",O
intragenic,O
deletions,O
were,O
shown,O
in,O
TSG101,B
genomic,O
DNA,O
and,O
transcripts,O
by,O
gel,O
and,O
sequence,O
analysis,O
",",O
and,O
mutations,O
affecting,O
two,O
TSG101,B
alleles,O
were,O
identified,O
in,O
four,O
of,O
these,O
cancers,O
.,O
No,O
TSG101,B
defects,O
were,O
found,O
in,O
matched,O
normal,O
breast,O
tissue,O
from,O
the,O
breast,O
cancer,B
patients,O
.,O
These,O
findings,O
strongly,O
implicate,O
TSG101,B
mutations,O
in,O
human,O
breast,O
cancer,B
Moderate,O
intergenerational,O
and,O
somatic,O
instability,O
of,O
a,O
55,O
-,O
CTG,O
repeat,O
in,O
transgenic,O
mice,O
.,O
Myotonic,B
dystrophy,I
(,O
DM,B
),O
is,O
associated,O
with,O
the,O
expansion,O
of,O
a,O
(,O
CTG,O
),O
n,O
trinucleotide,O
repeat,O
in,O
the,O
3,O
untranslated,O
region,O
(,O
UTR,O
),O
of,O
the,O
DM,B
protein,I
kinase,I
gene,I
(,O
DMPK,B
),O
.,O
The,O
(,O
CTG,B
),O
n,O
repeat,O
is,O
polymorphic,O
and,O
varies,O
in,O
size,O
between,O
5,O
and,O
37,O
repeats,O
in,O
unaffected,O
individuals,O
whereas,O
in,O
affected,O
patients,O
there,O
are,O
between,O
50,B
and,O
4,I
",",I
000,I
CTGs,I
.,O
The,O
size,O
of,O
the,O
(,O
CTG,B
),O
n,O
repeat,O
",",O
which,O
increases,O
through,O
generations,O
",",O
generally,O
correlates,O
with,O
clinical,O
severity,O
and,O
age,O
of,O
onset,O
.,O
The,O
instability,O
of,O
the,O
CTG,B
repeat,I
appears,O
to,O
depend,O
on,O
its,O
size,O
as,O
well,O
as,O
on,O
the,O
sex,O
of,O
the,O
transmitting,O
parent,O
.,O
Moreover,O
",",O
mitotic,O
instability,O
analysis,O
of,O
different,O
human,O
DM,B
tissues,O
shows,O
length,O
mosaicism,O
between,O
different,O
cell,O
lineages,O
.,O
The,O
molecular,O
mechanisms,O
of,O
triplet,B
instability,I
remain,O
elusive,O
.,O
To,O
investigate,O
the,O
role,O
of,O
genomic,O
sequences,O
in,O
instability,B
",",O
we,O
produced,O
transgenic,O
mice,O
containing,O
a,O
45,O
-,O
kb,O
genomic,O
segment,O
with,O
a,O
55,O
-,O
CTG,B
repeat,I
cloned,O
from,O
a,O
mildly,O
affected,O
patient,O
.,O
In,O
contrast,O
to,O
other,O
mouse,O
models,O
containing,O
CAG,B
repeats,I
within,O
cDNAs,O
",",O
these,O
mice,O
showed,O
both,O
intergenerational,O
and,O
somatic,O
repeat,B
instability,I
.,O
Missense,O
mutations,O
in,O
the,O
Fas,B
gene,O
resulting,O
in,O
autoimmune,B
lymphoproliferative,I
syndrome,I
:,O
a,O
molecular,O
and,O
immunological,O
analysis,O
.,O
Programmed,O
cell,O
death,O
(,O
or,O
apoptosis,O
),O
is,O
a,O
physiological,O
process,O
essential,O
to,O
the,O
normal,O
development,O
and,O
homeostatic,O
maintenance,O
of,O
the,O
immune,O
system,O
.,O
The,O
Fas,B
/,O
Apo,B
-,I
1,I
receptor,I
plays,O
a,O
crucial,O
role,O
in,O
the,O
regulation,O
of,O
apoptosis,O
",",O
as,O
demonstrated,O
by,O
lymphoproliferation,O
in,O
MRL,O
-,O
lpr,O
/,O
lpr,O
mice,O
and,O
by,O
the,O
recently,O
described,O
autoimmune,B
lymphoproliferative,I
syndrome,I
(,O
ALPS,B
),O
in,O
humans,O
",",O
both,O
of,O
which,O
are,O
due,O
to,O
mutations,O
in,O
the,O
Fas,B
gene,I
.,O
We,O
describe,O
a,O
novel,O
family,O
with,O
ALPS,B
in,O
which,O
three,O
affected,O
siblings,O
carry,O
two,O
distinct,O
missense,O
mutations,O
on,O
both,O
the,O
Fas,B
gene,I
alleles,I
and,O
show,O
lack,O
of,O
Fas,B
-,I
induced,I
apoptosis,I
.,O
The,O
children,O
share,O
common,O
clinical,O
features,O
including,O
splenomegaly,B
and,O
lymphadenopathy,B
",",O
but,O
only,O
one,O
developed,O
severe,O
autoimmune,O
manifestations,O
.,O
In,O
all,O
three,O
siblings,O
",",O
we,O
demonstrated,O
the,O
presence,O
of,O
anergic,O
CD3,B
+,O
CD4,B
-,O
CD8,B
-,O
(,O
double,O
negative,O
",",O
[,O
DN,O
],O
),O
T,O
cells,O
;,O
moreover,O
",",O
a,O
chronic,O
lymphocyte,O
activation,O
was,O
found,O
",",O
as,O
demonstrated,O
by,O
the,O
presence,O
of,O
high,O
levels,O
of,O
HLA,B
-,I
DR,I
expression,O
on,O
peripheral,O
CD3,B
+,O
cells,O
and,O
by,O
the,O
presence,O
of,O
high,O
levels,O
of,O
serum,O
activation,O
markers,O
such,O
as,O
soluble,O
interleukin,O
-,O
2,O
receptor,O
(,O
slL,B
-,I
2R,I
),O
and,O
soluble,O
CD30,B
(,O
sCD30,B
),O
.,O
The,O
ataxia,B
-,I
telangiectasia,I
gene,I
product,O
",",O
a,O
constitutively,O
expressed,O
nuclear,O
protein,O
that,O
is,O
not,O
up,O
-,O
regulated,O
following,O
genome,O
damage,O
.,O
The,O
product,O
of,O
the,O
ataxia,B
-,I
telangiectasia,I
gene,I
(,O
ATM,B
),O
was,O
identified,O
by,O
using,O
an,O
antiserum,O
developed,O
to,O
a,O
peptide,O
corresponding,O
to,O
the,O
deduced,O
amino,O
acid,O
sequence,O
.,O
The,O
ATM,B
protein,I
is,O
a,O
single,O
",",O
high,O
-,O
molecular,O
weight,O
protein,O
predominantly,O
confined,O
to,O
the,O
nucleus,O
of,O
human,O
fibroblasts,O
",",O
but,O
is,O
present,O
in,O
both,O
nuclear,O
and,O
microsomal,O
fractions,O
from,O
human,O
lymphoblast,O
cells,O
and,O
peripheral,O
blood,O
lymphocytes,O
.,O
ATM,B
protein,I
levels,O
and,O
localization,O
remain,O
constant,O
throughout,O
all,O
stages,O
of,O
the,O
cell,O
cycle,O
.,O
Truncated,O
ATM,B
protein,I
was,O
not,O
detected,O
in,O
lymphoblasts,O
from,O
ataxia,B
-,I
telangiectasia,I
patients,O
homozygous,O
for,O
mutations,O
leading,O
to,O
premature,O
protein,O
termination,O
.,O
Exposure,O
of,O
normal,O
human,O
cells,O
to,O
gamma,O
-,O
irradiation,O
and,O
the,O
radiomimetic,O
drug,O
neocarzinostatin,O
had,O
no,O
effect,O
on,O
ATM,B
protein,I
levels,O
",",O
in,O
contrast,O
to,O
a,O
noted,O
rise,O
in,O
p53,B
levels,O
over,O
the,O
same,O
time,O
interval,O
.,O
These,O
findings,O
are,O
consistent,O
with,O
a,O
role,O
for,O
the,O
ATM,B
protein,O
in,O
ensuring,O
the,O
fidelity,O
of,O
DNA,B
repair,O
and,O
cell,O
cycle,O
regulation,O
following,O
genome,O
damage,O
.25,O
Type,O
III,B
collagen,I
is,O
crucial,O
for,O
collagen,O
I,O
fibrillogenesis,O
and,O
for,O
normal,O
cardiovascular,O
development,O
.40,O
Type,O
III,B
collagen,I
is,O
a,O
fibrillar,O
forming,O
collagen,O
comprising,O
three,O
alpha1,O
(,O
III,O
),O
chains,O
and,O
is,O
expressed,O
in,O
early,O
embryos,O
and,O
throughout,O
embryogenesis,O
.65,O
In,O
the,O
adult,O
",",O
type,O
III,B
collagen,I
is,O
a,O
major,O
component,O
of,O
the,O
extracellular,O
matrix,O
in,O
a,O
variety,O
of,O
internal,O
organs,O
and,O
skin,O
.,O
Mutations,O
in,O
the,O
COL3A1,B
gene,O
have,O
been,O
implicated,O
as,O
a,O
cause,O
of,O
type,O
IV,B
Ehlers,I
-,I
Danlos,I
syndrome,I
",",O
a,O
disease,O
leading,O
to,O
aortic,O
rupture,O
in,O
early,O
adult,O
life,O
.,O
To,O
directly,O
study,O
the,O
role,O
of,O
Col3a1,B
in,O
development,O
and,O
disease,O
",",O
we,O
have,O
inactivated,O
the,O
Col3a1,B
gene,O
in,O
embryonic,O
stem,O
cells,O
by,O
homologous,O
recombination,O
.,O
The,O
mutated,O
allele,O
was,O
transmitted,O
through,O
the,O
mouse,O
germ,O
line,O
and,O
homozygous,O
mutant,O
animals,O
were,O
derived,O
from,O
heterozygous,O
intercrosses,O
.,O
About,O
10,O
%,O
of,O
the,O
homozygous,O
mutant,O
animals,O
survived,O
to,O
adulthood,O
but,O
have,O
a,O
much,O
shorter,O
life,O
span,O
compared,O
with,O
wild,O
-,O
type,O
mice,O
.,O
The,O
major,O
cause,O
of,O
death,O
of,O
mutant,O
mice,O
was,O
rupture,O
of,O
the,O
major,O
blood,O
vessels,O
",",O
similar,O
to,O
patients,O
with,O
type,B
IV,I
Ehlers,I
-,I
Danlos,I
syndrome,I
.,O
Ultrastructural,O
analysis,O
of,O
tissues,O
from,O
mutant,O
mice,O
revealed,O
that,O
type,O
III,O
collagen,B
is,O
essential,O
for,O
normal,O
collagen,B
I,I
fibrillogenesis,O
in,O
the,O
cardiovascular,O
system,O
and,O
other,O
organs,O
.,O
Nonsense,O
mutation,O
in,O
exon,O
3,O
of,O
the,O
proteolipid,O
protein,O
gene,O
(,O
PLP,O
),O
in,O
a,O
family,O
with,O
an,O
unusual,O
form,O
of,O
Pelizaeus,B
-,I
Merzbacher,I
disease,I
.,O
We,O
report,O
a,O
G,O
-,O
-,O
>,O
A,O
transition,O
at,O
nucleotide,O
431,O
of,O
the,O
proteolipid,O
protein,O
gene,O
(,O
PLP,O
),O
results,O
in,O
a,O
nonsense,O
codon,O
in,O
a,O
family,O
with,O
an,O
unusual,O
form,O
of,O
Pelizaeus,B
-,I
Merzbacher,I
disease,I
(,O
PMD,O
),O
.,O
The,O
mutation,O
",",O
which,O
creates,O
a,O
second,O
AluI,O
restriction,O
site,O
",",O
results,O
in,O
a,O
nonsense,O
mutation,O
in,O
PLP,O
.,O
The,O
clinical,O
picture,O
resembles,O
somewhat,O
that,O
of,O
X,O
-,O
linked,O
spastic,O
paraplegia,O
(,O
SPG,O
),O
.,O
It,O
differs,O
from,O
this,O
and,O
both,O
the,O
classical,O
and,O
connatal,O
forms,O
of,O
PMD,B
in,O
that,O
it,O
is,O
relatively,O
mild,O
in,O
form,O
",",O
onset,O
is,O
delayed,O
beyond,O
age,O
2,O
years,O
",",O
nystagmus,B
is,O
absent,O
",",O
tremors,B
are,O
prominent,O
",",O
mental,O
retardation,B
is,O
not,O
severe,O
",",O
some,O
patients,O
show,O
dementia,B
or,O
personality,O
disorders,O
",",O
the,O
disease,B
is,O
progressive,O
rather,O
than,O
static,O
in,O
some,O
",",O
and,O
several,O
females,O
show,O
signs,O
of,O
disease,B
.,O
The,O
nonsense,O
mutation,O
",",O
which,O
is,O
in,O
exon,O
3B,O
",",O
should,O
block,O
the,O
synthesis,O
of,O
normal,O
PLP,B
but,O
spare,O
DM20,B
",",O
the,O
isoform,O
whose,O
persistence,O
has,O
been,O
associated,O
with,O
mild,O
forms,O
of,O
PLP,B
-,O
associated,O
disease,O
in,O
both,O
humans,O
and,O
mice,O
.,O
Common,O
BRCA1,B
variants,O
and,O
susceptibility,O
to,O
breast,O
and,O
ovarian,O
cancer,B
in,O
the,O
general,O
population,O
.,O
Most,O
multiple,O
case,O
families,O
of,O
young,O
onset,O
breast,B
cancer,I
and,O
ovarian,B
cancer,I
are,O
thought,O
to,O
be,O
due,O
to,O
highly,O
penetrant,O
mutations,O
in,O
the,O
predisposing,O
genes,O
BRCA1,B
and,O
BRCA2,B
.,O
However,O
",",O
these,O
mutations,O
are,O
uncommon,O
in,O
the,O
population,O
and,O
they,O
probably,O
account,O
for,O
only,O
a,O
few,O
percent,O
of,O
all,O
breast,B
cancer,I
incidence,O
.,O
A,O
much,O
larger,O
fraction,O
of,O
breast,B
cancer,I
might,O
",",O
in,O
principle,O
",",O
be,O
due,O
to,O
common,O
variants,O
which,O
confer,O
more,O
modest,O
individual,O
risks,O
.,O
There,O
are,O
several,O
common,O
polymorphisms,O
in,O
the,O
BRCA1,B
gene,I
which,O
generate,O
amino,O
acid,O
substitutions,O
.,O
We,O
have,O
examined,O
the,O
frequency,O
of,O
four,O
of,O
these,O
polymorphisms,O
Gln356Arg,O
",",O
Pro871Leu,O
",",O
Glu1038Gly,O
and,O
Ser1613Gly,O
in,O
large,O
series,O
of,O
breast,B
and,O
ovarian,B
cancer,I
cases,O
and,O
matched,O
controls,O
.,O
Due,O
to,O
strong,O
linkage,O
disequilibrium,O
",",O
these,O
four,O
sites,O
generate,O
only,O
three,O
haplotypes,O
with,O
a,O
frequency,O
>,O
1,O
.17,O
3,O
%,O
.,O
The,O
most,O
common,O
haplotypes,O
",",O
defined,O
by,O
the,O
alleles,O
Gln356Pro871Glu1038Ser1613,B
and,O
Gln356Leu871Gly1038Gly1613,B
",",O
have,O
frequencies,O
of,O
0,O
.38,O
57,O
and,O
0,O
.42,O
32,O
respectively,O
",",O
and,O
these,O
frequencies,O
do,O
not,O
differ,O
significantly,O
between,O
patient,O
and,O
control,O
groups,O
.,O
Thus,O
the,O
most,O
common,O
polymorphisms,O
of,O
the,O
BRCA1,B
gene,O
do,O
not,O
make,O
a,O
significant,O
contribution,O
to,O
breast,O
or,O
ovarian,B
cancer,I
risk,O
.,O
However,O
",",O
our,O
data,O
suggest,O
that,O
the,O
Arg356,B
allele,O
may,O
have,O
a,O
different,O
genotype,O
distribution,O
in,O
breast,O
cancer,I
patients,O
from,O
that,O
in,O
controls,O
(,O
Arg356,B
homozygotes,O
are,O
more,O
frequent,O
in,O
the,O
control,O
groups,O
",",O
P,O
=,O
0,O
.,O
01,O
,O
",",O
indicating,O
that,O
it,O
may,O
be,O
protective,O
against,O
breast,B
cancer,I
.,O
If,O
this,O
finding,O
can,O
be,O
confirmed,O
",",O
it,O
may,O
provide,O
an,O
insight,O
into,O
the,O
structural,O
features,O
of,O
the,O
BRCA1,B
protein,I
that,O
are,O
important,O
for,O
its,O
function,O
.,O
Kniest,B
dysplasia,I
:,O
Dr,O
.,O
W,O
.,O
Kniest,O
",",O
his,O
patient,O
",",O
the,O
molecular,O
defect,O
.,O
Kniest,B
dysplasia,I
is,O
a,O
severe,O
chondrodysplasia,O
caused,O
by,O
the,O
defective,O
formation,O
of,O
type,O
II,O
collagen,O
.,O
We,O
report,O
about,O
Dr,O
.,O
Kniest,O
",",O
who,O
first,O
described,O
the,O
condition,O
in,O
1952,O
",",O
and,O
his,O
patient,O
",",O
who,O
",",O
at,O
the,O
age,O
of,O
50,O
years,O
is,O
severely,O
handicapped,O
with,O
short,B
stature,I
",",O
restricted,O
joint,O
mobility,O
",",O
and,O
blindness,B
but,O
is,O
mentally,O
alert,O
and,O
leads,O
an,O
active,O
life,O
.,O
Molecular,O
analysis,O
of,O
the,O
patients,O
DNA,O
showed,O
a,O
single,O
base,O
(,O
G,O
),O
deletion,O
involving,O
the,O
GT,O
dinucleotide,O
at,O
the,O
start,O
of,O
intron,O
18,O
destroying,O
a,O
splice,O
site,O
of,O
the,O
COL2A1,B
gene,O
.,O
This,O
is,O
in,O
accordance,O
with,O
molecular,O
findings,O
in,O
other,O
patients,O
with,O
Kniest,B
dysplasia,I
and,O
confirms,O
",",O
in,O
the,O
original,O
patient,O
",",O
that,O
the,O
disorder,O
is,O
caused,O
by,O
small,O
inframe,O
deletions,O
often,O
due,O
to,O
exon,O
skipping,O
as,O
a,O
result,O
of,O
COL2A1,O
splice,O
site,O
mutations,O
.,O
Cloning,O
of,O
the,O
homogentisate,B
1,I
",",O
2,I
-,I
dioxygenase,I
gene,I
",",O
the,O
key,O
enzyme,O
of,O
alkaptonuria,B
in,O
mouse,O
.,O
We,O
determined,O
48,O
amino,O
acid,O
residues,O
from,O
five,O
peptides,O
from,O
the,O
homogeneous,O
monomer,O
of,O
homogentisate,B
1,I
",",O
2,O
-,O
dioxygenase,O
(,O
HGO,B
;,O
E,O
.,O
C,O
.,O
1,O
.,O
13,O
.,O
11,O
.,O
15,O
),O
of,O
mouse,O
liver,O
.,O
After,O
digestion,O
with,O
trypsin,O
",",O
peptides,O
were,O
separated,O
by,O
reversed,O
phase,O
chromatography,O
and,O
amino,O
acid,O
sequenced,O
.,O
The,O
deduced,O
codon,O
sequence,O
of,O
three,O
peptides,O
was,O
used,O
to,O
derive,O
degenerated,O
oligomeres,O
.,O
By,O
combining,O
these,O
oligos,O
",",O
we,O
were,O
able,O
to,O
amplify,O
fragments,O
from,O
100,O
to,O
300,O
bases,O
(,O
b,O
),O
from,O
mouse,O
liver,O
cDNA,O
by,O
polymerase,O
chain,O
reaction,O
after,O
reverse,O
transcription,O
(,O
RT,O
-,O
PCR,O
),O
.,O
A,O
fragment,O
of,O
200,O
b,O
was,O
cloned,O
and,O
used,O
as,O
a,O
probe,O
to,O
screen,O
a,O
mouse,O
liver,O
cDNA,O
library,O
.,O
One,O
clone,O
from,O
this,O
library,O
contained,O
the,O
complete,O
cDNA,O
-,O
insert,O
for,O
HGO,B
as,O
determined,O
by,O
sequencing,O
.,O
The,O
cDNA,O
encodes,O
for,O
a,O
protein,O
of,O
50,O
kDa,O
",",O
as,O
predicted,O
.,O
The,O
cDNA,O
of,O
mouse,O
HGO,B
has,O
an,O
overall,O
identity,O
of,O
41,O
%,O
to,O
the,O
corresponding,O
gene,O
hmgA,B
from,O
Aspergillus,B
.,O
Sequence,O
similarities,O
to,O
human,O
expressed,O
sequence,O
tags,O
(,O
EST,O
),O
clones,O
ranged,O
from,O
70,O
%,O
to,O
20,O
%,O
.,O
The,O
positions,O
of,O
122,O
conserved,O
amino,O
acids,O
could,O
be,O
determined,O
by,O
multiple,O
sequence,O
alignment,O
.,O
We,O
identified,O
one,O
first,O
intron,O
of,O
928,O
b,O
in,O
the,O
mouse,O
gene,O
.,O
The,O
gene,O
for,O
HGO,B
seems,O
to,O
be,O
expressed,O
in,O
various,O
tissues,O
",",O
as,O
shown,O
by,O
RT,O
-,O
PCR,O
on,O
different,O
cDNAs,O
.,O
FISH,O
experiments,O
with,O
the,O
whole,O
murine,O
cDNA,O
as,O
probe,O
clearly,O
revealed,O
signals,O
at,O
the,O
human,O
chromosomal,O
band,O
3q13,O
.,O
3,O
-,O
q21,O
.,O
This,O
corresponds,O
well,O
to,O
the,O
previous,O
assignment,O
of,O
the,O
locus,O
for,O
the,O
human,O
alkaptonuria,B
gene,O
(,O
AKU,O
),O
to,O
the,O
same,O
chromosomal,O
region,O
by,O
multipoint,O
linkage,O
analysis,O
.,O
We,O
therefore,O
conclude,O
that,O
the,O
HGO,B
cDNA,I
encodes,O
the,O
gene,O
responsible,O
for,O
alkaptonuria,B
.,O
PTEN,B
",",O
a,O
putative,O
protein,O
tyrosine,O
phosphatase,O
gene,O
mutated,O
in,O
human,O
brain,B
",",O
breast,B
",",O
and,O
prostate,B
cancer,I
.,O
Mapping,O
of,O
homozygous,O
deletions,O
on,O
human,O
chromosome,O
10q23,O
has,O
led,O
to,O
the,O
isolation,O
of,O
a,O
candidate,O
tumor,O
suppressor,O
gene,O
",",O
PTEN,B
",",O
that,O
appears,O
to,O
be,O
mutated,O
at,O
considerable,O
frequency,O
in,O
human,O
cancers,O
.,O
In,O
preliminary,O
screens,O
",",O
mutations,O
of,O
PTEN,B
were,O
detected,O
in,O
31,O
%,O
(,O
13,O
/,O
42,O
),O
of,O
glioblastoma,B
cell,I
lines,I
and,O
xenografts,O
",",O
100,O
%,O
(,O
4,O
/,O
4,O
),O
of,O
prostate,B
cancer,I
cell,I
lines,I
",",O
6,O
%,O
(,O
4,O
/,O
65,O
),O
of,O
breast,B
cancer,I
cell,I
lines,I
and,O
xenografts,O
",",O
and,O
17,O
%,O
(,O
3,O
/,O
18,O
),O
of,O
primary,B
glioblastomas,I
.,O
The,O
predicted,O
PTEN,B
product,O
has,O
a,O
protein,O
tyrosine,O
phosphatase,O
domain,O
and,O
extensive,O
homology,O
to,O
tensin,O
",",O
a,O
protein,O
that,O
interacts,O
with,O
actin,O
filaments,O
at,O
focal,O
adhesions,O
.,O
These,O
homologies,O
suggest,O
that,O
PTEN,B
may,O
suppress,O
tumor,B
cell,I
growth,O
by,O
antagonizing,O
protein,O
tyrosine,O
kinases,O
and,O
may,O
regulate,O
tumor,B
cell,I
invasion,O
and,O
metastasis,O
through,O
interactions,O
at,O
focal,O
adhesions,O
.,O
Heterogeneity,O
in,O
Schwartz,B
-,I
Jampel,I
chondrodystrophic,I
myotonia,I
.,O
The,O
Schwartz,B
-,I
Jampel,I
syndrome,I
(,O
SJS,B
;,O
chondrodystrophic,B
myotonia,I
;,O
McK,B
255,I
",",O
800,I
),O
is,O
a,O
recessively,O
inherited,O
condition,O
defined,O
by,O
myotonia,B
",",O
short,O
stature,O
",",O
and,O
bone,B
dysplasia,I
.,O
Genetic,O
linkage,O
between,O
SJS,B
and,O
chromosomal,O
region,O
1q36,O
-,O
34,O
has,O
been,O
observed,O
in,O
several,O
families,O
",",O
but,O
the,O
gene,O
has,O
not,O
yet,O
been,O
identified,O
.,O
We,O
studied,O
the,O
clinical,O
and,O
radiological,O
features,O
in,O
81,O
patients,O
from,O
the,O
literature,O
and,O
5,O
own,O
patients,O
trying,O
to,O
identify,O
distinct,O
subgroups,O
.,O
In,O
addition,O
",",O
we,O
tested,O
genetic,O
linkage,O
to,O
the,O
SJS,B
locus,O
on,O
chromosome,O
1,O
in,O
one,O
family,O
with,O
two,O
affected,O
sibs,O
.,O
We,O
found,O
that,O
a,O
group,O
of,O
patients,O
have,O
mild,O
skeletal,B
changes,O
which,O
may,O
be,O
secondary,O
consequences,O
of,O
myotonia,B
",",O
while,O
another,O
group,O
of,O
patients,O
appear,O
to,O
have,O
primary,O
bone,B
dysplasia,I
with,O
myotonia,B
.,O
Within,O
this,O
latter,O
group,O
",",O
there,O
are,O
differences,O
in,O
age,O
of,O
manifestation,O
",",O
clinical,O
course,O
and,O
pattern,O
of,O
bone,B
changes,O
.,O
We,O
tentatively,O
isolate,O
three,O
different,O
types,O
of,O
SJS,B
type,I
1A,I
",",O
usually,O
recognized,O
in,O
childhood,O
",",O
with,O
moderate,O
bone,B
dysplasia,I
",",O
corresponding,O
to,O
the,O
original,O
descriptions,O
of,O
Schwartz,O
",",O
Jampel,O
and,O
Aberfeld,O
;,O
type,O
1B,B
",",O
similar,O
to,O
type,O
1A,O
but,O
recognizable,O
at,O
birth,O
",",O
with,O
more,O
pronounced,O
bone,B
dysplasia,I
resembling,O
Kniest,O
dysplasia,O
;,O
and,O
type,O
2,B
",",O
manifest,O
at,O
birth,O
",",O
with,O
increased,O
mortality,O
and,O
bone,B
dysplasia,I
resembling,O
Pyle,O
disease,O
.,O
Genetic,O
analysis,O
of,O
the,O
family,O
with,O
two,O
sibs,O
affected,O
by,O
SJS,B
type,I
2,I
showed,O
evidence,O
against,O
linkage,O
to,O
chromosome,O
1p36,O
-,O
34,O
.,O
CONCLUSIONS,O
SJS,B
is,O
clinically,O
and,O
radiologically,O
heterogeneous,O
.,O
The,O
causes,O
of,O
heterogeneity,O
are,O
not,O
known,O
yet,O
but,O
are,O
likely,O
to,O
include,O
both,O
different,O
mutations,O
at,O
the,O
SJS,B
locus,O
on,O
chromosome,O
1,O
and,O
the,O
presence,O
of,O
a,O
second,O
SJS,B
locus,O
.,O
A,O
tentative,O
clinico,O
-,O
radiological,O
classification,O
can,O
be,O
useful,O
for,O
the,O
characterization,O
of,O
patients,O
and,O
the,O
development,O
of,O
genotype,O
-,O
phenotype,O
correlations,O
.,O
A,O
clinical,O
overview,O
of,O
WT1,B
gene,I
mutations,I
.,O
Mutations,O
in,O
the,O
WT1,B
gene,I
were,O
anticipated,O
to,O
explain,O
the,O
genetic,O
basis,O
of,O
the,O
childhood,O
kidney,O
cancer,O
",",O
Wilms,B
tumour,I
(,O
WT,B
),O
.,O
Six,O
years,O
on,O
",",O
we,O
review,O
100,O
reports,O
of,O
intragenic,O
WT1,B
mutations,O
and,O
examine,O
the,O
accompanying,O
clinical,O
phenotypes,O
.,O
While,O
only,O
5,O
%,O
of,O
sporadic,O
Wilms,B
tumours,O
have,O
intragenic,O
WT1,B
mutations,O
",",O
>,O
90,O
%,O
of,O
patients,O
with,O
the,O
Denys,B
-,I
Drash,I
syndrome,I
(,O
renal,B
nephropathy,I
",",O
gonadal,B
anomaly,I
",",O
predisposition,O
to,O
WT,B
),O
carry,O
constitutional,O
intragenic,O
WT1,B
mutations,O
.,O
WT1,B
mutations,O
have,O
also,O
been,O
reported,O
in,O
juvenile,O
granulosa,B
cell,I
tumour,I
",",O
non,O
-,O
asbestos,O
related,O
mesothelioma,B
",",O
desmoplastic,B
small,I
round,I
cell,I
tumour,I
and,O
",",O
most,O
recently,O
",",O
acute,B
myeloid,I
leukemia,I
.,O
A,O
mutation,O
in,O
autosomal,O
dominant,O
myotonia,B
congenita,I
affects,O
pore,O
properties,O
of,O
the,O
muscle,O
chloride,O
channel,O
.,O
Autosomal,B
dominant,I
myotonia,I
congenita,I
is,O
an,O
inherited,O
disorder,O
of,O
skeletal,O
muscle,O
caused,O
by,O
mutations,O
in,O
a,O
voltage,O
-,O
gated,O
Cl,O
-,O
channel,O
gene,O
(,O
CLCN1,B
",",O
7q35,O
),O
.,O
Here,O
",",O
we,O
report,O
that,O
a,O
mutation,O
predicting,O
the,O
substitution,O
of,O
Gly,O
230,O
by,O
glutamic,O
acid,O
(,O
G230E,B
),O
between,O
segments,O
D3,O
and,O
D4,O
dramatically,O
alters,O
the,O
pore,O
properties,O
of,O
a,O
recombinant,O
human,O
muscle,O
Cl,O
-,O
channel,O
(,O
hCIC,O
-,O
1,O
),O
expressed,O
in,O
a,O
mammalian,O
cell,O
line,O
(,O
tsA201,O
),O
.,O
The,O
G230E,B
mutation,O
causes,O
substantial,O
changes,O
in,O
anion,O
and,O
cation,O
selectivity,O
as,O
well,O
as,O
a,O
fundamental,O
change,O
in,O
rectification,O
of,O
the,O
current,O
-,O
voltage,O
relationship,O
.,O
Whereas,O
wild,O
-,O
type,O
channels,O
are,O
characterized,O
by,O
pronounced,O
inward,O
rectification,O
and,O
a,O
Cl,B
>,O
thiocyanate,B
>,O
Br,B
>,O
NO,B
(,O
3,O
),O
>,O
I,B
>,O
CH,B
(,O
3,O
),O
SO,B
(,O
3,O
),O
selectivity,O
.,O
G230E,B
exhibits,O
outward,O
rectification,O
at,O
positive,O
potentials,O
and,O
a,O
thiocyanate,B
>,O
NO,B
(,O
3,O
),O
>,O
I,B
>,O
Br,B
>,O
Cl,B
>,O
CH,B
(,O
3,O
),O
SO,B
(,O
3,O
),O
selectivity,O
.,O
Furthermore,O
",",O
the,O
cation,O
-,O
to,O
-,O
anion,O
permeability,O
ratio,O
of,O
the,O
mutant,O
is,O
much,O
greater,O
than,O
that,O
of,O
the,O
wild,O
-,O
type,O
channel,O
.,O
Voltage,O
-,O
dependent,O
blocks,O
by,O
intracellular,O
and,O
extracellular,O
iodide,B
help,O
to,O
distinguish,O
two,O
distinct,O
ion,O
binding,O
sites,O
within,O
the,O
hClC,O
-,O
1,O
conduction,O
pathway,O
.,O
Both,O
binding,O
sites,O
are,O
preserved,O
in,O
the,O
mutant,O
but,O
have,O
decreased,O
affinities,O
for,O
iodide,B
.,O
These,O
findings,O
suggest,O
that,O
Gly,B
230,I
is,O
critical,O
for,O
normal,O
ion,O
conductance,O
in,O
hClC,O
-,O
1,O
and,O
that,O
this,O
residue,O
resides,O
within,O
the,O
channel,O
pore,O
.,O
The,O
incidence,O
of,O
PAX6,B
mutation,O
in,O
patients,O
with,O
simple,O
aniridia,B
:,O
an,O
evaluation,O
of,O
mutation,O
detection,O
in,O
12,O
cases,O
.,O
Twelve,O
aniridia,B
patients,O
",",O
five,O
with,O
a,O
family,O
history,O
and,O
seven,O
presumed,O
to,O
be,O
sporadic,O
",",O
were,O
exhaustively,O
screened,O
in,O
order,O
to,O
test,O
what,O
proportion,O
of,O
people,O
with,O
aniridia,O
",",O
uncomplicated,O
by,O
associated,O
anomalies,O
",",O
carry,O
mutations,O
in,O
the,O
human,O
PAX6,B
gene,O
.,O
Mutations,O
were,O
detected,O
in,O
90,O
%,O
of,O
the,O
cases,O
.,O
Three,O
mutation,O
detection,O
techniques,O
were,O
used,O
to,O
determine,O
if,O
one,O
method,O
was,O
superior,O
for,O
this,O
gene,O
.,O
The,O
protein,O
truncation,O
test,O
(,O
PTT,O
),O
was,O
used,O
on,O
RT,O
-,O
PCR,O
products,O
",",O
SSCP,O
on,O
genomic,O
PCR,O
amplifications,O
",",O
and,O
chemical,O
cleavage,O
of,O
mismatch,O
on,O
both,O
RT,O
-,O
PCR,O
and,O
genomic,O
amplifications,O
.,O
For,O
RT,O
-,O
PCR,O
products,O
",",O
only,O
the,O
translated,O
portion,O
of,O
the,O
gene,O
was,O
screened,O
.,O
On,O
genomic,O
products,O
exons,O
1,O
to,O
13,O
(,O
including,O
740,O
bp,O
of,O
the,O
3,O
untranslated,O
sequence,O
and,O
all,O
intron,O
/,O
exon,O
boundaries,O
),O
were,O
screened,O
",",O
as,O
was,O
a,O
neuroretina,B
specific,O
enhancer,O
in,O
intron,O
4,O
.,O
Ten,O
of,O
the,O
possible,O
12,O
mutations,O
in,O
the,O
five,O
familial,O
cases,O
and,O
five,O
of,O
the,O
sporadic,O
patients,O
were,O
found,O
",",O
all,O
of,O
which,O
conformed,O
to,O
a,O
functional,O
outcome,O
of,O
haploinsufficiency,B
.,O
Five,O
were,O
splice,O
site,O
mutations,O
(,O
one,O
in,O
the,O
donor,O
site,O
of,O
intron,O
4,O
",",O
two,O
in,O
the,O
donor,O
site,O
of,O
intron,O
6,O
",",O
one,O
in,O
each,O
of,O
the,O
acceptor,O
sites,O
of,O
introns,O
8,O
and,O
9,O
),O
and,O
five,O
were,O
nonsense,O
mutations,O
in,O
exons,O
8,O
",",O
9,O
",",O
10,O
",",O
11,O
",",O
and,O
12,O
.,O
SSCP,O
analysis,O
of,O
individually,O
amplified,O
exons,O
",",O
with,O
which,O
nine,O
of,O
the,O
10,O
mutations,O
were,O
seen,O
",",O
was,O
the,O
most,O
useful,O
detection,O
method,O
for,O
PAX6,B
.,O
Insulin,O
gene,O
region,O
contributes,O
to,O
genetic,O
susceptibility,O
to,O
",",O
but,O
may,O
not,O
to,O
low,O
incidence,O
of,O
",",O
insulin,O
-,O
dependent,O
diabetes,B
mellitus,I
in,O
Japanese,O
.,O
In,O
the,O
Caucasian,O
population,O
",",O
it,O
has,O
been,O
demonstrated,O
that,O
the,O
insulin,O
gene,O
(,O
INS,O
),O
region,O
contains,O
the,O
insulin,O
-,O
dependent,O
diabetes,B
mellitus,I
locus,O
(,O
IDDM2,O
),O
.,O
In,O
the,O
Japanese,O
population,O
",",O
however,O
",",O
there,O
has,O
been,O
no,O
report,O
demonstrating,O
the,O
contribution,O
of,O
IDDM2,B
to,O
the,O
pathogenesis,O
of,O
IDDM,B
.,O
We,O
conducted,O
an,O
association,O
study,O
of,O
IDDM,B
in,O
a,O
large,O
number,O
of,O
Japanese,O
subjects,O
with,O
multiple,O
polymorphisms,O
in,O
INS,B
region,O
.,O
We,O
found,O
a,O
significant,O
association,O
of,O
the,O
INS,B
region,O
with,O
IDDM,B
.,O
Alleles,O
positively,O
associated,O
with,O
IDDM,B
in,O
INS,O
region,O
were,O
the,O
same,O
as,O
those,O
positively,O
-,O
associated,O
with,O
IDDM,B
in,O
Caucasian,O
population,O
",",O
although,O
positively,O
-,O
associated,O
alleles,O
are,O
very,O
common,O
(,O
allele,O
frequencies,O
>,O
0,O
.35,O
9,O
),O
in,O
the,O
Japanese,O
general,O
population,O
.,O
These,O
data,O
suggest,O
that,O
IDDM2,B
is,O
involved,O
in,O
the,O
genetic,O
susceptibility,O
to,O
IDDM,B
in,O
Japanese,O
.,O
The,O
high,O
frequencies,O
of,O
disease,B
-,O
associated,O
alleles,O
in,O
the,O
general,O
population,O
suggest,O
that,O
IDDM2,B
locus,O
is,O
not,O
responsible,O
for,O
the,O
low,O
incidence,O
of,O
IDDM,B
in,O
Japanese,O
.,O
The,O
human,O
complement,B
C9,I
gene,I
:,O
identification,O
of,O
two,O
mutations,O
causing,O
deficiency,O
and,O
revision,O
of,O
the,O
gene,O
structure,O
.,O
The,O
ninth,O
component,O
of,O
human,O
complement,B
(,O
C9,I
),O
is,O
the,O
last,O
of,O
the,O
terminal,O
complement,O
components,O
creating,O
the,O
membrane,O
attack,O
complex,O
.,O
C9,B
is,O
a,O
single,O
-,O
chain,O
serum,O
protein,O
that,O
is,O
encoded,O
by,O
a,O
gene,O
located,O
on,O
chromosome,O
5p,O
.,O
Deficiency,B
of,O
terminal,O
complement,O
components,O
is,O
generally,O
associated,O
with,O
recurrent,O
neisseria,B
infections,O
.,O
We,O
studied,O
a,O
previously,O
described,O
Swiss,O
family,O
with,O
inherited,O
C9,B
deficiency,O
.,O
To,O
identify,O
the,O
genetic,O
basis,O
of,O
C9,B
deficiency,O
.,O
we,O
developed,O
an,O
approach,O
using,O
exon,O
-,O
specific,O
PCR,O
and,O
direct,O
DNA,O
sequencing,O
.,O
As,O
a,O
cause,O
of,O
C9,B
deficiency,O
",",O
we,O
found,O
two,O
different,O
point,O
mutations,O
",",O
both,O
generating,O
TGA,B
stop,I
codons,I
in,O
the,O
coding,O
sequence,O
.,O
One,O
mutation,O
",",O
a,O
C,B
to,I
A,I
exchange,I
",",O
was,O
detected,O
in,O
exon,O
2,O
at,O
cDNA,O
position,O
166,O
",",O
the,O
other,O
",",O
a,O
C,B
to,I
T,I
exchange,I
",",O
was,O
located,O
in,O
exon,O
4,O
(,O
cDNA,O
position,O
464,O
),O
.,O
In,O
family,O
studies,O
of,O
three,O
first,O
-,O
degree,O
relatives,O
with,O
heterozygous,O
C9,B
deficiency,O
",",O
we,O
demonstrated,O
that,O
the,O
two,O
mutations,O
are,O
segregating,O
independently,O
.,O
Therefore,O
",",O
these,O
mutations,O
are,O
sufficient,O
to,O
explain,O
the,O
complete,O
deficiency,O
of,O
both,O
the,O
probands,O
studied,O
.,O
DNA,O
sequencing,O
of,O
the,O
exon,O
-,O
intron,O
junctions,O
revealed,O
a,O
number,O
of,O
revisions,O
regarding,O
the,O
boundaries,O
between,O
exons,O
4,O
",",O
5,O
",",O
and,O
6,O
as,O
well,O
as,O
between,O
exons,O
10,O
and,O
11,O
.,O
No,O
additional,O
introns,O
were,O
detected,O
in,O
exons,O
6,O
and,O
10,O
.,O
Furthermore,O
",",O
DNA,O
marker,O
studies,O
were,O
conducted,O
using,O
known,O
polymorphisms,O
of,O
the,O
C6,O
",",O
C7,O
",",O
and,O
C9,O
genes,O
",",O
confirming,O
the,O
linkage,O
of,O
the,O
observed,O
C9,O
mutations,B
with,O
defined,O
haplotypes,O
.,O
.,O
BRCA1,B
mutations,I
in,O
women,O
attending,O
clinics,O
that,O
evaluate,O
the,O
risk,O
of,O
breast,O
cancer,O
.,O
BACKGROUND,O
To,O
define,O
the,O
incidence,O
of,O
BRCA1,B
mutations,I
among,O
patients,O
seen,O
in,O
clinics,O
that,O
evaluate,O
the,O
risk,O
of,O
breast,O
cancer,O
",",O
we,O
analyzed,O
DNA,O
samples,O
from,O
women,O
seen,O
in,O
this,O
setting,O
and,O
constructed,O
probability,O
tables,O
to,O
provide,O
estimates,O
of,O
the,O
likelihood,O
of,O
finding,O
a,O
BRCA1,B
mutation,I
in,O
individual,O
families,O
.,O
METHODS,O
Clinical,O
information,O
",",O
family,O
histories,O
",",O
and,O
blood,O
for,O
DNA,O
analysis,O
were,O
obtained,O
from,O
263,O
women,O
with,O
breast,B
cancer,I
.,O
Conformation,O
-,O
sensitive,O
gel,O
electrophoresis,O
and,O
DNA,O
sequencing,O
were,O
used,O
to,O
identify,O
BRCA1,B
mutations,I
.,O
RESULTS,O
BRCA1,B
mutations,I
were,O
identified,O
in,O
16,O
percent,O
of,O
women,O
with,O
a,O
family,O
history,O
of,O
breast,B
cancer,I
.,O
Only,O
7,O
percent,O
of,O
women,O
from,O
families,O
with,O
a,O
history,O
of,O
breast,B
cancer,I
but,O
not,O
ovarian,B
cancer,I
had,O
BRCA1,B
mutations,O
.,O
The,O
rates,O
were,O
higher,O
among,O
women,O
from,O
families,O
with,O
a,O
history,O
of,O
both,O
breast,B
and,O
ovarian,B
cancer,I
.,O
Among,O
family,O
members,O
",",O
an,O
average,O
age,O
of,O
less,O
than,O
55,O
years,O
at,O
the,O
diagnosis,O
of,O
breast,B
cancer,I
",",O
the,O
presence,O
of,O
ovarian,B
cancer,I
",",O
the,O
presence,O
of,O
breast,B
and,O
ovarian,B
cancer,I
in,O
the,O
same,O
woman,O
",",O
and,O
Ashkenazi,O
Jewish,O
ancestry,O
were,O
all,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
detecting,O
a,O
BRCA1,B
mutation,O
.,O
No,O
association,O
was,O
found,O
between,O
the,O
presence,O
of,O
bilateral,B
breast,I
cancer,I
or,O
the,O
number,O
of,O
breast,B
cancers,I
in,O
a,O
family,O
and,O
the,O
detection,O
of,O
a,O
BRCA1,B
mutation,I
",",O
or,O
between,O
the,O
position,O
of,O
the,O
mutation,O
in,O
the,O
BRCA1,B
gene,I
and,O
the,O
presence,O
of,O
ovarian,B
cancer,I
in,O
a,O
family,O
.,O
CONCLUSIONS,O
Among,O
women,O
with,O
breast,B
cancer,I
and,O
a,O
family,O
history,O
of,O
the,O
disease,O
",",O
the,O
percentage,O
with,O
BRCA1,B
coding,I
-,I
region,I
mutations,I
is,O
less,O
than,O
the,O
45,O
percent,O
predicted,O
by,O
genetic,O
-,O
linkage,O
analysis,O
.,O
These,O
results,O
suggest,O
that,O
even,O
in,O
a,O
referral,O
clinic,O
specializing,O
in,O
screening,O
women,O
from,O
high,O
-,O
risk,O
families,O
",",O
the,O
majority,O
of,O
tests,O
for,O
BRCA1,B
mutations,O
will,O
be,O
negative,O
and,O
therefore,O
uninformative,O
.,O
Mutations,O
in,O
the,O
arginine,B
-,I
rich,I
protein,I
gene,I
(,O
ARP,B
),O
in,O
pancreatic,O
cancer,O
.,O
The,O
ARP,B
gene,I
encodes,O
a,O
highly,O
conserved,O
arginine,B
-,I
rich,I
protein,I
from,O
chromosomal,O
band,O
3p21,O
.,O
1,O
1,O
At,O
the,O
cytogenetic,O
level,O
this,O
region,O
is,O
frequently,O
deleted,O
in,O
a,O
variety,O
of,O
different,O
solid,O
tumors,B
",",O
although,O
not,O
in,O
pancreatic,B
cancer,I
.,O
We,O
have,O
reported,O
the,O
presence,O
of,O
a,O
specific,O
mutation,O
(,O
ATG50,O
-,O
-,O
>,O
AGG,O
),O
or,O
deletion,O
of,O
codon,O
50,O
of,O
the,O
ARP,B
gene,I
in,O
different,O
tumor,B
types,I
(,O
Shridhar,O
et,O
al,O
.,O
",",O
1996,O
",",O
1996a,O
),O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
have,O
observed,O
mutations,O
involving,O
codon,O
50,B
in,O
11,O
of,O
37,O
pancreatic,O
tumors,O
.,O
The,O
frequency,O
of,O
codon,O
50,B
mutation,O
is,O
roughly,O
the,O
same,O
in,O
pancreatic,O
tumors,O
as,O
in,O
the,O
other,O
types,O
of,O
tumors,O
previously,O
examined,O
.,O
In,O
addition,O
",",O
we,O
have,O
detected,O
mutations,O
at,O
codon,O
51,B
in,O
multiple,O
PCR,O
subclones,O
in,O
two,O
other,O
pancreatic,O
tumors,O
.,O
Mutations,O
in,O
the,O
ARP,B
gene,O
are,O
thus,O
commonly,O
observed,O
in,O
pancreatic,B
cancer,I
",",O
as,O
well,O
as,O
many,O
other,O
cancers,O
.,O
Difficulties,O
in,O
the,O
ascertainment,O
of,O
C9,B
deficiency,O
:,O
lessons,O
to,O
be,O
drawn,O
from,O
a,O
compound,O
heterozygote,O
C9,B
-,I
deficient,I
subject,O
.,O
A,O
group,O
of,O
patients,O
with,O
long,O
-,O
surviving,O
mismatched,O
kidney,O
allografts,O
were,O
investigated,O
for,O
complement,O
function,O
using,O
haemolytic,O
assays,O
in,O
agarose,O
gels,O
.,O
One,O
patient,O
was,O
found,O
to,O
have,O
no,O
alternative,O
pathway,O
activity,O
but,O
a,O
low,O
normal,O
classical,O
pathway,O
.,O
Surprisingly,O
",",O
investigation,O
revealed,O
that,O
the,O
patients,O
complement,O
was,O
normal,O
for,O
all,O
components,O
except,O
C9,B
",",O
which,O
was,O
functionally,O
absent,O
.,O
The,O
patient,O
was,O
shown,O
to,O
be,O
heterozygous,O
for,O
DNA,O
markers,O
in,O
the,O
C6,B
",",O
C7,B
and,O
C9,B
region,O
of,O
chromosome,O
5,O
and,O
therefore,O
appears,O
to,O
be,O
a,O
compound,O
heterozygote,O
for,O
two,O
uncharacterized,O
C9,B
deficiency,O
genes,O
.,O
Serological,O
analysis,O
by,O
ELISA,O
revealed,O
that,O
he,O
has,O
trace,O
concentrations,O
of,O
a,O
non,O
-,O
functional,O
C9,B
molecule,O
.,O
Western,O
blot,O
analysis,O
was,O
not,O
sufficiently,O
sensitive,O
to,O
permit,O
detection,O
of,O
this,O
molecule,O
.,O
We,O
hypothesize,O
that,O
the,O
patient,O
is,O
heterozygous,O
for,O
a,O
complete,O
deficiency,O
of,O
C9,B
and,O
for,O
a,O
gene,O
directing,O
hyposynthesis,O
of,O
a,O
defective,O
C9,B
.,O
We,O
also,O
suggest,O
that,O
C9,B
deficiency,I
may,O
be,O
more,O
common,O
among,O
Caucasians,O
than,O
has,O
been,O
reported,O
.,O
Screening,O
for,O
ESR,B
mutations,O
in,O
breast,O
and,O
ovarian,O
cancer,O
patients,O
.,O
In,O
the,O
present,O
study,O
",",O
leukocyte,O
DNA,O
from,O
143,O
patients,O
with,O
familial,O
clustering,O
of,O
breast,O
and,O
/,O
or,O
ovarian,O
cancer,O
and,O
tumour,O
DNA,O
from,O
96,O
breast,O
carcinomas,O
were,O
screened,O
for,O
base,O
mutations,O
in,O
the,O
estrogen,O
receptor,O
gene,O
(,O
ESR,B
),O
.,O
Three,O
patients,O
with,O
a,O
family,O
history,O
of,O
cancer,B
were,O
carrying,O
a,O
Gly160Cys,O
germline,O
substitution,O
.,O
This,O
alteration,O
was,O
also,O
detected,O
in,O
eight,O
(,O
four,O
females,O
and,O
four,O
males,O
),O
of,O
729,O
controls,O
(,O
366,O
female,O
",",O
363,O
males,O
),O
",",O
indicating,O
that,O
the,O
substitution,O
probably,O
represents,O
a,O
polymorphism,O
.,O
However,O
",",O
in,O
the,O
229,O
female,O
controls,O
in,O
whom,O
family,O
history,O
of,O
cancer,O
was,O
known,O
",",O
one,O
of,O
two,O
who,O
had,O
a,O
sister,O
with,O
breast,B
cancer,I
was,O
carrying,O
the,O
variant,O
allele,O
.,O
Hence,O
",",O
a,O
possible,O
clinical,O
significance,O
of,O
the,O
glycine,B
into,O
cysteine,B
cannot,O
be,O
completely,O
ruled,O
out,O
and,O
should,O
be,O
further,O
investigated,O
.,O
Somatic,O
mutations,O
were,O
not,O
detected,O
in,O
any,O
of,O
the,O
tumours,O
studied,O
",",O
and,O
the,O
present,O
data,O
do,O
not,O
provide,O
support,O
for,O
somatic,O
ESR,B
base,I
mutations,O
as,O
an,O
important,O
mechanism,O
for,O
hormonal,O
therapy,O
resistance,O
in,O
estrogen,B
receptor,I
-,I
positive,I
breast,I
carcinomas,I
.,O
Molecular,O
bases,O
of,O
C7,B
deficiency,I
:,O
three,O
different,O
defects,O
.,O
The,O
molecular,O
basis,O
of,O
C7,B
deficiency,I
has,O
been,O
investigated,O
in,O
two,O
Irish,O
families,O
and,O
a,O
number,O
of,O
Israeli,O
families,O
of,O
Moroccan,O
Sephardic,O
Jewish,O
origin,O
.,O
Exon,O
PCR,O
and,O
sequencing,O
revealed,O
a,O
heterozygous,O
point,O
mutation,O
at,O
the,O
3,O
splice,O
acceptor,O
site,O
of,O
intron,O
1,O
in,O
one,O
Irish,O
family,O
.,O
In,O
the,O
other,O
Irish,O
family,O
",",O
exons,O
7,O
and,O
8,O
failed,O
to,O
amplify,O
and,O
they,O
were,O
shown,O
to,O
be,O
deleted,O
.,O
Marker,O
haplotype,O
studies,O
of,O
the,O
C6,O
and,O
C7,O
gene,O
region,O
and,O
Southern,O
blots,O
show,O
that,O
the,O
Irish,O
family,O
with,O
the,O
splice,O
defect,O
also,O
segregate,O
for,O
the,O
deletion,O
",",O
which,O
is,O
not,O
easily,O
detected,O
in,O
heterozygotes,O
.,O
The,O
Israeli,O
C7,O
-,O
deficient,O
cases,O
all,O
share,O
a,O
C7,O
haplotype,O
and,O
are,O
homozygous,O
for,O
a,O
mis,O
-,O
sense,O
mutation,O
in,O
exon,O
9,O
.,O
However,O
",",O
one,O
individual,O
is,O
heterozygous,O
for,O
markers,O
at,O
adjacent,O
C6,O
loci,O
",",O
showing,O
that,O
there,O
has,O
been,O
an,O
intergenic,O
recombination,O
and,O
suggesting,O
that,O
the,O
deficiency,B
mutation,I
is,O
of,O
appreciable,O
antiquity,O
.,O
Molecular,O
heterogeneity,O
of,O
classical,O
and,O
Duarte,B
galactosemia,I
:,O
mutation,O
analysis,O
by,O
denaturing,O
gradient,O
gel,O
electrophoresis,O
.,O
Classical,B
galactosemia,I
is,O
caused,O
by,O
one,O
common,O
missense,O
mutation,O
(,O
Q188R,B
),O
and,O
by,O
several,O
rare,O
mutations,O
in,O
the,O
galactose,B
-,I
1,I
-,I
phosphate,I
uridyltransferase,I
(,O
GALT,B
),O
gene,O
.,O
The,O
most,O
common,O
variant,O
of,O
GALT,B
",",O
the,O
Duarte,B
variant,O
",",O
occurs,O
as,O
two,O
types,O
",",O
Duarte,B
-,I
1,I
(,I
D,I
-,I
1,I
),I
and,O
Duarte,B
-,I
2,I
(,I
D,I
-,I
2,I
),I
",",O
both,O
of,O
which,O
carry,O
the,O
sequence,O
change,O
N314D,O
.,O
D-0,O
1-1,O
increases-2,O
",-3",O
whereas-4,O
D-5,O
-6,O
2-7,B
decreases-8,O
GALT-9,B
activity-10,O
.-11,O
To-12,O
study-13,O
the-14,O
molecular-15,O
genetics-16,O
of-17,O
classical-18,B
and-19,O
Duarte-20,B
galactosemia-21,I
",-22",O
we-23,O
analyzed-24,O
the-25,O
GALT-26,B
mutations-27,O
in-28,O
30-29,O
families-30,O
with-31,O
classical-32,B
galactosemia-33,I
",-34",O
in-35,O
10-36,O
families-37,O
with-38,O
the-39,O
D-40,O
-41,O
2-42,B
variant-43,O
and-44,O
in-45,O
3-46,O
individuals-47,O
carrying-48,O
the-49,O
D-50,O
-51,O
1-52,B
allele-53,O
by-54,O
denaturing-55,O
gradient-56,O
gel-57,O
electrophoresis-58,O
(-59,O
DGGE-60,O
)-61,O
.-62,O
DGGE,O
detected,O
59,O
of,O
the,O
60,O
classical,B
galactosemia,I
alleles,I
.,O
Q188R,B
accounted,O
for,O
60,O
%,O
",",O
K285N,B
accounted,O
for,O
28,O
%,O
of,O
these,O
alleles,O
.,O
Eight,O
novel,O
candidate,O
galactosemia,B
mutations,I
were,O
found,O
.,O
On,O
all,O
D,B
-,I
2,I
alleles,I
N314D,B
occurred,O
in,O
cis,O
with,O
two,O
intronic,O
sequence,O
changes,O
",",O
on,O
the,O
D,B
-,I
1,I
alleles,I
in,O
cis,O
with,O
a,O
neutral,O
mutation,O
in,O
exon,O
7,O
.,O
We,O
conclude,O
that,O
the,O
mutations,O
causing,O
galactosemia,B
are,O
highly,O
heterogeneous,O
and,O
that,O
K285N,B
is,O
a,O
second,O
common,O
galactosemia,O
mutation,O
in,O
our,O
population,O
.,O
Isolation,O
of,O
full,O
-,O
length,O
ATM,B
cDNA,I
and,O
correction,O
of,O
the,O
ataxia,B
-,I
telangiectasia,I
cellular,O
phenotype,O
.,O
A,O
gene,O
mutated,O
in,O
the,O
human,O
genetic,O
disorder,O
ataxia,B
-,I
telangiectasia,I
(,O
A,O
-,O
T,O
),O
",",O
ATM,B
",",O
was,O
recently,O
identified,O
by,O
positional,O
cloning,O
.,O
ATM,B
is,O
a,O
member,O
of,O
the,O
phosphatidylinositol,O
-,O
3,O
-,O
kinase,O
superfamily,O
",",O
some,O
of,O
which,O
are,O
protein,O
kinases,O
and,O
appear,O
to,O
have,O
important,O
roles,O
in,O
cell,O
cycle,O
control,O
and,O
radiation,O
signal,O
transduction,O
.,O
We,O
describe,O
herein,O
",",O
to,O
our,O
knowledge,O
",",O
for,O
the,O
first,O
time,O
",",O
the,O
cloning,O
of,O
a,O
full,O
-,O
length,O
cDNA,O
for,O
ATM,B
and,O
correction,O
of,O
multiple,O
aspects,O
of,O
the,O
radio,O
-,O
sensitive,O
phenotype,O
of,O
A,B
-,I
T,I
cells,O
by,O
transfection,O
with,O
this,O
cDNA,O
.,O
Overexpression,O
of,O
ATM,B
cDNA,O
in,O
A,B
-,I
T,I
cells,O
enhanced,O
the,O
survival,O
of,O
these,O
cells,O
in,O
response,O
to,O
radiation,O
exposure,O
",",O
decreased,O
radiation,O
-,O
induced,O
chromosome,O
aberrations,O
",",O
reduced,O
radio,O
-,O
resistant,O
DNA,O
synthesis,O
",",O
and,O
partially,O
corrected,O
defective,O
cell,O
cycle,O
checkpoints,O
and,O
induction,O
of,O
stress,O
-,O
activated,O
protein,O
kinase,O
.,O
This,O
correction,O
of,O
the,O
defects,O
in,O
A,B
-,I
T,I
cells,O
provides,O
further,O
evidence,O
of,O
the,O
multiplicity,O
of,O
effector,O
functions,O
of,O
the,O
ATM,B
protein,O
and,O
suggests,O
possible,O
approaches,O
to,O
gene,O
therapy,O
.,O
Fusion,O
genes,O
resulting,O
from,O
alternative,O
chromosomal,O
translocations,O
are,O
overexpressed,O
by,O
gene,O
-,O
specific,O
mechanisms,O
in,O
alveolar,B
rhabdomyosarcoma,I
.,O
Chromosomal,O
translocations,O
identified,O
in,O
hematopoietic,O
and,O
solid,O
tumors,O
result,O
in,O
deregulated,O
expression,O
of,O
protooncogenes,B
or,O
creation,O
of,O
chimeric,O
proteins,O
with,O
tumorigenic,O
potential,O
.,O
In,O
the,O
pediatric,O
solid,O
tumor,B
alveolar,I
rhabdomyosarcoma,I
",",O
a,O
consistent,O
t,O
(,O
2,O
;,O
13,O
),O
(,O
q35,O
;,O
q14,O
),O
or,O
variant,O
t,O
(,O
1,O
;,O
13,O
),O
(,O
p36,O
;,O
q14,O
),O
translocation,O
generates,O
PAX3,B
-,I
FKHR,I
or,O
PAX7,B
-,I
FKHR,I
fusion,O
proteins,O
",",O
respectively,O
.,O
In,O
this,O
report,O
",",O
we,O
demonstrate,O
that,O
in,O
addition,O
to,O
functional,O
alterations,O
these,O
translocations,O
are,O
associated,O
with,O
fusion,O
product,O
overexpression,O
.,O
Furthermore,O
",",O
PAX3,B
-,I
FKHR,I
and,O
PAX7,B
-,I
FKHR,I
overexpression,O
occurs,O
by,O
distinct,O
mechanisms,O
.,O
Transcription,O
of,O
PAX3,B
-,I
FKHR,I
is,O
increased,O
relative,O
to,O
wild,O
-,O
type,O
PAX3,B
by,O
a,O
copy,O
number,O
-,O
independent,O
process,O
.,O
In,O
contrast,O
",",O
PAX7,B
-,I
FKHR,I
overexpression,O
results,O
from,O
fusion,O
gene,O
amplification,O
.,O
Thus,O
",",O
gene,O
-,O
specific,O
mechanisms,O
were,O
selected,O
to,O
overexpress,O
PAX3,B
-,I
FKHR,I
and,O
PAX7,B
-,I
FKHR,I
in,O
alveolar,O
rhabdomyosarcoma,B
",",O
presumably,O
due,O
to,O
differences,O
in,O
regulation,O
between,O
the,O
wild,O
-,O
type,O
loci,O
.,O
We,O
postulate,O
that,O
these,O
overexpression,O
mechanisms,O
ensure,O
a,O
critical,O
level,O
of,O
gene,O
product,O
for,O
the,O
oncogenic,O
effects,O
of,O
these,O
fusions,O
.,O
atm,B
and,O
p53,B
cooperate,O
in,O
apoptosis,O
and,O
suppression,O
of,O
tumorigenesis,O
",",O
but,O
not,O
in,O
resistance,O
to,O
acute,O
radiation,O
toxicity,O
.,O
Mutations,O
in,O
atm,B
and,O
p53,B
cause,O
the,O
human,O
cancer,B
-,I
associated,I
diseases,O
ataxia,B
-,I
telangiectasia,I
and,O
Li,B
-,I
Fraumeni,I
syndrome,O
",",O
respectively,O
.,O
The,O
two,O
genes,O
are,O
believed,O
to,O
interact,O
in,O
a,O
number,O
of,O
pathways,O
",",O
including,O
regulation,O
of,O
DNA,O
damage,O
-,O
induced,O
cell,O
-,O
cycle,O
checkpoints,O
",",O
apoptosis,O
and,O
radiation,O
sensitivity,O
",",O
and,O
cellular,O
proliferation,O
.,O
Atm,B
-,O
null,O
mice,O
",",O
as,O
well,O
as,O
those,O
null,O
for,O
p53,B
",",O
develop,O
mainly,O
T,B
-,I
cell,I
lymphomas,I
",",O
supporting,O
the,O
view,O
that,O
these,O
genes,O
have,O
similar,O
roles,O
in,O
thymocyte,O
development,O
.,O
To,O
study,O
the,O
interactions,O
of,O
these,O
two,O
genes,O
on,O
an,O
organismal,O
level,O
",",O
we,O
bred,O
mice,O
heterozygous,O
for,O
null,O
alleles,O
of,O
both,O
atm,B
and,O
p53,B
to,O
produce,O
all,O
genotypic,O
combinations,O
.,O
Mice,O
doubly,O
null,O
for,O
atm,B
and,O
p53,B
exhibited,O
a,O
dramatic,O
acceleration,O
of,O
tumour,B
formation,O
relative,O
to,O
singly,O
null,O
mice,O
",",O
indicating,O
that,O
both,O
genes,O
collaborate,O
in,O
a,O
significant,O
manner,O
to,O
prevent,O
tumorigenesis,O
.,O
With,O
respect,O
to,O
their,O
roles,O
in,O
apoptosis,B
",",O
loss,O
of,O
atm,B
rendered,O
thymocytes,O
only,O
partly,O
resistant,O
to,O
irradiation,O
-,O
induced,O
apoptosis,O
",",O
whereas,O
additional,O
loss,O
of,O
p53,B
engendered,O
complete,O
resistance,O
.,O
This,O
implies,O
that,O
the,O
irradiation,O
-,O
induced,O
atm,B
and,O
p53,B
apoptotic,O
pathways,O
are,O
not,O
completely,O
congruent,O
.,O
Finally,O
-,O
and,O
in,O
contrast,O
to,O
prior,O
predictions,O
-,O
atm,B
and,O
p53,B
do,O
not,O
appear,O
to,O
interact,O
in,O
acute,O
radiation,O
toxicity,O
",",O
suggesting,O
a,O
separate,O
atm,B
effector,O
pathway,O
for,O
this,O
DNA,O
damage,O
response,O
and,O
having,O
implications,O
for,O
the,O
prognosis,O
and,O
treatment,O
of,O
human,O
tumours,O
.,O
Trinucleotide,O
repeat,O
expansion,O
at,O
the,O
myotonic,B
dystrophy,I
locus,O
reduces,O
expression,O
of,O
DMAHP,O
.,O
Myotonic,B
dystrophy,I
",",O
or,O
dystrophia,B
myotonica,I
(,O
DM,B
),O
",",O
is,O
an,O
autosomal,O
dominant,O
multisystem,O
disorder,O
caused,O
by,O
the,O
expansion,O
of,O
a,O
CTG,O
trinucleotide,O
repeat,O
in,O
the,O
3,O
untranslated,O
region,O
of,O
the,O
DMPK,B
protein,I
kinase,I
gene,I
on,O
chromosome,O
19q13,O
.,O
3,O
(,O
refs,O
1,O
-,O
3,O
),O
.,O
Although,O
the,O
DM,B
mutation,O
was,O
identified,O
more,O
than,O
five,O
years,O
ago,O
",",O
the,O
pathogenic,O
mechanisms,O
underlying,O
this,O
most,O
prevalent,O
form,O
of,O
hereditary,O
adult,O
neuromuscular,B
disease,I
remain,O
elusive,O
.,O
Previous,O
work,O
from,O
our,O
laboratory,O
demonstrated,O
that,O
a,O
DNase,B
l,I
-,I
hypersensitive,I
site,I
located,O
adjacent,O
to,O
the,O
repeats,O
on,O
the,O
wild,O
-,O
type,O
allele,O
is,O
eliminated,O
by,O
repeat,O
expansion,O
",",O
indicating,O
that,O
large,O
CTG,B
-,I
repeat,I
arrays,I
may,O
be,O
associated,O
with,O
a,O
local,O
chromatin,O
environment,O
that,O
represses,O
gene,O
expression,O
.,O
Here,O
we,O
report,O
that,O
the,O
hypersensitive,O
site,O
contains,O
an,O
enhancer,O
element,O
that,O
regulates,O
transcription,O
of,O
the,O
adjacent,O
DMAHP,B
homeobox,I
gene,I
.,O
Analysis,O
of,O
DMAHP,B
expression,O
in,O
the,O
cells,O
of,O
DM,B
patients,O
with,O
loss,O
of,O
the,O
hypersensitive,O
site,O
revealed,O
a,O
two,O
-,O
to,O
fourfold,O
reduction,O
in,O
steady,O
-,O
state,O
DMAHP,B
transcript,O
levels,O
relative,O
to,O
wild,O
-,O
type,O
controls,O
.,O
Allele,O
-,O
specific,O
analysis,O
of,O
DMAHP,B
expression,O
showed,O
that,O
steady,O
-,O
state,O
transcript,O
levels,O
from,O
the,O
expanded,O
allele,O
were,O
greatly,O
reduced,O
in,O
comparison,O
to,O
those,O
from,O
the,O
wild,O
-,O
type,O
allele,O
.,O
Together,O
",",O
these,O
results,O
demonstrate,O
that,O
CTG,B
-,I
repeat,I
expansions,I
can,O
suppress,O
local,O
gene,O
expression,O
and,O
implicate,O
DMAHP,B
in,O
DM,B
pathogenesis,O
.,O
Constitutively,O
methylated,O
CpG,O
dinucleotides,O
as,O
mutation,O
hot,O
spots,O
in,O
the,O
retinoblastoma,B
gene,I
(,O
RB1,B
),O
.,O
A,O
wide,O
spectrum,O
of,O
mutations,O
",",O
ranging,O
from,O
point,O
mutations,O
to,O
large,O
deletions,O
",",O
have,O
been,O
described,O
in,O
the,O
retinoblastoma,B
gene,I
(,O
RB1,B
),O
.,O
Mutations,O
have,O
been,O
found,O
throughout,O
the,O
gene,O
;,O
however,O
",",O
these,O
genetic,O
alterations,O
do,O
not,O
appear,O
to,O
be,O
homogeneously,O
distributed,O
.,O
In,O
particular,O
",",O
a,O
significant,O
proportion,O
of,O
disease,B
-,I
causing,I
mutations,I
results,O
in,O
the,O
premature,O
termination,O
of,O
protein,O
synthesis,O
",",O
and,O
the,O
majority,O
of,O
these,O
mutations,O
occur,O
as,O
C,O
-,O
-,O
>,O
T,O
transitions,O
at,O
CpG,B
dinucleotides,I
(,O
CpGs,O
),O
.,O
Such,O
recurrent,O
CpG,B
mutations,I
",",O
including,O
those,O
found,O
in,O
RB1,B
",",O
are,O
likely,O
the,O
result,O
of,O
the,O
deamination,O
of,O
5,O
-,O
methylcytosine,O
within,O
these,O
CpGs,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
used,O
the,O
sodiumbisulfite,O
conversion,O
method,O
to,O
detect,O
cytosine,O
methylation,O
in,O
representative,O
exons,O
of,O
RB1,B
.,O
We,O
analyzed,O
DNA,O
from,O
a,O
variety,O
of,O
tissues,O
and,O
specifically,O
targeted,O
CGA,B
codons,O
in,O
RB1,B
",",O
where,O
recurrent,O
premature,O
termination,O
mutations,O
have,O
been,O
reported,O
.,O
We,O
found,O
that,O
DNA,O
methylation,O
within,O
RB1,B
exons,O
8,O
",",O
14,O
",",O
25,O
",",O
and,O
27,O
appeared,O
to,O
be,O
restricted,O
to,O
CpGs,O
",",O
including,O
six,O
CGA,B
codons,O
.,O
Other,O
codons,O
containing,O
methylated,O
cytosines,O
have,O
not,O
been,O
reported,O
to,O
be,O
mutated,O
.,O
Therefore,O
",",O
disease,B
-,I
causing,I
mutations,I
at,O
CpGs,O
in,O
RB1,O
appear,O
to,O
be,O
determined,O
by,O
several,O
factors,O
",",O
including,O
the,O
constitutive,O
presence,O
of,O
DNA,O
methylation,O
at,O
cytosines,O
within,O
CpGs,O
",",O
the,O
specific,O
codon,O
within,O
which,O
the,O
methylated,O
cytosine,O
is,O
located,O
",",O
and,O
the,O
particular,O
region,O
of,O
the,O
gene,O
within,O
which,O
that,O
codon,O
resides,O
.,O
The,O
von,B
Hippel,I
-,I
Lindau,I
tumor,I
suppressor,I
gene,I
product,I
interacts,O
with,O
Sp1,O
to,O
repress,O
vascular,O
endothelial,O
growth,O
factor,O
promoter,O
activity,O
.,O
The,O
von,B
Hippel,I
-,I
Lindau,I
tumor,I
suppressor,I
gene,I
(,O
VHL,B
),O
has,O
a,O
critical,O
role,O
in,O
the,O
pathogenesis,O
of,O
clear,O
-,O
cell,O
renal,O
cell,O
carcinoma,B
(,O
RCC,B
),O
",",O
as,O
VHL,B
mutations,O
have,O
been,O
found,O
in,O
both,O
von,B
Hippel,I
-,I
Lindau,I
disease,I
-,I
associated,I
and,O
sporadic,O
RCCs,B
.,O
Recent,O
studies,O
suggest,O
that,O
vascular,O
endothelial,O
growth,O
factor,O
(,O
VEGF,B
),O
mRNA,O
is,O
upregulated,O
in,O
RCC,B
-,I
and,O
von,O
Hippel,B
-,I
Lindau,I
disease,I
-,I
associated,I
tumors,O
.,O
We,O
have,O
therefore,O
assessed,O
the,O
effect,O
of,O
the,O
VHL,B
gene,I
product,I
on,O
VEGF,B
expression,O
.,O
VEGF,B
promoter,I
-,I
luciferase,I
constructs,I
were,O
transiently,O
cotransfected,O
with,O
a,O
wild,O
-,O
type,O
VHL,B
(,O
wt,I
-,I
VHL,I
),O
vector,O
in,O
several,O
cell,O
lines,O
",",O
including,O
293,O
embryonic,O
kidney,O
and,O
RCC,B
cell,I
lines,I
.,O
wt,O
-,O
VHL,B
protein,O
inhibited,O
VEGF,B
promoter,O
activity,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
up,O
to,O
5,O
-,O
to,O
10,O
-,O
fold,O
.,O
Deletion,O
analysis,O
defined,O
a,O
144,O
-,O
bp,O
region,O
of,O
the,O
VEGF,B
promoter,O
necessary,O
for,O
VHL,B
repression,O
.,O
This,O
VHL,B
-,I
responsive,I
element,I
is,O
GC,O
rich,O
and,O
specifically,O
binds,O
the,O
transcription,O
factor,O
Sp1,O
in,O
crude,O
nuclear,O
extracts,O
.,O
In,O
Drosophila,O
cells,O
",",O
cotransfected,O
VHL,B
represses,O
Sp1,B
-,O
mediated,O
activation,O
but,O
not,O
basal,O
activity,O
of,O
the,O
VEGF,B
promoter,O
.,O
We,O
next,O
demonstrated,O
in,O
coimmunoprecipitates,O
that,O
VHL,B
and,O
Sp1,B
were,O
part,O
of,O
the,O
same,O
complex,O
and,O
",",O
by,O
using,O
a,O
glutathione,O
-,O
S,O
-,O
transferase,O
-,O
VHL,B
fusion,O
protein,O
and,O
purified,O
Sp1,B
",",O
that,O
VHL,B
and,O
Sp1,B
directly,O
interact,O
.,O
Furthermore,O
",",O
endogenous,O
VEGF,B
mRNA,I
levels,O
were,O
suppressed,O
in,O
permanent,O
RCC,B
cell,I
lines,I
expressing,O
wt,O
-,O
VHL,B
",",O
and,O
nuclear,O
run,O
-,O
on,O
studies,O
indicated,O
that,O
VHL,B
regulation,O
of,O
VEGF,B
occurs,O
at,O
least,O
partly,O
at,O
the,O
transcriptional,O
level,O
.,O
These,O
observations,O
support,O
a,O
new,O
mechanism,O
for,O
VHL,B
-,I
mediated,I
transcriptional,I
repression,I
via,O
a,O
direct,O
inhibitory,O
action,O
on,O
Sp1,B
and,O
suggest,O
that,O
loss,O
of,O
Sp1,B
inhibition,O
may,O
be,O
important,O
in,O
the,O
pathogenesis,O
of,O
von,O
Hippel,O
-,O
Lindau,O
disease,B
and,O
RCC,B
.,O
Adult,O
onset,O
globoid,B
cell,I
leukodystrophy,I
(,O
Krabbe,B
disease,I
),O
:,O
analysis,O
of,O
galactosylceramidase,O
cDNA,O
from,O
four,O
Japanese,O
patients,O
.,O
We,O
examined,O
galactosylceramidase,O
(,O
GALC,O
),O
cDNA,O
in,O
four,O
Japanese,O
patients,O
with,O
adult,B
onset,I
globoid,I
cell,I
leukodystrophy,I
(,O
Krabbe,B
disease,I
;,O
AO,O
-,O
GLD,O
),O
by,O
polymerase,O
chain,O
reaction,O
/,O
single,O
-,O
strand,O
conformation,O
polymorphism,O
(,O
PCR,O
-,O
SSCP,O
),O
analysis,O
",",O
subsequent,O
sequence,O
determination,O
",",O
and,O
restriction,O
enzyme,O
digestion,O
of,O
PCR,O
products,O
",",O
initial,O
symptoms,O
were,O
the,O
onset,O
of,O
slowly,O
progressive,O
spastic,O
paraplegia,O
from,O
the,O
middle,O
of,O
the,O
second,O
decade,O
",",O
and,O
all,O
patients,O
had,O
diminished,O
GALC,O
activity,O
in,O
their,O
leukocytes,O
.,O
We,O
identified,O
three,O
missense,O
mutations,O
(,O
I66M,B
",",O
G270D,B
",",O
L618S,B
),O
and,O
one,O
exon,O
-,O
6,O
skipping,O
(,O
535,B
-,I
573del,I
),O
.,O
Two,O
of,O
the,O
patients,O
had,O
only,O
the,O
I66M,B
mutant,O
mRNA,O
",",O
and,O
one,O
only,O
the,O
G27OD,B
mutant,O
mRNA,O
.,O
The,O
fourth,O
patient,O
carried,O
a,O
compound,O
heterozygous,O
mutation,O
of,O
535,B
-,I
573del,I
and,O
L618S,B
.,O
To,O
determine,O
the,O
enzymatic,O
activities,O
produced,O
by,O
these,O
mutations,O
",",O
we,O
constructed,O
mutated,O
GALC,O
cDNAs,O
and,O
expressed,O
them,O
in,O
COS,O
-,O
1,O
cells,O
.,O
Three,O
mutations,O
",",O
viz,O
.,O
",",O
G270D,B
",",O
L618S,B
",",O
and,O
exon,O
-,O
6,O
skipping,O
(,O
535,B
-,I
573del,I
),O
",",O
produced,O
diminished,O
GALC,O
activity,O
as,O
expected,O
.,O
The,O
I66M,B
mutation,O
in,O
the,O
wild,O
-,O
type,O
GALC,O
cDNA,O
(,O
I289,O
),O
had,O
normal,O
activity,O
",",O
but,O
when,O
this,O
mutation,O
and,O
the,O
V289,O
polymorphism,O
were,O
introduced,O
into,O
the,O
same,O
allele,O
",",O
it,O
had,O
decreased,O
activity,O
.,O
Thus,O
",",O
the,O
combination,O
of,O
a,O
unique,O
mutation,O
and,O
polymorphism,O
causes,O
conformational,O
change,O
in,O
the,O
GALC,B
enzyme,O
",",O
resulting,O
in,O
low,O
enzymatic,O
activity,O
.,O
AO,B
-,I
GLD,I
mutations,O
",",O
including,O
those,O
found,O
here,O
",",O
are,O
located,O
in,O
the,O
N,B
-,I
terminus,I
(,O
I66M,B
",",O
G270D,B
",",O
535,B
-,I
573del,I
),O
or,O
C,B
-,I
terminus,I
(,O
L618S,B
),O
of,O
the,O
GALC,B
enzyme,O
",",O
whereas,O
the,O
reported,O
mutations,O
in,O
the,O
infantile,O
form,O
(,O
IF,B
-,I
GLD,I
),O
are,O
in,O
the,O
central,O
domain,O
.,O
This,O
difference,O
in,O
mutation,O
sites,O
may,O
affect,O
the,O
clinical,O
features,O
of,O
GLD,B
.,O
